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General introduction 
Background 
Osteoporosis is a systemic disease, which is characterised by low bone mass and 
micro-architectural deterioration of bone tissue, leading to enhanced bone 
fragility and a consequent increase in fracture risk. (1) Osteoporotic fractures, 
the clinical endpoint of osteoporosis, are associated with increased morbidity, 
mortality and high socio-economic costs. (2-8) The most important osteoporotic 
fractures are those of the vertebrae, the hip and the distal forearm. The 
diagnosis osteoporosis is made primarily on basis of measurement of bone 
mineral density (BMD), which is a measure of the amount of bone mass present. 
Around the age of 30 years, a peak in BMD is reached, after which BMD starts 
to decrease with age. For di~onostic use in clinical practice, a working group of 
the World Health Organisation (WHO) developed the T-score from the BMD. 
(9) The T -score reflects the number of standard deviations of the BMD below 
the average BMD in young adult individuals. 
The diagnostic criteria for osteoporosis are given in Table 1.1. 
Table 1.1. Dia,.,onostic criteria for osteoporosis 
T -score value Diagnosis 
Above- 1.0 Normal bone 
Below - 1.0 and above -2.5 
Below- 2.5 
Below - 2.5 and at least one fr~o:ility 
fracture 
Osteopenia 
Osteoporosis 
Established osteoporosis 
There are two types of bone present in the human skeleton, namely cortical 
("compact'') bone and trabecular ("spongy'') bone, the latter of which is the 
most metabolically active. (Fig 1.1) Therefore, the sudden decrease in estrogen 
exposure during menopause influences trabecular bone more than cortical bone. 
In the femoral neck, there is proportionally less trabecular bone than in the 
spine, and this suggests that factors that influence the turnover of bone may 
have stronger effects on spine BMD than on femoral neck BMD. 
Figure 1.1. Different types of bone 
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Incidence of fractures 
Recently, Wee! et al. studied the incidence of non-vertebral fractures in both 
men and women from the Rotterdam Study (Fig 1.2 and 1.3). (10) 
Figure 1.2. The incidence of non-vertebral fractures per 1000 person years 
in men 
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Figure 1.3. The incidence of non-vertebral fractures per 1000 person years 
in women 
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In contrast to non-vertebral fractures, tbe incidence of vertebral fractures is not 
well known, especially in men. (11-14) In part, this is due to tbe fact tbat only 
about one third of vertebral fractures come to medical attention, whereas tbe 
majority remains unnoticed. (15) Vertebral fractures can be very debilitating, for 
tbey are associated witb increased functional impainnent, (16) back pain and 
l.:yphosis. (8,1 T) Furthermore, even in subjects 'l.vitbout symptoms, vertebral 
fractures are associated witb a decreased quality of life, which is not only tbe 
result of back problems, but also of otber conditions, such as depression. (6,18) 
In addition, some studies have shown tbat tbe presence of a vertebral fracture is 
associated "ritb an increased mortality risk. ( 4, 19) Subjects witb vertebral 
fractures have an increased risk of botb new vertebral and non-vertebral 
fractures, such as hip fractures. (20-24) Thus, it is important to know how often 
tbese fractures occur in tbe general population. We studied tbe incidence of 
vertebral fractures in botb men and women, as is described in chapter 2.1. 
Risk factors for osteoporotic fractures 
Several studies have invest:So-ated risk factors for incident fractures, but most of 
tbese studies have been focussed on hip fractures. (20,25-36) One of tbe most 
important risk factors for incident fractures is a low BMD. (25,29,31) Witb 
decreasing BMD, tbe risk of an incident non-vertebral fracture increases rapidly, 
botb in men and in women. Besides BMD, tbe most important risk factors for 
non-vertebral fractures are age, female gender, low body weight, a history of 
prior fractures and family history of fractures, see Table 1.2. (26-35) 
For vertebral fractures, however, only two studies on risk factors for incident 
vertebral fractures were performed, and resultS were presented for women only. 
Ross et al. showed tbat botb pre-e.:cisting vertebral fractures and a low bone 
mass were strong predictors for incident vertebral fractures in almost 900 elderly 
women. (21) 
Table 1.2. Risk factors for incident non-vertebral fractures 
Increased risk 
Increasing age 
Female gender 
Low body weight 
Early age at menopause 
Smoking 
LowBMD 
History of previous fractures 
Maternal history of fracture 
Low calcium intake 
Low physical activity 
Corticosteroid use 
Decreased risk 
Starin use 
Thiazide diuretic use 
5 
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Furthermore, Gregg et al. suggested that an increased physical acnVlty is 
associated with a decreased incidence of vertebral fractures. (36) This prompted 
us to study risk factors for incident vertebral fractures in both men and women, 
as is described in chapter 2.2. 
Fracture prevention 
Even though the above described definition of osteoporosis, a T-score at or 
below -2.5, was designed for dia,onostic purposes only, it appears that in clinical 
practice this cut-off value of -2.5 is often used as a treannent threshold. It is not 
known, however, what proportion of all fractures in the general population will 
be captured using such an approach. It is important that one can accurately 
identify subjects who will fracture, in order to optimally aim fracture prevention. 
Therefore, we studied the sensitivity of using a T -score at or below -2.5 in order 
to identify subjects who will fracture, as is described in chapter 3.1. 
Besides uncertainties about the sensitivity of the T -score, it is cunendy also 
unclear whether a same T -score should be used for both men and women, or 
whether a gender-specific T -score is to be preferred. This was studied in chapter 
0? 
:J.-. 
The effects of endogenous estrogen on bone 
It is well known that women after menopause have an accelerated bone loss, 
suggesting that estrogen deficiency plays an important role in this loss. (37-39) 
Also, in vitro models have shown that estrogen stimulates osteoblast 
differentiation and enhances bone formation. ( 40) .High estrogen exposure, both 
endogenous and exogenous, is associated with a high BMD. (41,42) 
Furthermore, since estrogens are thought to mainly affect the metabolically 
more active trabecular bone, lumbar spine BMD might be more influenced by 
estrogen e:,.-posure than femoral neck BMD is. 
It is hypothesized that BMD can be regarded a marker for long-term estrogen 
exposure. (43) In addition, exposure to estrogens may stimulate the 
development and progression of breast cancer, by stimulating mitotic activity of 
mammary cells and thereby increasing mutation risk. (44) An association 
between endogenous estrogen levels and atherosclerosis is also suggested. ( 45-
48) Bone density, reflecting estrogen exposure throughout life, may therefore be 
associated -w-ith both incident breast cancer and atherosclerosis risk. We 
therefore invest:i,o-ated the interrelationships between bone mineral density, 
atherosclerosis and breast cancer, as is described in chapters 4.1 and 4.2. 
Therapeutical options for osteoporosis and fracture prevention 
One of the therapeutical options for osteoporosis is treannent with estrogens, in 
the form of hormone replacement therapy (HRT), to increased BMD and 
decrease fracture risk. In addition, there are also several other types of drugs, 
which can be offered to a patient for fracture prevention. The most important 
types of drugs, besides HRT are bisphosphonates and selective estrogen 
receptor modulators (SER.M:s). Bisphosphonates, such as risedronate and 
6 
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alendronate, are compounds that inhibit osteoclast-mediated bone resorption. In 
addition, bisphosphonates have been shown to reduce fracture risk (both 
vertebral and non-vertebral) by as much as fifty percent. (50-57) Raloxifene, so 
far the only SER...'v! available for osteoporosis treatment, is a nonsteroidal 
benzotbiophene that binds to the estrogen receptor and inhibits bone 
resorption, thereby increasing B:MD and decreasing (mainly vertebral) fracture 
risk. (49,50) 
A brief summary of all randomized controlled trials (RCT) with fractures as an 
endpoint, that have been performed on HRT, SERJ.\1s and bisphosphonates, the 
drugs we will evaluate in tbis thesis in terms of fracture prevention, is shown in 
Tables 1.3, 1.4 and 1.5, respectively. (50-62) 
Effects of HRT and SERMs on tissues other than bone 
Besides the anabolic effects on bone, estrogens are also thought to increase 
serum HDL-cholesterol levels, decrease serum LDL-cholesterol levels and 
influence the coagulation pathway resulting in an 2-3 times increased risk of 
thrombo-embolisms. ( 40,48,63-65) In addition, literature suggests that estrogen 
stimulates the occurrence and progression of breast cancer, increasing breast 
cancer risk by approximately 2 % per each additional year of taking HRT. (66-
68) Finally, HRT is thought to increase the risk of endometrial cancer. (65) 
SER.Ms are thought to have the same effects on bone and the cardiovascular 
system as estrogens have. (50,69,70) In contrast to estrogen, though, there is 
recent evidence that SERJ.\1s substantially decrease the risk of breast and 
endometrial cancer in women. (69,71) 
Based on these observations, we compared the cost-effectiveness of HRT, 
SER.Ms and bisphosphonates for fracture prevention, taking into account the 
effects of HRT and SER.Ms on breast cancer risk in elderly women, as described 
in chapter 6. 
Study population 
The results of the studies presented in tbis thesis were based on the Rotterdam 
Study, a prospective population-based cohort study, which was initiated to 
assess the prevalence, incidence, and determinants of diseases of the elderly. (72) 
The main focus was on cardiovascular disease, neurogeriatric disease, 
ophthalmologic disease, and locomotor disease. At baseline, between 1990 and 
1993, all inhabitants aged 55 years a,.-,d over (n=10,275) of the district of 
Ommoord in Rotterdam, were invited to take part in the study. A total of 7,983 
subjects (response rate 78 %), 4878 of which were women, entered the study. At 
baseline, and ~o-ain at the first and second follow-up visits (between 1994-1995 
and 1997-1999, respectively), information was gathered concerning amongst 
others lifestyle habits, socio-economic status, medical history and 
phartnacotherapy history. In addition to an interview, all subjects were invited to 
visit our research centre for physical examination, including measurement of 
height and weight. B:MD of the femoral neck and lumbar spine was measured by 
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General introduction 
Dual Energy X-ray Absorptiometry (DEXA, Lunar DPX-L) and radiographs of 
the thoracolumbar spine were made. 
For information on prevalent and incident vertebral fractures, all radiographs of 
the second follow-up visit were morphometrically evaluated for the presence of 
vertebral fractures by the McCloskey-Kanis method. (73) If a vertebral fracture 
was present at the follow-up radiographs, the baseline radiographs was 
additionally evaluated. If the fracture was already present at baseline, it was 
considered prevalent. Othenvise, the fracture was considered an incident 
vertebral fracture. 
For the entire cohort, information on vital stams was obtained continuously 
from the municipal authorities in Rotterdam. For subjects who moved outside 
the research area, mortality data are obtained from general practitioners (GPs). 
GPs in the research area (covering 80% of the cohort) reponed all relevant fatal 
and non-fatal events, such as fractures, through a computerized system. 
Research physicians verified follow-up information by checking GPs' patient 
records. This is possible because in the Netherlands the GP has a gate keeper 
function, which means that the GP retains all medical information of his 
patients. For the remaining 20 % of the population, research physicians 
collected data from their GP's patient records. For hospitalised patients, 
discharge reports and letters from medical specialists were additionally used for 
verification. All non-fatal events, such as fractures, were coded independently by 
two research physicians according to the International Classification of Diseases, 
10"' revision (ICD-10) (30). If there was disagreement, consensus was reached in 
a separate session. A medical expert in the field reviewed all coded events for a 
final classification. 
Aim of this thesis 
The main purposes of this thesis are to study the incidence of and risk factors 
for vertebral fractures and to evaluate the interrelations between bone mineral 
density, atherosclerosis and breast cancer, all of which are considered to be 
influenced by estrogen exposure. We will look into fracture prevention; are the 
current methods for identifying subjects at risk for fractures adequate and 
should men and women be treated equally. Finally, the results of these studies 
are combined in a model on cost-effectiveness of fracture prevention. 
Description of chapters 
In Chapter 2, vertebral fractures are investigated in both men and women. In 
chapter 2.1, the incidence of vertebral fractures will be described. In addition, the 
associations of incident vertebral fractures with both BMD and the presence of 
baseline prevalent vertebral fractures are studied. In chapter 2.2, we extended the 
analyses on risk factors for incident vertebral fractures for men and women. At 
first, we evaluated potential risk factors univariately for an association \Vith 
incident vertebral fractures. Then, we evaluated whether univariately sigoificant 
11 
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risk factors were independent from BMD, prevalent vertebral fractures and 
from each other. 
In Chapter 3, we study the value of a T -score of BMD in fracture prevention. 
In Chapter 3.1 it is evaluated whether the current criterion for osteoporosis, as 
defined by the 'WHO, of a T-score at or below -2.5, is useful in accurately 
identifying women who will fracture within the coming years. Chapter 3.2 
discusses whether the association between BMD and fractures is similar for 
both men and women and if so, whether using a gender specific T -score of 
BMD is useful in describing the problem of osteoporosis in men. 
Chapter 4 describes the associations between BMD and diseases other than 
osteoporosis that are also considered to be influenced by estrogen exposure. 
First, in Chapter 4.1, the association between BMD and peripheral arterial 
disease, which is a measure for generalised atherosclerosis, is described. Chapter 
4.2 then shows the association between BMD and incident breast cancer in 
women. 
Following the associations between BMD and morbidity, the association 
between femoral neck BMD and overall mortality is described for both men and 
women in Chapter 5. 
The results of a mathematical model on the cost-effectiveness of fracture 
prevention are discussed in Chapter 6. This model is an example of how the 
results as described in the previous chapters can be used to evaluate the cost-
effectiveness of fracture prevention. In this model, different treatment strategies 
ofHRT, SERMs and bisphosphonates are compared. 
Finally, in Chapter 7 the overall results of this thesis are placed in perspective in 
a general discussion. We further discuss pitfalls, as well as the clinical relevance 
of the research that was presented in this thesis. The general discussion ends 
with some suggestions for further research. 
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Abstract 
Vertebral fractures are considered the most common fractures in osteoporosis. 
Nevertheless, little is known about the epidemiology of these fractures, especially 
in males. Therefore, the incidence of vertebral fractures was studied in 3469 men 
and women from the Rotterdam Study. Spinal radiographs were obtained at 
baseline and a.,o-ai.n after a mean follow-up of 6.3 years. The follow-up 
radiographs were scored for vertebral fractures using the McCloskey-Kanis 
assessment method. Whenever a vertebral fracture was detected the radiograph 
was compared with the baseline radiograph. If this fracture was not already 
present at baseline, it was considered an incident fracture. The incidence 
increased strongly with age, ranging from 7.8 per 1000 person years (PY) at ages 
55-65 to 19.6 per 1000 PY at ages over 75 for women, and 5.2 to 9.3 per 1000 
PY for men, respectively. Analyses repeated in strata of presence or absence of 
prevalent vertebral fractures showed that both in men and women, the increase 
in incidence with age was almost exclusively observed in subjects with one or 
more prevalent fractures present at baseline. For both genders, the incidence of 
vertebral fractures doubled per standard deviation (SD) decrease in lumbar spine 
or femoral neck bone mineral density (BMD). This study shows that overall the 
incidence of vertebral fractures is higher in women than in men. In both 
genders, the incidence increases with age. Furthermore, the presence of a 
prevalent vertebral fracture and a low BMD are strong independent predictors of 
incident vertebral fractures in men and women. 
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Introduction 
Vertebral fractures are the most common and yet least well investigated fractures 
in osteoporosis, especially in men. (1-4) In part, this is due to the fact that only 
about one third of vertebral fractures come to medical attention, whereas the 
majority remains unnoticed.(5) Vertebral fractures can be very debilitating, for 
they are associated with increased functional impairment, (6) back pain and 
k-yphosis. (7 ,8) Furthermore, even in subjects without symptoms, vertebral 
fractures are associated with a decreased quality of life, which is not only the 
result of back problems, but also of other conditions, such as depression. (9, 1 0) 
Several smdies have shown that the presence of a vertebral fracture is associated 
with an increased mortality risk. (11,12) Furthermore, subjects with vertebral 
fractures have an increased risk of both new vertebral and non-vertebral 
fractures, such as hip fractures.(l3-17) A limited number of other studies 
investigated the incidence of vertebral fractures. Cooper et al. studied the 
incidence of clinically detected vertebral fractures in Rochester, United States.(5) 
In the same population, Melton et al. estimated the incidence of all vertebral 
fractures from the prevalence.(3) Furthermore, some studies have shown 
cumulative incidence of vertebral fractures in women.(13,15,16) Several studies 
have investigated the prevalence of vertebral fractures.(18-21) The largest of 
those, the European Vertebral Osteoporosis Study, is currently also studying the 
incidence of vertebral fractures in European countries. 
The present study is, to our knowledge, the first single-cohort study in both men 
and women to investi,o-ate the incidence of vertebral fractures in nearly 3500 
subjects aged 55 years and over during more than 6 years of follow-up. 
Materials and methods 
Study population 
The Rotterdam Study is a prospective population-based cohort study of men and 
women aged 55 and qver and has the objective to investigate the incidence of, 
and risk factors for, chronic disabling diseases. Both the rationale and the study 
design have been described previously.(22) The focus of the Rotterdam Study is 
on neurologic, cardiovascular, ophthalmologic and locomotor diseases. All 
10,275 inhabitants of Ommoord, a district in Rotterdam, the Netherlands, were 
invited to participate. Of these, 7,983 (4,878 women) participated in the study 
(resulting in a response rate of 78%). The Medical Ethics Committee of the 
Erasmus University Medical School has approved the Rotterdam Study. 
Clinical examination 
Between 1990 and 1993, an extensive baseline home interview on medical 
history, risk factors for chronic diseases and medication use was performed on 
all participants by trained interviewers. After the home interview, the participa..."lts 
were invited to come to the research center for clinical examination and 
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laboratory assessments. Bone mineral density measurement of tbe femoral neck 
and lumbar spine was performed by dual energy X-ray absorptiometry (DXA) 
(Lunar DPX-L densitometer, Madison, Wisconsin, USA) as described 
previously.(23) 
Vertebral deformity assessment 
Botb at baseline, between 1990 and 1993, and at tbe second follow-up VlSlt, 
between 1997 and 1999, a trained research technician obtained lateral 
radiographs of tbe tboracolumbar spine of subjects who were able to come to 
tbe research center. At baseline, tbere were two research technicians available, 
and one of tbem took all tbe radiographs at tbe follow-up visit. All radiographs 
were taken following a standard protocol, witb a distance between source and 
plate of 120 em, using a Solarize FV (General Electric CGR, Utrecht, tbe 
Netberlands). The follow-up radiographs were available for 3549 individuals 
(2022 women), who survived after an average 6.3 years after tbeir baseline center 
visit and who were still able to come to our research center. The fact tbat all 
subjects had to survive to this point and still had to be mobile enough to visit tbe 
center caused a healtb selection bias in our study population, \vitb participants 
being younger tban non-participants (mean age of 65.5 (SD 6.6) in participants 
and 74.5 (SD 10.0) in non-participants, respectively). Overall, participants were 
generally more healtby tban non-participants. All follow-up radiographs were 
evaluated morphometrically in Sheffield by tbe McCloskey-Kanis metbod, as 
described previously.(24) If a vertebral fracture was detected, tbe baseline 
radiograph was evaluated as well. If tbe fracture was already present at baseline it 
was considered a baseline prevalent fracture. If, however, the vertebra was 
determined to be normal at baseline and any of tbe three vertebral heights 
(anterior, central or posterior) showed a minimum decrease of at least 4.6 mm 
and 15% in absolute height on tbe later film; it was considered an incident 
fracture. All vertebral fractures were confirmed by visual interpretation by an 
expert in tbe field (EMC), to rule out artefacts and otber etiologies, such as 
patbological fractures. We excluded 80 individuals who had not attended tbe 
baseline visit. Therefore, tbe population for analysis consisted of 3469 
individuals (1971 women) witb information on incidence of vertebral fractures. 
Statistical analysis 
Differences in baseline characteristics were compared using student's t- test for 
continuous variables and Chi-square for categorical variables. Since we have no 
information on tbe exact date of fracture, we estimated this date by using tbe 
date halfway in between tbe baseline and follow-up radiograph dates. This date 
was also used to estimate tbe average age during follow-up for botb cases and 
non-cases. For tbe calculation of follow-up time, tbe time between tbe two 
radiographs was used for non-cases, whereas for cases we used tbe time between 
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the date of the first radiograph and the date halfway in between the baseline and 
follow-up radiograph, the estimated date of fracture. In a first analysis, we 
calculated overall incidence rates, for men and women separately. Analyses were 
repeated in five- and ten-year age strata and we estimated an e:~:ponential curve 
through the incidence rates. Analyses were also repeated in strata of presence or 
absence of a prevalent vertebral fracture at baseline. To analyze the gender 
difference in vertebral fracture incidence, we calculated age adjusted odds ratios 
(OR) with 95% confidence intervals (CI) for the risk of an incident vertebral 
fracture for women compared to men with logistic regression analysis. 
Additionally we adjusted for lumbar spine BMD. To assess whether BMD 
measured at another site equally predicts incident vertebral fracture risk, we 
compared OR with 95% CI for incident vertebral fractures per standard 
deviation decrease in lumbar spine and femoral neck BMD. 
For men and women separately, we modeled the association between lumbar 
spine BMD and incident vertebral fractures, adjusting for age and the presence 
of prevalent vertebral fractures, using logistic regression. 
SPSS 9.0 for windows was used for all analyses (SPSS Inc., Chicago, Illinois). 
Results 
Figure 2.1.1 shows a radiograph on which a vertebral fracture is visible. During 
an average follow-up period of 6.3 years, 240 new vertebral fractures occurred in 
176 individuals, 129 of which were females. The study generated a total of 
22,046 person years (PY) (12,461 for females). 
Figure 2.1.1. Radiograph with vertebral fracture visible 
Table 2.1.1 shows the baseline characteristics for subjects with and without 
incident vertebral fractures. Individuals with incident fractures are older, thinner 
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Both in men and women, the incidence of vertebral fractures increases with age, 
even though this is most pronounced in women. This is ~aain shown in 5-year 
age strata in figure 2.1.3. 
Figure 2.1.3. The incidence of vertebral fractures per 5-year age strata in 
men and women 
• 
0+---------------------------------~ 
55-60 60-65 65-70 70-75 75+ 
AGE CATEGORIES 
The increased incidence with age in women is primarily observed in those with a 
baseline prevalent fracture present. In men, a similar pattern is observed though 
the incidence rates were significant!y lower than in the women. At ages of 75 
years and over, the incidence rate ratio bet\Veen subjects with and "\Vi.thout a 
prevalent vertebral fracture at baseline was very similar for both genders, about 6 
for men and 8 for women. 
After adjustment for age, the risk of an incident vertebral fracture was higher in 
women than in men (OR 2.1; 95% CI 1.5-3.0). After adjustment for age and 
lumbar spine BMD, these risk estimates dropped and were no longer statistically 
significant (OR 1.3; 95% CI 0.9-1.8). When adjustment was made for femoral 
neck BMD instead of lumbar spine BMD, odds ratios again dropped but 
remained higher and were still statistically significant (OR 1.6; 95% CI 1.1-2.3). 
Further adjustment for the presence or absence of baseline prevalent vertebral 
fractures did not essentially change these risk estimates. 
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Table 2.1.3. Incidence per 1000 person years of vertebral fractures in 
elderly men 
Nr of fractures Person zears Incidence 
Overall 
55-65 17 3294 5.2 (3.2-8.3) 
65-75 24 4682 5.1 (3.4-7.7) 
75+ 16 1736 9.3 (5.7-15.1) 
No vertebral fracture 
present 
55-65 16 3156 5.1 (3.1-8.3) 
65-75 17 4359 3.9 (2.4-6.3) 
75+ 9 1534 5.9 (3.1-11.3) 
Vertebral fracture 
present 
55-65 1 138 7.2 (1.0-51.3) 
65-75 7 323 21.6 (10.3-45.4) 
75+ 7 193 36.4 (17.3-76.3) 
Table 2.1.4. Incidence per 1000 person years of vertebral fractures in 
elderly women 
Nr of fractures Person vears Incidence 
Overall 
55-65 33 4210 7.8 (5.6-11.0) 
65-75 99 5811 17.0 (14.0-20.7) 
75+ 51 2598 19.6 (14.9-25.8) 
No vertebral fracture 
present 
55-65 '? :L 4064 7.9 (5.6-11.1) 
65-75 61 5358 11.4 (8.8-14.6) 
75+ 26 ?'?-_:;_/ 11.2 (7 .6-16.4) 
Vertebral fracture 
present 
55-65 1 146 6.9 (1.0-48.7) 
65-75 38 454 83.7 (60.9-115.0) 
75+ ?--~ 271 92.4 (62.4-136.7) 
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Especially in men, the age-adjusted rehltive risk of an incident vertebral fracture 
was higher per 1 SD decrease in lumbar spine Bl'viD than per SD decrease in 
femoral neck Bl'viD (OR 2.6; 95% CI 1.8-3.7 and 1.8; 95% CI 1.3-2.4, 
respectively; p-value for difference 0.061). A similar, but less obvious trend was 
observed for women (2.2; 95% CI 1.7-2.7 and 1.9; 95% CI 1.6-2.4, respectively; 
p-value for difference 0.225). 
Figure 2.1.4 shows the odds ratios for incident vertebral fractures by absolute 
values of lumbar spine BMD for men and women separately. Adjustment was 
made for age and the presence of prevalent vertebral fractures at baseline. 
Especially for the higher Bl'viD values, the lines completely overhlpped for men 
and women. At very low Bl'viD levels, the line for men was somewhat higher 
than for women. This is mainly due to the low numbers of men at very low 
Bl'viD levels. 
Figure 2.1.4. Age and prevalent vertebral fracture adjusted odds ratios for 
incident vertebral fractures by lumbar spine BMD, in men and women 
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Discussion 
In this large popuhltion-based cohort study, we found that both in men and in 
women, the incidence of vertebral fractures strongly increased "'~th age. This 
increase with age occurred mainly in subjects who had a prevalent vertebral 
fracture present at baseline. 
At higher ages, the incidence rate ratio bet\Veen subjects with and 'Without 
prevalent vertebral fractures was almost similar for men and women. 
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The absolute incidence of vertebral fractures is lower in men than in women, but 
after adjustment for age and the presence or absence of prevalent vertebral 
fractures, the risk of an incident vertebral fracture is similar at any given level of 
lumbar spine BMD in men and women. Therefore, the difference in absolute 
incidence in men and women may be due to the fact that overall, men have a 
higher peak bone mineral density and loose bone at a lower rate than women 
do.(25) In line with this finding, Lunt and colleagues also suggested that BMD, 
together with age, explain much of the differences in risk of vertebral fractures 
between men and women in a cross-sectional analysis. (26) 
For both men and women, the presence of prevalent vertebral fractures as well 
as a low BMD were strong independent risk factors for incident vertebral 
fractures. 
Ross et a!. already showed prevalent vertebral fractures to be a strong risk factor 
for incident vertebral fractures in women. (13) This study shows that prevalent 
vertebral fractures are also important predictors for incident vertebral fractures 
mmen. 
A limited number of other studies investigated the incidence of vertebral 
fractures. Cooper et a!. studied the incidence of clinically detected vertebral 
fractures during a 5 years period in the population of Rochester, Minnesota. (5) 
For women, these incidence rates were about one third of our incidence rates. 
This is similar to what could be expected from earlier studies, since it was 
estimated that only about one third of all vertebral fractures spontaneously come 
to clinical attention.(27) For men this was less obvious, probably due to low 
numbers. In a sample from the same study population, Melton et a!. estimated 
the incidence of all vertebral fractures in women from the prevalence using the 
method of Leske et al.(3,28) Their estimated incidence is similar to our incidence 
at lower ages, but from around age 70 their incidence rates are higher than ours 
are. However, in order to estimate the incidence from the prevalence, it is 
assumed that subjects with vertebral fractures have a similar risk of mortality as 
subjects \vithout a vertebral fracture. Several recent studies have shown that 
prevalent vertebral fractures are associated with an increased mortality risk. 
(11,12) Since the absolute mortality risk increases with age, this could explain 
why results deviate at higher ages. 
Furthermore, some other studies reported the cumulative incidence of vertebral 
fractures in women.(13,15,16) The Study of Osteoporotic Fractures showed a 
vertebral fracture cumulative incidence of 5.4 % over an average follow-up rime 
of 3.7 years in women aged 65 years and over, (16) whereas this was 6.8% over 
4.7 years in postmenopausal Japanese-American women. (13) Comparison with 
these studies is hampered, though, by the fact that different methods for 
defining vertebral fractures are used, and that large differences in duration of 
follow-up and age distribution of the subjects exist. 
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The absence of consensus about the definition of a vertebral fracture is indeed 
the major problem in studying the incidence of vertebral fractures. (24),(29-32) 
Several methods have been developed for the evaluation of spinal radiographs. 
For this study, we used the McCloskey-Kanis method, which is a method that is 
especially developed for assessing both the prevalence and incidence of vertebral 
osteoporosis in the population and in prospective studies. In contrast to other 
methods, this method predicts vertebral heights and ratios for the individual 
patient rather than comparing them exclusively to a reference population, 
resulting in a lower false positive rate. (24) 
Even though this is a large population-based cohort study there are some 
weaknesses. There is a selection bias in our study population, since in order to be 
eligible for this study, subjects had to be able to come to our third center visit. 
Therefore, only the subjects who survived over 6 years of follow-up and were 
still mobile enough were included in this study. Due to this selection bias, our 
incidence rates are probably an underestimation of the true incidence in the 
population. However, since vertebral fractures only come to medical attention in 
one third of all cases, this is the only way to estimate the real incidence of 
vertebral fractures. Our assessment of vertebral deformities was based solely on 
morphometry, which is not commonly used in clinical practice. Because at older 
ages most vertebral fractures occur after minor or no trauma, (5) \.Ve assumed 
that most incident vertebral fractures in this group of elderly participants were 
caused by osteoporosis. 
Altogether, we show that the incidence of vertebral fractures increases strongly 
with age in both men and women. Subjects "'~th a prevalent vertebral fracture 
present at baseline primarily accounted for this increase of incidence with age. 
Even though overall incidence rates are higher in women than in men, the risk 
of an incident vertebral fracture at any given level of absolute BMD is similar for 
men and for women. The presence of a prevalent vertebral fracture and a low 
BMD are strong and independent risk indicators for incident vertebral fractures 
in both men and women. 
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Abstract 
A low bone mineral density (BMD) and the presence of prevalent vertebral 
fractures have been reported as risk factors for incident vertebral fractures. little 
is known, however, about other risk factors for incident vertebral fractures. We 
investigated potential risk factors for incident vertebral fractures in 3001 men 
and women aged 55 or over from the Rotterdam Study, a prospective 
population-based cohort study. Spinal radiographs were obtained at baseline and 
again after a mean follow-up of 6.3 years. Presence of incident vertebral fractures 
was evaluated morphometrically using the McCloskey-Kanis assessment method. 
For men and women separately, all potential risk factors were tested un.ivariately, 
and when significant, tested for independence from age, BMD, and additionally 
from prevalent vertebral fractures. Finally all significant risk factors were entered 
into a multivariate model. For women age, early menopause (at or below age 45 
years), current smoking and walking aid use were additional independent risk 
factors, apart from low BMD and presence of prevalent vertebral fractures. For 
men, only a history of non-vertebral fractures at or after age 50 years was a 
significant independent risk factor besides low BMD and prevalent vertebral 
fractures. Many of the risk factors studied here have more impact on the 
pathogenesis of incident vertebral fractures than either hypercholesterolemia or 
hypertension have on myocardial infarction. Finally, although a model including 
all risk factors best predicted incident vertebral fractures, a model 'W~th easily 
assessable risk factors only also resulted in good vertebral fracture prediction in 
women. For both genders, low BMD and prevalent vertebral fractures are strong 
independent risk factors for incident vertebral fractures. Increasing age, 
prevalent non-vertebral fractures, early menopause, current smoking and walking 
aid use are also associated with increased vertebral fracture risk. 
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Introduction 
Vertebral fractures are common fractures in osteoporosis, and they are 
associated \vith increased morbidity and mortality. (1-8) However, in contrast to 
other fractures, especially hip fractures, risk factors for incident vertebral 
fractures have not been extensively studied. The most important risk factors for 
non-vertebral fractures are age, gender, low bone mineral density (BMD), low 
body weight, a history of prior fractures and family history of fractures. (9-19) It 
is uncertain whether these same risk factors are equally important for vertebral 
fractures, or whether other factors play a role. We and others have previously 
reported that low BMD and the presence of baseline vertebral fractures are 
strong and independent risk factors for incident vertebral fractures. (20,21) 
Furthermore, Gregg et al. suggested that an increased physical activity is 
associated with a decreased incidence of vertebral fractures. (22) For men, no 
studies on other risk factors for incident vertebral fractures have been performed 
to our knowledge. Several cross-sectional studies have been performed on risk 
factors for prevalent vertebral fractures. (23-31) These studies suggest that age, 
low bone mass, smoking, alcohol intake and low physical activity are associated 
\vith an increased risk of vertebral fractures. However, these fractures may have 
occurred several years before, and conclusions on causality are less secure from 
these analyses. 
In this study we evaluated potential risk factors for incident vertebral fractures 
in both elderly men and women from a large prospective population-based 
cohort study, the Rotterdam Study. 
Materials and methods 
Study population 
The Rotterdam Study is a large prospective population-based cohort study of 
men and women aged 55 years and over. The study objective is to investigate the 
incidence of, and risk factors for, chronic disabling diseases. Both the rationale 
and the study design have been described previously. (32) All 10,27 5 inhabitants 
of Ommoord, a district in Rotterdam, the Netherlands, were invited to 
participate. Of these, 7,983 participated in the study (response rate 78%). All 
participants signed informed consent and the Medical Ethics Committee of the 
Erasmus Medical Centre has approved the Rotterdam Study. 
Data collection for potential risk factors 
Home interview 
Between 1990 and 1993, an extensive baseline home interview on medical 
history was performed by trained interviewers. Information on drug use, such as 
use of diuretics, systemic glucocorticoids, thyroid hormone, statins, hormone 
replacement therapy (HRT) and oral contraceptives (OC) was gathered. Calcium 
intake was assessed, as was total caloric intake. For the current analyses, calcium 
35 
Chapter 2.2 
intake was adjusted for total caloric intake. Smoking habits were categorized as 
current, former or never. Recent falling was described as at least one fall in the 
year before the baseline interview. Data on history of non-vertebral fractures at 
or after age 50 and use of a walking aid were obtained. Lower limb disability was 
assessed using a modified version of the Stanford Health Assessment 
Questionnaire, as described previously. (33,34) Information was obtained on age 
at and reason for menopause, defined as cessation of menses for 12 consecutive 
months. Natural menopause was defined as menopause occurnng 
spontaneously, not after any intervention that would have stopped the menses. 
For non-natural menopause, we validated the date and indication of surgery by 
checking the GPs patient records and hospital discharge letters. 
Clinical examination 
After the home interview, subjects '~sited the research center for a clinical 
examination and laboratory and BMD measurements. Height and weight were 
measured with subjects wearing indoor clothing and without shoes. Body mass 
index (BMI) was computed as weight in kilograms divided by height in meters 
squared (kg/m'). Subjects were classified as diabetics when they reported use of 
antidiabetic therapy (code A010 of the Anatomical Therapeutical Chemical 
classification index, WHO 1992), or when the pre- or post!oad serum glucose 
level was equal to or higher than 11.1 mmol/1. BMD measurements of the 
femoral neck and the lumbar spine (I2-L4) were performed by dual energy X-ray 
absorptiometry (DXA, Lunar DPX-L densitometer) as described previously. (34) 
Vertebral deformity assessment 
Both at baseline, between 1990 and 1993, and at the second follow-up visit, 
between 1997 and 1999, a trained research technician obtained lateral 
radiographs of the thoracolumbar spine of subjects who were able to come to 
the research center. At baseline, there were t\V"o research technicians available, 
and one of them took all the radiographs at the follow-up visit. All radiographs 
were taken following a standard protocol, \V~th a distance between source and 
plate of 120 em, using a Solarize FV (General Electric CGR, Utrecht, the 
Netherlands). The follow-up radiographs were available for 3549 individuals 
(2022 women), who survived after an average 6.3 years after their baseline center 
visit and who were still able to come to our research center. All follow-up 
radiographs were evaluated morphometrically in Sheffield by the McCloskey-
Kanis method, as described previously. (20,35) If a vertebral fracture was 
detected, the baseline radiograph was evaluated as well. If the fracture was 
already present at baseline it was considered a baseline prevalent fracture. If, 
however, the vertebra was determined to be normal at baseline and any of the 
three vertebral heights (anterior, central or posterior) showed a minimum 
decrease of at least 4.6 mm or 15 o/o in absolute height on the later film; it was 
considered an incident fracture. All vertebral fractures were confirmed by visual 
interpretation by an expert in the field, to rule out artifacts and other etiologies, 
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such as pathological fractures. We excluded SO individuals who had not attended 
the baseline visit. We also excluded 468 men and women for whom data on one 
or more risk factors were missing. The final population for analysis consisted of 
3001 individuals (1624 women) with information both on vertebral deformities 
and on potential risk factors. 
Statistical analysis 
Differences in baseline characteristics were compared using student's t- test for 
continuous variables and Chi-square for categorical variables. Age was evaluated 
in 5-year strata, whereas BMD was evaluated per gender-specific standard 
deviation decrease. Height and weight were evaluated in qllilrtiles. All potential 
risk factors were tested for significance in univariate models using logistic 
regression. To take account of those relatively weak potential risk factors that do 
not reach statistical significance at a p-value of 0.05 due to low numbers, risk 
factors were considered statistically significant when the p-value was below 0.10 
(two-tailed). All risk factors that were statistically significant in the univariate 
analyses for either men or women were evalllilted for independence from age, by 
adjusting for age in the model. When still significant, additional independence 
from BMD and subsequendy from both BMD and the prevalence of baseline 
prevalent vertebral fractures was tested. This was done in order to test whether 
the risk factors studied reflect a low BMD and/ or the presence of vertebral 
fractures, or whether these risk factors independendy add to the etiology of 
incident vertebral fractures. The risk factors that were still in the model then 
were entered in a full multivariate model. All analyses were performed for men 
and women separately. Finally, attributable risks and population attributable risks 
were calculated for all independent risk factors. (36) The attributable risk (RR -
1/ RR) expresses which fraction of the risk of incident vertebral fractures in the 
exposed is due to the exposure itself. The population attributable risk (R - Ro / 
R, where R is the risk in the total population, and Ro is the risk in the non-
exposed) e>.-presses what proportion of all incident vertebral fractures in the total 
population is due to the exposure under study. Since age and BMD are 
continuous variables, these variables were dichotomized. Age was categorized as 
above or below 70 years. For lumbar spine BMD, we used aT-score of -2.5 or 
below as a cut-off. The T-score is the number of standard deviations below the 
gender-specific young adult mean lumbar spine BMD. Attributable risks were 
based on age-adjusted odds ratios. \Ve created three models for prediction of 
incident vertebral fractures: the first included easily assessable risk factors, age, 
weight, current smoking, use of a walking aid, history of non-venebral fractures 
and, for women, age at menopause. The second model included only BMD and 
the presence of baseline prevalent vertebral fractures and the third model 
included all of the above. Differences in predictive value for incident vertebral 
fractures berw-een the three models were evaluated by comparing the area under 
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the receiver operating characteristic curves (ROC area) with standard error. A 
ROC curve of a multivariate logistic regression model plots the sensitivity and 1-
specificity at each consecutive threshold in the range of predicted probabilities of 
the model. The ROC area is a measure of the discriminative or predictive ability 
of the model that can range from 0.5 (no discrimination between subjects with 
and without incident vertebral fractures) to 1.0 (perfect discrimination. (37,38) 
SPSS 10.0 for Windows was used for all analyses. 
Results 
Table 2.2.1 shows baseline characteristics of men and women 'CV'ith and "''ithout 
incident vertebral fractures. Both men and women with incident vertebral 
fractures had a lower BMD, more often had a history of fractures, both vertebral 
and non-vertebral, and tended to smoke more, even though this was not 
statistically significant in men. In addition, women with incident vertebral 
fractures were older, thinner, more frequently used a walking aid and had an 
earlier age at natural menopause. No differences in calcium intake, adjusted for 
caloric intake, were observed between subjects with and without incident 
vertebral fractures. 
In a univariate analysis, incident vertebral fracture risk increased v."'ith age in 
women, but not in men (fable 2.2.2). Similarly, low body weight and small 
height were associated "-'i.th increased incident vertebral fracture risk in women 
only. The presence of at least one prevalent vertebral fracrure, however, was 
associated with an increased risk of new vertebral fractures in both genders, as 
was ha,'ing had a prevalent non-vertebral fracture at or after age 50 years. As 
reported earlier, a low BMD at both the femoral neck and lumbar spine was 
associated with a strongly increased vertebral fracture risk. (30) Especially in 
men, the association 'With incident vertebral fractures appeared stronger for the 
site specific, lumbar spine BIVID than for femoral neck BMD. Only in women, 
the use of a walking aid and a moderate or severe lower limb disability were 
univariate risk factors for incident vertebral fractures. Current smoking was 
associated with an increased vertebral fracture risk in both genders, although 
statistically significant in women only. 
For women, several estrogen-related factors were univariate predictors for 
incident vertebral fractures. We stratified age at menopause into natural and non-
natural menopause. \Vomen in our cohort ..-..vi:th a non-natural menopause (e.g. 
surgery) took HRT more often and longer (data not shown). Women '-N'ith an 
early natural menopause, defined as an age at menopause at or before age 45, 
had a 2.7 times increased risk of an incident vertebral fractures, when compared 
"''ith women who had their menopause above age 50. 
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Table 2.2.1. Baseline characteristic for men and women with and without 
incident vertebral fractures from the Rotterdam Study 
Men Women 
No incident Incident No incident Incident 
vertebral vertebral vertebral vertebral 
fracture fracture fracture fracture 
(n =1333) (n =44) (n =1511) (n =113) 
Age 65.2 (6.5) 66.3 (6.3) 65.7 (6.6) 68.6 (7.1)** 
Weight 80.1 (10.5) 78.7 (1 0.2) 70.6 (10.7) 67.3 (11.9)** 
Height 175.6 (6.8) 176.5 (7.8) 162.6 (6.4) 161.9 (7.1) 
FNB:MD 0.89 (0.12) 0.82 (0.10)** 0.83 (0.13) 0.75 (0.13)** 
LSBMD 1.17 (0.19) 1.03 (0.18)** 1.01 (0.17) 0.93 (0.16)** 
Calcium intake 1161.5 1148.2 1107.5 1088.9 
(g/day) (399.1) (340.9) (332.5) (304.8) 
Smoking(%) 
Current 25.3% 38.6% 17.3% 25.7 %* 
Former 65.3% 56.8% 31.8% 29.2% 
l'•.Tever 9.4% 4.5% 51.0% 45.1% 
Prevalent 6.5% 20.5 %** 6.5% 30.1 %** 
vertebral 
fracture (%) 
Non-vertebral 13.7% 29.5 %** 21.7% 30.1 %** 
fracture >=age 
50 years (%) 
Use of walking 2.6% 2.3 °/o 3.2 °/o 9.7 %** 
aid(%) 
Age at na m:al 49.9 (4.4) 48.5 ( 4.8)** 
menopause 
HRTuse (%) 
1\Tever 57.7% 70.0 %** 
<3yr 26.6% 17.3% 
>=3yr 15.7% 12.7% 
Values are means with standard deviations or numbers with percentages 
·spontaneous menopause not caused by any intervention 
** p-value < 0.05, * p-value < 0.10 
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Table 2.2.2. Univariate analyses of potential risk factors for incident 
vertebral fractures 
Men Women 
Cases/ OR (95% CI) Cases/ OR (95% CI) 
PTOU QTOU 
Age (years) 
55-59 10/339 1 (reference) 11/366 1 (reference) 
60-64 9/387 0.8 (0.3-2.0) 27/438 2.1 (1.0-4.3)** 
65-69 11/330 1.1 (0.5-2.7) 28/366 2.7 (1.3-5.5)** 
70-74 11/200 1.9 (0.8-4.6) 27/281 3.4 (1.7-7.0)** 
75-79 3/90 1.1 (0.3-4.2) 13/128 3.6 (1.6-8.4)** 
>=so 0/31 DNC 7/45 5.9 (2.2-16.2)** 
w cigh t ( quartil cs) 
1 Qowcst) 12/337 1.2 (0.5-2.9) 42/407 2.6 (1.5-4.7)** 
2 10/353 1.0 (0.4-2.3) 31/402 1.9 (1.0-3.5)** 
3 12/339 1.2 (0.5-2.8) 21/405 1.3 (0.7-2.4) 
4 10/339 1 (reference) 17/406 1 (reference) 
Height (quartiles) 
1 0-0\VCSt) 12/361 0.7 (03-1.5) 36/451 1.3 (0.8-2.2) 
2 10/385 0.6 (0.2-1.2) 27/376 1.2 (0.7-2.1) 
3 7/296 0.5 (0.2-1.2) 23/390 0.9 (0.5-1.7) 
4 15/326 1 (reference) 25/403 1 (reference) 
Baseline prevalent 
vertebral fracture 
None 35/1281 1 (reference) 79/1492 1 (reference) 
>= 1 9/96 3.7 (1.7-7.9)** 34/132 6.2 (4.0-9.7)** 
History of any non-
vertebral fracture 
No 31/1150 1 (reference) 79/1262 1 (reference) 
Yes 13/183 2.6 (1.4-5.1)** 34/362 1.6 (1.0-2.4)** 
FN BMD (SD decrease) 43/1351 1.9 (1.3-2.6)** 108/1584 2.1 (1.7-2.6)** 
LS BMD (SD decrease) 44/1377 2.6 (1.8-3.7)** 113/1624 2.2 (1.7-2.7)** 
Use of a walking aid 
No 43/1342 1 (reference) 102/1564 1 (reference) 
Yes 1/35 0.9 (0.1-6.6) 11/60 3.2 (1.6-6.4)** 
Lower limb disability 
No 30/962 1 (reference) 50/878 1 (reference) 
Moderate 6/178 1.1 (0.4-2.6) 29/393 1.4 (1.0-2.2)* 
Severe 8/235 1.1 (0.5-2.4) 34/351 2.2 (1.1-4.6)** 
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Table 2.2.2. Univariate analyses of potential risk factors for incident 
vertebral fractures, continued 
Smoking 
Current 
Former 
Never 
Recent falling 
No 
Yes 
Diabetes mellitus 
No 
Yes 
Age at natural 
menopause 
<= 45 yr 
46-50 yr 
>50 yr 
f,.Ton~natura! 
menopause 
Use of hormone 
replacement therapy 
(HR'I) 
Never 
< 3 years 
>= 3 years 
Ever use of oral 
contraceptives 
No 
Yes 
17/354 
25/896 
2/127 
33/1151 
3/86 
36/1119 
2/115 
** p < 0.05; * p < 0.10 
3.1 (0.7-13.8) 
1.8 (0.4-7.6) 
1 (reference) 
1 (reference) 
1.2 (0.4-4.1) 
1 (reference) 
0.5 (0.1-2.2) 
29/290 
33/513 
51/821 
90/1340 
23/281 
89/1349 
9/102 
19/189 
35/436 
31/513 
19/486 
77/917 
19/406 
14/243 
87/1021 
25/574 
1.7 (1.0-2.7)** 
1.0 (0 .7 -1.6) 
1 (reference) 
1 (reference) 
1.2 (0.8-2.0) 
1 (reference) 
1.4 (0.7-2.8) 
2.7 (1.6-4.6)** 
1.4 (0.8-2.2) 
1 (reference) 
0.6 (0.4-1.1) 
1 (reference) 
0.5 (0.3-0.9)** 
0.7 (0.4-1.2) 
1 (reference) 
0.5 (0.3-0.8)** 
iDNC =did not compute (due to lack of cases in this subgroup) 
Women with a non-natural menopause had a somewhat decreased vertebral 
fracture risk. The use of HRT and OC were also univariately associated "~th a 
decreased vertebral fracture risk. Furthermore, the use of several other types of 
medications at baseline (diuretics, systemic glucocorticoids, thyroid hormone and 
statins) was evaluated in relation to incident vertebral fractures, but due to lack 
of power no significant associations were observed with incident vertebral 
fractures (data not shown). 
Univariately significant risk factors were evaluated for independence from age. 
In women, the risk of an incident vertebral fractures in women with at least one 
baseline prevalent vertebral fracture decreased from 6.2 to 5.3, but remained 
statistically significant. Similarly, the OR for use of a walking aid at baseline 
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decreased, but remained significant. In contrast to men, a history of a non-
vertebral fracture at of after age 50 was no longer a risk factor for incident 
vertebral fractures in women. In addition, a lower limb disability and tbe use of 
HRT or OC were no longer associated witb increased vertebral fracture risk in 
women, suggesting that these factors may be merely markers for older age only 
in women. 
We tested whetber risk factors were independent of lumbar spine BMD and 
additionally of tbe presence of baseline prevalent vertebral fractures. When 
adjusting for BMD, weight was no longer a risk factor for incident vertebral 
fractures. For tbe association between tbe presence of a baseline prevalent 
vertebral fracture and incident vertebral fractures, however, ORs dropped from 
3.6 [1.7-7.8] after adjusting for age, to 2.4 [1.1-5.4] after additionally adjusting for 
BMD in men. In women, a similar effect was observed (OR 5.4 [3.4-8.5] and 4.7 
[2.9-7.6], respectively). The risk of an incident vertebral fracture in women witb 
an early menopause decreased from 2.5 [1.4-4.3] after adjustment for age to 2.1 
[1.2-3.7] after additional adjustment for BMD. All risk factors tbat were 
independent from BMD were also independent from tbe presence of a baseline 
prevalent vertebral fracture. 
Finally, all remaining risk factors were entered into a multivariate model (Table 
2.2.3). For women, age, low BMD, tbe presence of a prevalent vertebral fracture 
at baseline, use of a walking aid, (natural) menopause before or at age 45 and 
current smoking at baseline were all strong, independent risk factors for incident 
vertebral fractures. For men, only a low BMD and prevalent non-vertebral and 
vertebral fractures were independent risk factors for incident vertebral fractures, 
even tbough tbe presence of prevalent vertebral fractures was only borderline 
significant now, due to a low number of cases. 
Table 2.2.4 shows attributable risks and population attributable risks for all 
independent risk factors. For men, low LS BMD contributed to 77.8% of 
incident vertebral fracture cases amongst all men witb low BMD and was 
involved in tbe pathogenesis of 25% of all vertebral fracture cases in tbe total 
male study population. Similarly, in women low BMD contributed to 68.8% of 
cases in women vrith a low B11D, and was involved in the pathogenesis of 
32.9% of all incident vertebral fracture cases in tbe general population. In terms 
of (population) attributable risks, low BMD and tbe presence of baseline 
prevalent vertebral fractures have tbe highest impact on tbe etiology of incident 
vertebral fractures in botb men and women. Figure 2.2.1 shows tbe ROC curves 
for three models for incident vertebral fracture prediction for men and women 
separately. The first model includes only easily assessable risk factors, namely 
age, weight, current smoking, use of a walking aid, a history of prevalent non-
vertebral fractures at or after age 50 years and, for women, age at menopause. 
The second model includes only BMD and tbe presence of a baseline prevalent 
vertebral fracture, whereas tbe tbird model includes all of tbese variables. In 
addition, table 2.2.5 shows tbe corresponding areas under tbe curves. 
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Table 2.2.3. Multivariate model of independent risk factors for incident 
vertebral fractures 
Age (years) 
55-59 
60-64 
65-69 
70-74 
75-79 
>=so 
Baseline prevalent vertebral 
fracrurc 
None 
>= 1 
History of any non-vertebral 
fracture 
No 
Yes 
LS BMD (SD decrease) 
Usc of a walking aid 
No 
Yes 
Age at natttraf menopause 
<= 45 }''I 
46-50 yr 
>SO yr 
f\Ton-natural menopause 
Smoking 
Current 
Former 
Never 
Men 
Full model 
OR (95% CI)~ 
1 
0.8 (0.3-1.9) 
1.0 (0.4-2.5) 
1.9 (0.7-4.8) 
1.5 (0.4-6.2) 
DNct 
1 (reference) 
2.2 (0.9-5.0)* 
1 (reference) 
2.4 (1.2-4.8)** 
2.3 (1.6-3.3)** 
1 (reference) 
1.0 (0.1-8.7) 
2.3 (0.5-10.5) 
1.6 (0.4-6.9) 
1 (reference) 
Women 
Full model 
OR (95% CI)~ 
1 
1.8 (0.9-3.8) 
2.0 (1.0-4.3)* 
2.2 (1.1-4.7)'* 
2.4 (0.9-5.9)* 
2.6 (0.8-8.5) 
1 (reference) 
4.1 (2.5-6.7)** 
1 
1.1 (0.7-1.8) 
2.1 (1.6-2.6)** 
1 (reference) 
2.5 (1.1-5.5)** 
1.9 (1.1-3.5)** 
1.3 (0.7-2.2) 
1 (reference) 
0.7 (0.4-1.3) 
2.1 (1.2-3.5)** 
1.2 (0.7-2.0) 
1 (reference) 
11MuJtivariate model, adjusted for age, lumbar spine BMD, presence of a 
prevalent vertebral fracture, history of any non-vertebral fracture at or after age 
50 years, age at menopause (for women only) and smoking habits. ** P < 0.05; * 
p < 0.10 
iDNC =did not compute (due to lack of cases in this subgroup) 
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Table 2.2.4. Attributable risk percentages and population attributable risk 
percentages for independent risk factors for incident vertebral fractures 
Men Women 
ORt AR(%) PAR(%) oRt AR(%) PAR(%) 
Age>= 70 1.6 37.5% 12.5% 1.9 47.4% 20.0% 
Prevalent 3.4 70.6% 15.6% 5.3 81.1% 24.3% 
vertebral 
fracture 
Non-vertebral 2.7 63.0% 18.8% 1.4 28.6% 10.0% 
fracture > = age 
50 yr 
Lumbar spineT- 4.5 77.8% 25.0% 3.2 68.8% 32.9% 
score <= -2.5 
Age atmeno- 2.5 60.0% 14.3% 
pause<= 45 
Walking aid use 0.9 0% 0% 2.4 58.3% 7.1% 
Current smoking 3.3 69.7% 50% ?' --~ 56.7% 11.4% 
tAll odds ratio's (except for age over 70) were adjusted for age 
AR = Attributable risk 
PAR = Population attributable risk 
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Figure 2.2.1. ROC curves for incident vertebral fractures in men and 
women 
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Table 2.2.5. Areas under the curves for men and women 
Modell 
Model2 
Model3 
Men 
0.65 (0.56-0. 73) 
0.74 (0.66-0.81) 
0.78 (0.71-0.85) 
Women 
0.71 (0.66-0.76) 
0.74 (0.69-0.79) 
0.78 (0.73-0.83) 
Model 1 includes age, weigh4 current smoking, use of a walking aid, history of 
prevalent non-vertebral fractures at or after age 50 years and, for women, age at 
menopause. Model 2 includes BMD and the presence of prevalent vertebral 
fractures at baseline. Model 3 includes age, weight, current smoking, use of a 
walking aid, history of prevalent non-vertebral fractures at or after age 50 years 
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and, for women, age at menopause, as well as BMD and the presence of 
prevalent vertebral fractures at baseline. 
Overall, both for men and for women, incident vertebral fracture prediction was 
strongest when combining all factors. In women, however, the clinical risk 
factors alone also provided a relatively good prediction model. For men, 
vertebral fracture prediction was much improved when (additional) information 
on BMD and prevalent vertebral fractures was present. This could be expected 
since in men, only a history· of non-vertebral fracru.res was a significant risk 
factor for incident vertebral fracture. 
Discussion 
In a previous study we have already shown that a low BMD and the presence of 
at least one baseline prevalent vertebral fracture are strong independent risk 
factors for incident vertebral fractures in both men and women. (20) In the 
present study we observed that age, current smoking, use of a walking aid and an 
early menopause are also strong, independent risk factors for incident vertebral 
fractures in women. In men, only a history of a prevalent non-vertebral fracture 
is an additional significant risk factor for incident vertebral fractures. 
In the present study, our aim was to investigate potential risk factors for incident 
vertebral fractures. Those risk factors investigated are known risk factors for a 
low BMD, hip fractures or both. (11,13,15,17,19,34,39) To our knowledge, so far 
no studies on risk factors for incident vertebral fractures were performed, other 
than low BMD, prevalent vertebral fractures and physical activity. (21,22) Some 
cross-sectional studies on risk factors for prevalent vertebral fractures have been 
performed, but due to the cross-sectional design it is difficult to draw 
conclusions on causality and temporal relationships from these studies. (23-31) 
In contrast to hip fractures, vertebral fractures mainly occur spontaneously. 
(40,41) Therefore, is was not surprising that recent falling before baseline was 
not associated ·with increased vertebral fracture risk. In addition, a lower limb 
disability was no longer associated with increased vertebral fracture risk after 
adjustment for age, suggesting that lower limb disability is merely a marker for 
older age. 
In women, but not in men, incident vertebral fractures risk increased strongly 
with age. Cross-sectional data from the EVOS study already suggested that age 
was more strongly associated with prevalent vertebral fractures in women than in 
men. ( 42) The lack of association between increasing age and incident vertebral 
fractures in men is probably related to selective survival. To be eligible for this 
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study, subjects had to visit our research center for the second follow-up 
examination, resulting in a health selection bias. Men have a lower life 
expectancy than women do and vertebral fractures are associated '.Vith increased 
mortality. This could imply that primarily d1e older men with vertebral fractures 
would no longer be in our study, resulting in selection of healthier elderly men. 
The effects of estrogen on bone are well established. (43-45) This study 
strengthens the importance of estrogen exposure further by showing that an 
early age at menopause is associated with an increased incident vertebral fracture 
risk. This effect appears limited to women whose age at menopause was before 
or at age 45 years, which was 11 percent of the whole female population. 
\Vomen with a non-natural menopause more often took HRT, thereby 
supplementing their estrogen deficiency. Long-term and short-term HRT use 
and oral contraceptive use were all univariately associated "W-ith a decreased 
incident vertebral fracture risk, but these associations disappeared after adjusting 
for age. In the Netherlands oral contraceptives were not frequendy prescribed 
until the mid si.~ties, resulting in only the; younger women in our cohort ever 
using these drugs. 
The impact of the risk factors described on overall vertebral fracture incidence 
was evaluated by calculating both attributable risks and population attributable 
risks. In comparison, Hak et a!. recendy reported that in women from the 
Rotterdam Study, the population attributable risks of hypercholesterolemia and 
hypertension in myocardial infarction were 18 % and 14 %, respectively. ( 46) 
Thus, many of the risk factors studied here have more impact on the 
pathogenesis of incident vertebral fractures than either hypercholesterolemia or 
hypertension have on myocardial infarction. 
Overall, for both men and women, a model including both easily assessable risk 
factors, BMD and presence or absence of prevalent vertebral fractures best 
predicted incident vertebral fractures. For women, however, a model including 
only easily assessable risk factors resulted in approximately the same predictive 
value for incident vertebral fractures as known cardiovascular risk factors have in 
the prediction of cardiovascular and cerebrovascular disease (area's were 0.71 
and 0.72, respectively). (37) This suggests that these risk factors might be used in 
a clinical setting as a first screening tool for incident vertebral fracture risk. On 
basis of the outcome of such a risk score, it can be assessed whether measuring 
BMD would be of additional value. 
There are limitations to this study. Even though this is a large single-cohort 
population-based study, some health selection bias is present, as mentioned. In 
contrast to other types of fractures, vertebral fractures primarily occur 
spontaneously and only about one third of subjects has such complaints that 
they will come to clinical attention. (40,41) Thus, the only way to investigate all 
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incident vertebral fractures is to examine baseline and follow-up radiographs of 
the spine. Therefore, a selection bias is unavoidable in studies on incident 
vertebral fractures. Due to this selection bias, the subjects included in our study 
may not be representative for all subjects 'W~th vertebral fractures in the general 
population. 
In conclusion, the results of this study show that in women, besides low BMD 
and the presence of baseline prevalent vertebral fracture, age, early menopause 
(at or below age 45), current smoking and use of a walking aid are strong and 
independent risk factors for incident vertebral fractures. In men, only a positive 
history of non-vertebral fractures is an additional independent risk factor. 
Current smoking was associated with an increased vertebral fracture risk, but in 
men this did not reach statistical significance. 
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Chapter 3.1 
Abstract 
Osteoporosis is defined by the World Health Organization as a bone mineral 
density (BMD) of 2.5 standard deviations or more below the young adult mean 
(T-score of -2.5 or less). 
We studied the sensitivity of using a T -score at or below -2.5 in order to 
identify subjects who will fracture in 3357 women aged 55 years and over from 
the population-based Rotterdam Study. BMD of the femoral neck was measured 
by dual X-ray energy absorptiometry (DXA, Lunar, DPX-L). T-scores of BMD 
were calculated for women using the NHANES reference population. Follow-
up of fractures was conducted by regularly checking the GPs patient records. 
Information on vertebral fractures was gathered by a morphometrical evaluation 
of both follow-up and baseline radiographs of the thoracolumbar spine. In total, 
517 non-vertebral fractures and 120 vertebral fractures occurred during an 
average follow-up of 6. 7 years for non-vertebral fractures and 6.3 years for 
vertebral fractures. Overall, two thirds of all fractures occurred in women with a 
T-score above -2.5. For hip fractures only, half of all fractures occurred in 
women with aT -score above -2.5. 
Thus, although using a T -score of - 2.5 SD will help to identify individuals at 
high fracture risk, overall most fractures occur above this value. The public 
health burden of fractures will not be relieved using the current criterion for 
osteoporosis. 
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Introduction 
A working group of the World Health Organization (WHO) has defined 
osteoporosis as a bone mineral density of 2.5 standard deviations or more below 
the average bone mineral density in young adult women (the T-score).(1) This 
cut-off value was ori,oinally intended for di""'onostic purposes only, and not, as is 
common practice nowadays, to be used as a treatment threshold. Given this 
development there is a clear need to investigate what the consequence of this 
approach will be for the reduction of the population burden of osteoporotic 
fractures. 
Therefore, we studied the sensitivity of using aT-score at or below -2.5 in order 
to identify subjects who will fracture in 3357 women aged 55 years and over 
from the population-based Rotterdam Study. 
Methods 
At baseline, between 1990 and 1993, bone mineral density was measured at the 
femoral neck by DXA (Lunar DPX-L). From the bone mineral density, T -scores 
were calculated using the NHANES reference population. (2) Peak bone mass, 
as converted to Lunar values, was 1.04 g/cm2 (SD 0.14). The absolute bone 
mineral density cut-offvalue for osteoporosis (T-score = -2.5) was 0.69 g/cm2• 
The occurrence of incident non-vertebral fractures was continuously monitored 
through general practitioners. Each reported event was independently validated. 
All non-vertebral fractures were coded according to 10rl' revision of the 
International Classification of Diseases independently by two research 
physicians. If there was disagreement, consensus was reached in a separate 
session. A medical expert in the field reviewed all coded events for a final 
classification. During an average follow-up of 7.2 years, 517 women suffered at 
least one non-vertebral fracture. 
For vertebral fractures, spinal radiographs were obtained at baseline and again 
after an average follow-up of 6.3 years. The follow-up radiographs were scored 
for vertebral fractures using the McC!oskey-I<znis assessment method.(3) 
Whenever a vertebral fracture was detected the radiograph was compared with 
the baseline radiograph. If this fracture was not present at baseline, it was 
considered an incident fracture. Data on vertebral fractures were available for a 
subset of 1785 women, 120 of which suffered an incident vertebral fracture. 
Results 
Figure 3.1.1 shows the prevalence of osteoporosis and osteopenia for women 
from the Rotterdam Study. Overall, the prevalence of osteoporosis in the 
Rotterdam Study was 16.9 % for women. The prevalence of osteoporosis 
increased v.rith age, reaching 41.9 °/o in women aged 85 years or over. 
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randomized controlled trials have sho'>m a 50% risk reduction 'CV-ith both hip 
and vertebral fractures for bisphosphonates. (5-11) In addition, several other 
therapeutical options for fracture prevention are available, such as hormone 
replacement therapy (HR1) and selective estrogen receptor modulators 
(SER.J.\1s). (12-16) However, as the !Ugh-risk group of incli,-iduals with 
osteoporosis constimtes only 15 % of the population over 55 years, reducing the 
incidence of fractures in that group only will not be sufficient to adequately 
relieve the public health burden of fractures. 
This smdy shows that using only a T -score at or below -2.5 SD as a criterion for 
interventions will unfortunately not resolve the population burden of fractures. 
There is a clear need for the development of more sensitive risk tools, using not 
only bone mineral density, but also other clinical predictors of for fractures. 
Using such an approach, we might be able to more accurately identify those 
subjects who are at risk for fractures. 
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Abstract 
In post-menopausal women, the T-score for bone mineral density (Bl\ID) is a 
well-accepted diagnostic criterion for osteoporosis. It is also used to assess 
fracture risk. It is unclear, however, whether in elderly men similar BMD 
thresholds should be used. Different hypotheses have been proposed for the 
relation of Bl\ID with hip fracture risk in men. In this study we tested those 
hypotheses using a mathematical model and we compared the calculated results 
with observed prospective data from the Rotterdam Study. In the model, we 
combined the observed femoral neck Bl\ID distribution for men and women 
with previously derived hip fracture risk functions based on age and Bl\ID. For 
men, we tested different hypotheses for the relation of Bl\ID "'ith hip fracture 
risk. Either, the relation of Bl\ID 'W~th hip fracture risk is similar in men and 
women (scenario 1), or the relative risk (RR) per standard deviation (SD) 
decrease of BMJ) is either larger or smaller in men than in women (scenario 2a 
and 2b), or at a similar absolute fracture risk, men have a higher Bl\ID (scenario 
3). In the prospective data men with a hip fracture had an average Bl\ID that was 
0.070 g/ cm2 higher than women with a hip fracture. The calculated results from 
the first scenario were consistent with those data and were also consistent with 
the observed hip fracture incidence and the observed female to male (F /M) risk 
ratio (1.7). When the RR for each SD decrease of Bl\ID was assumed to be 
either larger or smaller in men than in women (second scenario) the calculated 
average BMD difference in men and women became respectively smaller or 
larger than observed. When men would have a higher fracture risk at similar 
Bl\ID levels (third scenario), the calculated total number of hip fractures 
increased and even exceeded that in women, with a F /M risk ratio of 0.94 in our 
example. In women a larger proportion of hip fractures occurs at a T -score 
below .-2.5 than in men using the same absolute Bl\ID threshold, but using a 
male specific T-score largely solves this dia,onostic problem. Taken together, the 
average hip fracture risk in men is much lower than in women, but appeared to 
be similar at the same Bl\ID. Therefore, we propose the use of the same absolute 
Bl\ID thresholds for decisions about interventions. 
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Introduction 
Osteoporotic fractures and mainly hip fractures cause major morbidity and 
mortality in the elderly. (1) Consequently, fractures generate substantial costs due 
to acute hospital treatment and subsequent rehabilitation. (2,3) Most of those 
fractures occur in women since they have a higher incidence of fractures at any 
given age and because of their higher life e."pectancy. ( 4) Therefore, most 
attention in hip fracture prevention was focused on women and only few 
epidemiological studies have investigated osteoporosis and fractures in men. (5-
7) Recently, however, osteoporotic fractures in men have attracted more 
attention, also in intervention trials. (8-10) Even though the societal burden is 
smaller, osteoporotic fractures also have an important impact on men. 
Therefore, it is necessary to develop diagnostic and intervention standards for 
men. 
Osteoporosis is defined as a condition characterized by low bone mass and 
rn.icro-architecrural deterioration of bone tissue, with a consequent increase in 
bone fra,oility and susceptibility to fracture. (11) For dia,onostic purposes 
osteoporosis in women was defined as a bone mineral density (BMD) of 2.5 
standard deviations (SD) below the average for young adult women, the so-
called T-score. (12) 
There is uncertainty about how this defmition should be used in men. Should the 
same T -score be used in men based on female reference values or should a 
gender-specific T-score be calculated, based on the BMD in young adult men 
and if so what are the appropriate thresholds? This debate was recently 
summarized in a review article published in this journal. (13) Some studies have 
suggested that men fracture at the same absolute B1v1D level as women do, 
(4,5,13,14) and that therefore the same absolute BMD threshold should be used. 
Other studies suggest a relation between B;yrr) and hip fracture risk that is 
different in men and women.(13,15,16) Orwoll pointed out that in most studies 
on fracture patients, men have, on average, a higher B;yrr) than women. (13) At 
first sight this appears to be at odds with a relation between BMD and fracture 
risk that is similar in men and women. 
We studied whether the relation of BMD 'With hip fracture risk is similar in men 
and women, whether the gradient of risk per SD lower BMD is either higher or 
lower or whether men llitve a similar hip fracture risk at a higher BMD than 
women. We have approached this question by mathematical modeling, 
combining the different hip fracture risk assumptions 'With the known BMD 
distribution in men and women to calculate the hip fracture distribution by 
BMD. Subsequently we compared the calculated results with observed 
prospective data from the Rotterdam Study. We also used the results to discuss 
diagnostic and intervention BMD thresholds in men. 
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Methods 
Iaputdata 
In a mathematical model we combined the relation of BMD and hip fracture risk 
with the BMD distribution to calculate the hip fracture distribution by BMD in 
the population. Previously, we estimated the hip fracture risk by gender, age and 
BMD, based on Dutch hip fracture registration data and the distribution of 
BMD. (4) The resulting risk functions (one-year cumulative hip fracture 
incidence) were validated over almost 4 years of follow-up in the prospective 
part of the Rotterdam Study. (5) This is a population-based prospective cohort 
study of the occurrence and determinants of disease and disability in 7983 elderly 
men and women in a suburb of Rotterdam, the Netherlands. Aims and design of 
this study were described previously. (17) 
We also used the BMD distributions for men and women observed cross-
sectionally in the Rotterdam Study in a sample of 5814 independently living men 
and women aged 55 years and over. ( 4) BMD was measured at the femoral neck 
using a Lunar DPX-L densitometer. 
The model was developed using an Excel spreadsheet (Microsoft Corp. USA). 
Calculations were made for several ages between 65 and 80 years and results are 
described for age 70. We have chosen this age because at 70 the hip fracture risk 
begins to increase rapidly. 
Modeling assumptions 
The baseline hip fracture risk functions by age, gender and BMD were described 
previously. (4,5) These risk functions show an exponential increase in hip 
fracture risk 'With lowering BMD and additionally an increase in risk with a,oing. 
The curves for men and women (at the same age) almost overlap. For women 
we used the baseline risk function. For men we used different scenarios 
reflecting the different hypotheses about the relation of BMD "'ith hip fracture 
risk in men. 
Scenario 1 
In scenario 1 we used the baseline risk function for men. In this scenario the 
relative risk (RR) for hip fracture per SD decrease in BMD is 2.6 for both men 
and women while the absolute risk level by BMD is very similar. ( 4) 
Scenario 2 
In scenario 2 the risk function was modified to reflect either a higher or lower 
RR per SD decrease in BMD in men. Arbitrarily, we choose a RR of either 3.6 or 
1.6 for men in this second scenario and they will be referred to as scenario 2a 
and 2b. 
Scenario 3 
In scenario 3 the RR was assumed to be the same in men as in women but now 
the relation of BMD with fracture risk was shifted so that men had a similar 
64 
Osteoporosis in men and women 
fracture risk at a BJ.\!ID level 0.070 g/ em' higher than in women. This shift 
corresponds to the average BJ.\!ID difference between men and women at the 
same age. ( 4) 
The relation of femoral neck BJ.\!ID with the one-year hip fracture risk at age 70 
for women and for the different scenarios in men is shown in·figure 3.2.1. 
Figure 3.2.1. One-year hlp fracture risk by femoral neck BMD at age 70 in 
women (F), and for the three different scenarios in men (similar risk M1, 
higher or lower RR per SD M2a and M2b, or a higher risk at the same 
BMDM3). 
0%0~==:~~~~~ ..... 
0.5 0.6 0.7 0.8 0.9 1.0 
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Number of Hip Fractures 
From the BJ.\!ID distribution at a given age we derived the proportion of the 
population at a specific BJ.\!ID level. Next, we calculated the hip fracture risk that 
corresponds to this BJ.\!ID level, as shown in figure 3.2.1. Finally, we multiplied 
the proportion of the population at a specific BJ.\!ID level with the corresponding 
hip fracture risk to obtain the number of hip fractures at that specific BJ.\!ID 
level. \Vhen this was done across the whole range of BJ.\!ID values, we obtained 
the distribution of hip fractures. The sum of all these values corresponds to the 
one-year cumulative .incidence at that age. 
In women at age 70, for example, about 3% have a BJ.\!ID of exactly 0.80 g/ em'. 
This BJVID corresponds to a one-year hip fracture risk of 0.2 %. The calculated 
number of fractures, at age 70, contributed by women with a BJ.\!ID of 0.80 
g/cm' was therefore 0.006% (3% * 0.2%). \Vhen the same was done for all 
BJ.\!ID values the total 1-year incidence for women at age 70 became 0.31 % or 
3.1/1000. 
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Comparison with observed data 
We compared these distributions to the observed prospective data to determine 
which of the different scenarios are possible. Femoral neck B:MD was measured 
at baseline between 1990 and 1993 and hip fracture follow-up was obtained as 
described previously. (5,18) For this analysis, follow-up started at the time of 
B:MD measurement and ended either at the time of hip fracture, death or 
December 31, 1999, whichever occurred first. 
We also used the hip fracture distributions to examine diagnostic and 
intervention B:MD thresholds in men. To do this, we calculated at which 
threshold of B:MD a similar proportion of hip fractures would be captured in 
men as would be in women at a T -score of -2.5. 
Results 
Observed BMD in Hip Fracture cases and controls in the Rotterdam Study 
Valid hip fracture follow-up in individuals with femoral neck B:MD measured at 
baseline was available for 5794 participants, and 156 hip fractures occurred 
during an average follow-up of 7 years (range 0.01 - 9.4). The average baseline 
B:MD in men and women "IN-ith and without hip fractures during follow-up is 
given in table 3.2.1. Average B:MD was 0.070 g/cm2 (95 % CI: 0.025-0.115) 
higher in male fracture cases than in females, and an almost similar difference of 
0.065 g/ cm2 (0.058-0.072) was observed in controls. 
Table 3.2.1. Observed average baseline femoral neck BMD (g/ cm1 in 
men and women with and without hip fracture during follow-up. 
Number 
Average B:MD 
95 %CI 
Men 
Hip fracture No hip 
36 
0.768 
(0.739-0.797) 
fracture 
2401 
0.878 
(0.872-0.883) 
Women 
Hip fracture No hip 
120 
0.698 
(0.675-0.721) 
fracture 
3237 
0.813 
(0.808-0.817) 
Observed BMD distributions and Hip Fracture incidmce rates 
Figure 3.2.2 shows the femoral neck B:MD distribution for women and men 
aged 70 based on data from the Rotterdam Study. ( 4) The average B:MD at age 
70 was 0.802 g/ cm2 in women and 0.869 g/ cm2 in men. In Dutch national 
registration data the absented one-year cumulative hip fracnrre incidence at age 
70 was 3.2/1000 in women and 1.9/1000 in men, and the female to male 
fracture incidence ratio was 1.7. (4) 
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Figure 3.2.2. The distributions of femoral neck BMD in men (M) and 
women (F) at age 70. 
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Calculated Hip Fraaure distributions by BMD 
The calcuhted hip fracture distributions at age 70 for women and for the 
different scenarios in men are shown in figure 3.2.3 and detailed results for all 
ages are shown in table 3.2.2. For women the calculated average femoral neck 
B:MD in female fracture cases at age 70 was 0.679 g/ em' and the calcuhted one-
year hip fracture incidence was 3.1/1000. 
Scenario 1 
Using the baseline scenario in men (similar fracture risk in men as in women, see 
fJgUte 1 ), the calculated average B:MD in 70 year old male fracture cases was 
0.743 g/cm2• This was 0.064 g/cm2 higher than in women. The calculated one-
year incidence in men was 1.9/1000 and the female to male risk ratio was 1.7. 
Scenario 2 
In scenario 2a, assuming a higher RR in men than in women (RR 3.6 versus 2.6), 
the distribution of hip fractures by B:MD in men shifts to the left, and the 
calculated average B:MD at age 70 was only 0.021 g/ em' higher than in women. 
In scenario 2b, assuming a lower RR in men (RR 1.6 versus 2.6) the average 
B:MD difference at age 70 was 0.126 g/cm2• With both assumptions the female 
to male ratio was 1.7. 
Scenario 3 
In the third scenario we assumed that the relation of B:MD with fracture risk was 
shifted to the right in men by 0.070 g/ cm2 and that the RR was similar in men 
and women. Here, the calcuhted average B:MD in fracture cases was higher in 
men that in women and the same as in scenario 1. But, in scenario 3 the 
calculated number of hip fractures at the age of 70 increased to 3.3/1000, 
exceeding that in women and the female to male incidence ratio was only 0.94. 
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Figure 3.2.3. Hip fracture distribution by femoral neck BMD at age 70 in 
women (F), and for the three different scenarios in men (similar risk M1, 
higher or lower RR per SD M2a and M2b, and a higher risk at the same 
BMDM3). 
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Hip fractttres and BMD thresholds: men compared to women 
Figure 3.2.3 shows that for all scenarios, the proportion of fractures occurring 
below any specific BMD value was higher in women than in men. In figure 3.2.4 
this is illustrated for a female T-score of -2.5 comparing the calculated hip 
fracture distributions at age 70 for women and for the first scenario in men. The 
bone densities measured in our female population corresponded to the Lunar 
US Female Reference Data Base used by the machine (Lunar Corp, Madison, 
WI, USA), and a female-specific T -score of -2.5 corresponded to a BMD of 
0.675 g/ cm2• In the model, half of the hip fractures in women occurred at or 
below this threshold at the age of 70. Using the same absolute BMD value in 
men only 32 % of the hip fractures were captured. If we wanted a threshold that 
also captures half of the hip fractures in men the threshold needed to move 
upward and became 0.740 g/cm2• Based on female reference values this 
corresponded to a T-score of -2.0, but using male reference data this 
corresponded to a T-score of -2.7. \Vith a male specific T-score equaling -2.5 
(0.769 g/ cm2) almost 60 % of the hip fractures were captured. 
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Figure 3.2.4. BMD threshold that captures the same proportion of hip 
fractures In men (M) as a T-score=-2.5 In women (F). 
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Other ages 
The above results were described for men and women aged 70. Table 3.2.2 also 
gives these results at other ages. At those other ages we obtained simihr results 
but at other levels of absolute incidence and average B.MD. The general 
conclusions, however~ are similar to those at age 70. 
Discussion 
In participants from the Rotterdam Study who suffered a hip fracture during 
follow-up, the average baseline B.MD was 0.070 g/ cm2 higher in men than it was 
in women. Assuming a similar relation between femoral neck B.MD and hip 
fracture risk in men and women the difference in the calculated average B.MD 
was almost the same in the modeL Moreover, the results were also consistent 
with the observed hip fracture incidence in the Netherlands and with the 
observed female to male (F /M) risk ratio of 1.7. (4) 
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Table 3.2.2. Women compared to men at different ages: calculated 
average femoral neck BMD (g/ em") in hip fracture cases, calculated one-
year hip fracture incidence (/1000), female to male (F /M) hip fracture 
incidence ratio and proportion of hip fractures occurring at or below a 
female T -score of -2.5. 
Aue 
65 70 
Mean Inc. F/M T<-2.5 Mean Inc. F/M T<-2.5 
BMD BMD 
Women 0.70 1.6 44% 0.68 3.1 50% 
Men 
Scenario 1 (RR=2.6) 0.76 0.96 1.7 28% 0.74 1.9 1.7 32% 
Scenario 2a (RR=3.6) 0.72 0.96 1.7 39% 0.70 1.8 1.7 44% 
Scenario 2b (P.R=1.6) 0.82 0.95 1.7 14% 0.81 1.9 1.7 17% 
Scenario 3 0.76 1.7 0.92 28% 0.74 3.3 0.94 32% 
(shifted 0.07 J!.l m/) 
Aue 
75yr 85yr 
Mean Inc. F/M T<-2.5 Mean Inc. F/M T<-2.5 
BMD BMD 
Women 0.66 5.9 57% 0.63 10.5 64% 
Men 
Scenario 1 (P.R=2.6) 0.73 3.4 1.7 36% 0.71 6.0 1.7 40% 
Scenario 2a (RR:=3.6) 0.69 3.4 1.7 48% 0.67 6.0 1.8 53% 
Scenario 2b (P.R=1.6) 0.79 3.4 1.7 20% 0.78 6.1 1.7 23% 
Scenario 3 0.73 6.2 0.95 36% 0.71 10.9 0.96 40% 
(shifted 0.07 J!.l em') 
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\'V'hen we assumed that the RR per SD decrease in BMD was either higher or 
lower in men than in women, the calculated difference in average B::rvill 'i.Vas 
respectively smaller or higher than observed. Therefore, we consider this 
hypothesis less likely and, even if the RR is different in men and women, this 
difference can only be small 
Assuming that men have a simihr hip fracture risk at a higher BMD the 
calculated incidence of hip fractures seriously increased and the female to male 
hip fracture risk ratio even reversed. This does not correspond to observations 
in the Netherlands and in most other countries, ( 4,5, 19) making this third 
scenario highly unlikely. 
\'V'hen we repeated the calculations at ages other than 70 we confirmed that the 
scenario where the relation of BMD with hip fracture risk is very simihr in men 
and women is the most consistent with the prospective obser;rations in our 
population. 
This conclusion is important for the definition of a BMD threshold in men. We 
illustrated this using aT-score of -2.5, the agreed definition of osteoporosis in 
women. (12) In women at age 70, only half of the hip fractures occurred below 
that threshold. This is so because hip fractures also occur in women who do not 
have osteoporosis. At the age of 70 this group of non-osteoporotic women is 
relatively large. With a,<>ing the proportion of women '>Tith a T -score below -2.5 
increases and as a consequence the calculated proportion of hip fractures 
occurring below that threshold also increased up to 64% at the age of 80 (table 
3.2.2). In men, using the same absolute BMD threshold, the proportion of hip 
fractures below that female specific value was much lower. 
Capturing a similar proportion of fractures in a population is important if we 
have the intention to evenly reduce the burden of illness in both men and 
women. Our analyses show that, whatever the proportion of fractures we want 
to capture, the absolute BMD cutoff value will always be higher in men than in 
women. The use of a gender-specific T-score largely solves this dia,onostic 
problem. (12) 
However, when cost-effectiveness of inter;rentions is the goal, and assuming 
equal efficacy in men and women, absolute fracture risks are more important 
since the numbers needed to treat with an intervention are directly influenced by 
the fracture incidence in those in whom an intervention is undertaken. This is 
demonstrated in intervention trials where including populations with a different 
fracture incidence leads to different numbers needed to treat even with the same 
intervention. (20,21) Since men have a lower hip fracture incidence than women, 
fewer men than women reach the required fracture risk threshold to make an 
intervention cost-effective. Therefore, when cost-effectiveness is the main 
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Abstract 
Low estrogen exposure throughout life is thought to result in low bone mineral 
density (BMD) and an increased incidence of cardiovascular disease. In the 
Rotterdam Study, we cross-sectionally examined the relation between BMD and 
peripheral arterial disease (PAD), as assessed by an ankle-arm index (AAI) of < 
0.9 in either leg. Data on BMD and PAD were available for 5268 individuals 
(3053 women). From the BMD, Z-scores were calculated, which were 
subsequently divided into tertiles. Logistic regression analysis was used to 
compute odds ratios (OR) for PAD in tertiles ofBMD, using the upper tertile as 
a reference. When adjusting for age, women with a low femoral neck BMD had a 
significantly increased risk of PAD (OR= 1.49, 95% CI 1.16-1.91) This could 
not be found for men (1.14, 0.84-1.53). The mid tertile did not differ from the 
reference in either men or women. In women, additional adjustment for several 
potential confounders resulted in a somewhat lowered risk estimate (1.35, 1.02-
1.79). In contrast, no association between lumbar spine BMD and PAD could be 
observed in either men or women. Our study shows an association between low 
femoral neck BMD and PAD in women only. This association is unlikely to be 
causal. Estrogen deficiency may be the common denominator in osteoporosis 
and PAD, resulting in clustering of these two major diseases in postmenopausal 
women. 
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Introduction 
Recently, an association bet\Veen osteoporosis and atherosclerosis, t\VO frequent 
diseases of the elderly has been suggested in women. (1-6) Since both 
osteoporosis and atherosclerosis share major risk factors such as low estrogen 
exposure, low physical activity, body mass index and smoking, it is relevant to 
study these common etiological factors. These factors may at least in part explain 
the suggested relation bet\N·een these t\Vo major diseases. 
In women, the association between bone mineral density (BMD) and 
atherosclerosis at different sites has been investigated in several studies, (1,2,4-6) 
whereas in men only one small study has been performed. (3) 
In elderly women, V ogt et a!. found that after adjusting for age, BMD decreased 
\vith a decreasing ankle-arm index (AAl). (4) However, after additional 
adjustment for smoking and body mass index this relationship disappeared. In 
addition, women with a decrease in AAl during a year lost more bone than 
women whose AAl remained stable. Furthermore, in women, studies have been 
performed focussing on other sites of atherosclerosis, such as in the coronary 
arteries, (1) the aortic wall, (2,5) or in the carotid arteries. (6) Although most of 
these studies have found an association between BMD and atherosclerosis as 
well, not all potential confounders (such as age at menopause and exercise) have 
been fully investigated. Furthermore, these studies have all assumed the 
relationship between BMD and atherosclerosis to be linear, which is not 
necessarily the case. One small study has observed a local effect of 
atherosclerosis on bone mineral density in men --w-ith asymmetrical peripheral 
arterial disease (PAD). (3) 
In the present study, we investigate the association betw"een B11D measured at 
the femoral neck and PAD, a marker of both local and generalized 
atherosclerosis. (!,8) This study is the first large population based study of 
osteoporosis and PAD to include both elderly Caucasian men and women. 
Materials and methods 
Study population 
The Rotterdam Study is a prospective cohort study of individuals aged 55 years 
and over. Its aim is to investigate the incidence of, and risk factors for, chronic 
disabling diseases in the elderly. The rationale and study design have been 
described previously. (9) The focus of the Rotterdam Study is on neurologic, 
cardiovascular, ophthalmologic and locomotor diseases. All10,275 inhabitants of 
Ommoord, a district in Rotterdam, the Netherlands, were invited to participate. 
Of these participants, 7,983 entered the study (response rate 78%). At baseline, 
between 1990 and 1993, 6,451 were able to visit the research center. Of those, 
BMD was measured in 5,819 participants (3,374 women), all of whom were 
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living independently. Of these, information on AAI was available for 5,268 
persons, of whom 3,053 were females. The Rotterdam Study has been approved 
by the Medical Ethics Committee of Erasmus Medical Center. 
Clinical examination 
Peripheral arterial disease measurement. 
The presence of PAD was evaluated by measuring the systolic blood pressure 
level of the posterior tibial artery at both legs using an 8 MHz continuous wave 
Doppler probe (Huntleigh 500 D, Huntleigh Technology, Bedfordshire, UK) 
and a random-zero sphygmomanometer. (10,11) For each leg, a single blood 
pressure reading was taken '>lith the subject in supine position. The blood 
pressure in the arm was calculated as the mean of two consecutive 
measurements v.rith a random-zero sphygmomanometer at the right brachial 
artery in sitting position. The ratio of the systolic blood pressure at the ankle to 
the systolic blood pressure at the arm (ankle-arm index) was calculated for each 
leg. The lowest ankle-arm index (AAI) in either leg was used in the current 
analysis. In agreement \>lith the approach used by Fowkes et al. and by Schroll 
and Munck, peripheral arterial disease was considered present when the AAI was 
lower than 0.90 in at least one leg. (12,13) We excluded 178 participants "'-ith an 
AAI > 1.50, since this AAI usually reflects arterial rigidity preventing arterial 
compression, leading to spuriously high ankle blood pressure values. (14) 
Bone mineral densitv measurement. 
Bone mineral density measurement of the femoral neck and lumbar spine (L2-
L4) was performed by dual energy X-ray absorptiometry (DXA, Lunar DPX-L 
densitometer) as described previously. (15) BMD of the femoral neck was 
measured in one leg only. 
Measurement of covariates. 
A tralned interv--iewer performed an extensive home interv-iew on medical 
history, risk factors for chronic diseases and medication use, such as estrogen 
replacement therapy and diuretics. We categorized subjects as current, former or 
never smokers. Information on menopause, such as age and its cause, was 
obtained. Intermittent claudication was dia,onosed according to the criteria of 
WHO/Rose- questionnaire, which was included in the home interview. (16) 
Walking ability was assessed as a combination of questions on ability to walk 
outdoors and ability to climb stairs as scored in the Stanford Health Assessment 
Questionnaire. (17) After the home interview, subjects were invited to the 
research center for clinical examination and laboratory measurements. Height 
and weight were measured '>lith subjects wearing indoor clothing 'W-ithout shoes. 
Body mass ind""" was computed as weight in kilograms divided by height in 
meters squared. Subjects were classified as diabetics when they reported use of 
antidiabetic therapy (code a010 of the Anatomical Therapeutical Chemical 
classification index, WHO 1992), or when the pre- or postload serum glucose 
so 
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level was equal to or higher than 11.1 mmol/1. Serum total cholesterol levels 
were assessed by an automated enzymatic procedure in a non-fasting blood 
sample. 
Statistics 
At first, we compared continuous variables between subjects with and \Vithout 
PAD with the student's T-test. For categorical variables, a chi-square test was 
used. Subsequendy, we calculated Z-scores of both femoral neck and lumbar 
spine B.MD for men and women separately. These were then divided into 
tertiles. The Z score is the number of standard de,iations from the gender- and 
age-adjusted mean. In all our analyses, we used the upper tertile as a reference. 
We used stepwise logistic regression to compute odds ratios for PAD in tertiles 
of Z-score, adjusting for age. Analyses were repeated additionally adjusting for 
body mass index, blood pressure, smoking (current, past, never), serum 
cholesterol levels and walking ability in men. In women, besides these additional 
confounders, we also adjusted for age at menopause and use of hormone 
replacement therapy. We also computed odds ratios in strata of age ( < 65, 65-7 5, 
>75 years). For women, odds ratios were also calculated in strata of age at 
menopause. Analyses were repeated additionally adjusting for presence or 
absence of diabetes mellitus and after exclusion of subjects using diuretics, who 
had suffered a myocardial infarction or who reported the presence of 
intermittent claudication. 
Results 
Baseline characteristics are shown in Table 4.1.1. Both men and women with 
PAD are older, have diabetes mellitus more often, use diuretics more often, and 
are more likely to be current smokers. Women \Vith PAD have a lower B.MD 
than women without PAD, whereas in men this is absent. 
When adjusting for age only, women in the lower tertile of femoral neck B.MD 
had a significandy increased risk of PAD (OR = 1.49, 95% CI 1.16,1.91), 
whereas this could not be found for men (OR= 1.14; 0.84,1.53). The mid tertile 
did not significandy differ from the reference in women (OR = 1.05; 0.81,1.37) 
or in men (OR= 1.13; 0.83,1.53). (fable 4.1.2) Additional adjustment for body 
mass inde..'l:, systolic blood pressure, smoking (current, past, never), serum 
cholesterol levels and walking ability was made. In women, we also adjusted for 
age at menopause and use of estrogen. This resulted in somewhat lower odds 
ratios for women and men respectively (OR = 1.35; 1.02,1.79 and OR = 0.89; 
0.64,1.23). Again, the mid tertile did not significandy differ from the reference. 
These analyses were repeated for lumbar spine bone density. However, neither in 
men, nor in women a relationship between lumbar spine B.MD and PAD could 
be observed (data not shown). 
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Table 4.1.1. Baseline characteristics for subjects with and without PAD 
Men Women 
No PAD PAD No PAD PAD 
Number 1787 329 2507 477 
Age 66.4 (7.1) 71.3 (8.4) 67.2 (7.8) 72.1 (8.9) 
FNBMD 0.88 (0.13) 0.87 (0.14) 0.82 (0.13) 0.78 (0.14) 
LSBMD 1.16 (0.19) 1.16 (0.20) 1.03 (0.18) 1.03 (0.18) 
FN BMD Z-score 0.001 (0.97) 0.008 (1.02) 0.010 (0.97) -0.11 (1.06) 
LS BMD Z-score -0.013 (0.97) -0.031 (1.03) -0.011 (0.98) -0.019 (1.02) 
Body mass inde."<: 25.8 (2.9) 25.4 (3.0) 26.7 (1.0) 26.7 (4.2) 
Weight 79.2 (10.7) 76.4 (10.0) 70.1 (10.9) 68.3 (11.2) 
Age at menopause 49.0 (4.9) 48.0 (4.9) 
Serum cholesterol 6.3 (1.1) 6.4 (1.1) 6.9 (1.2) 7.0 (1.2) 
Systolic blood 137.5 (20.9) 149.0 (21.9) 137.6 (21.4) 150.7 (24.3) 
pressure 
Diabetes mellitus 9.5 18.6 9.3 18.1 
(%) 
Prevalent 15.8 27.0 6.2 14.0 
myocardial 
infarction (%) 
Diuretic users (%) 7.9 16.4 14.0 26.0 
Intermittent 0.7 9.8 0.5 4.9 
claudication(%) 
Walking disability 
(%) 
]\To 78.5 55.2 61.4 41.6 
Moderate 20.5 41.8 36.2 53.1 
Set'ere 1.1 3.0 2.4 5.3 
Smoking(%) 
Current 26.1 45.7 18.3 25.3 
Former 65.8 50.0 29.7 25.9 
1\Tever 8.2 4.3 52.1 48.7 
Values are means with standard deviations or percentages 
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In women, analyses were repeated in strata of age at menopause (Table 4.1.3). 
The risk of PAD in women with a Blv:ID in the lowest tertile is similar in 
women with an early menopause and in women -w-ith a late menopause (OR 
1.36; 0.96,1.94 and 1.42; 0.90,2.25, respectively). Additionally, both for men and 
for women, analyses were repeated in age strata of below 65 years, between 65 
and 75 years and 75 years and above (Table 4.1.4 and 4.1.5). In men, the risk of 
PAD was similar in all age categories. For women, however, the risk estimate in 
the youngest group was somewhat higher than in the two older groups. 
All analyses were repeated with adjustment for presence of diabetes mellitus and 
after exclusion of subjects with a prevalent myocardial infarction, intermittent 
claudication or current use of diuretics. All these analyses yielded similar risk 
estimates. 
Discussion 
The results of our study show that women with a Blv:ID in the lowest tertile 
have a 30 % increased risk of peripheral arterial disease as compared to women 
with a high Blv:ID, whereas subjects with an average Blv:ID did not have an 
increased risk as compared to the reference. This suggests that there is some 
threshold in Blv:ID below which an increased risk of PAD arises. In men, 
neither crude, nor after adjustment for potential confounders did we observe a 
relation between Blv:ID and PAD. 
In women, previous studies have already shown an inverse relationship between 
Blv:ID and ankle-arm index or with the prevalence of various other measures of 
atherosclerosis. (1,2,4-6) In men, however, only one small study within 17 men 
with asymmetrical severe peripheral arterial disease has been performed. (3) 
They found that the bone mineral content of the affected leg was significantly 
lower than in the unaffected leg and, therefore, they suggested that arterial 
disease could lead to local bone mineral loss. However, our study population 
consists of mainly asymptomatic subjects. 
PAD, as measured by an ankle-arm index of< 0.90, is a measure for both local 
and generalised atherosclerosis. (7,8) Both osteoporosis and atherosclerosis are 
related to several risk factors, some of which are similar for both diseases. For 
instance aging, smoking and physical inactivity both lower the Blv:ID, (18) and 
increase the risk of atherosclerosis. (19) In our analyses, adjusting for these 
potential confounders did not fundamentally affect the calculated risk estimates. 
Furthermore, analyses were repeated excluding subjects with intermittent 
claudication, which also yielded similar risk estimates. The results of these 
additional analyses suggest that the relation found is unlikely to be explained by 
these factors. 
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Table 4.1.2. Risk of peripheral arterial disease in tertiles ofZ score of 
femoral neck BMD 
Tertiles ofZ-score of femoral neck BMD 
Lower tertile Middle tertile Upper tertile 
OR (95% CI) OR (95% CI) OR (95 % CI) 
Men 
Nr of cases 
Crude 
Age acijusted 
Full mode! 
Women 
Nr of cases 
Crude 
Age acijusted 
Fullmodelf" 
119 109 
1.1 (0.8-1.5 1.0 (0.8-1.4) 
1.1 (0.8-1.5) 1.1 (0.8-1.5) 
0.9 (0.6-1.2) 1.1 (0.8-1.5) 
200 146 
1.5 (1.2-1.9) 1.1 (0.8-1.4) 
1.5 (1.2-1.9) 1.1 (0.8-1.4) 
1.4 (1.0-1.8) 1.0 (0.8-1.4) 
· Additional adjustment was made for body mass index, 
systolic blood pressure, smoking (current, former, never), 
serum cholesterol levels and walking ability. 
t Additional adjustment was made for body mass index, 
systolic blood pressure, smoking (current, former, never), 
101 
1.0 
1.0 
1.0 
130 
1.0 
1.0 
1.0 
serum cholesterol levels, walking ability, age at menopause and use of estrogen. 
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Table 4.1.3. Relationship between femoral neck BMD and PAD in strata 
of age at menopause 
Tertiles ofZ-score of femoral neck BMD 
Lower tertile Middle tertile Upper tertile 
OR (95% CI) OR (95% CI) OR (95% CI) 
50 years and 
below 
Nr of cases 
Age adjusted 
Full mode!f" 
Over 50 years 
Nr of cases 
Age adjusted 
Full modef(· 
125 
1.3 (1.0-1.8) 
1.4 (1.0-1.9) 
65 
1.6 (1.1-2.4) 
1.4 (0.9-2.3) 
100 
1.1 (0.8-1.5) 
1 2 (0.9-1.7) 
42 
0.9 (0.6-1.4) 
0.8 (0.5-1.3) 
t Additional adjustment was made for body mass index, 
systolic blood pressure, smoking (current, former, never), 
serum cholesterol levels, walking ability and use of estrogen. 
84 
1.0 
1.0 
45 
1.0 
1.0 
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Table 4.1.4. Risk of peripheral arterial disease in tertiles ofZ-score of 
femoral neck BMD in women, divided in strata of age 
Tertiles of Z-score of femoral neck BMD 
Lower tertile Middle tertile 
OR (95% CI) OR (95% CI) 
< 65 
Nr of cases 56 46 
Crude 1.8 (1.1-2.9) 1.5 (0.9-2.4) 
Full modelf 1.8 (1.1-3.0) 1.4 (0.8-2.4) 
65-75 
Nr of cases 61 46 
Crude 1.4 (0.9-2.2) 1.0 (0.7-1.6) 
Full modelf 1.3 (0.8-2.1) 1.1 (0.7-1.8) 
>75 
Nr of cases 83 54 
Crude 1.3 (0.9-2.0) 0.8 (0.5-1.2) 
Full mode!f 1.2 (0.7-1.9) 0. 7 (0.5-1.2) 
t Additional adjustment was made for body mass index, 
systolic blood pressure, smoking (current, former, never), 
Upper tertile 
OR (95% CI) 
29 
1.0 
1.0 
43 
1.0 
1.0 
58 
1.0 
1.0 
serum cholesterol levels, walking ability, age at menopause and use of estrogen. 
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Table 4.1.5. Risk of peripheral arterial disease in tertiles ofZ-score of 
femoral neck BMD in men, divided in strata of age 
Tertiles ofZ-score of femoral neck BMD 
Lower tertile Middle tertile 
OR (95% CI) OR (95% CI) 
< 65 
Nr of cases 30 38 
Crude 1.3 (0.7-2.3) 1.5 (0.9-2.7) 
Fullmodelf 1.0 (0.5-1.9) 1.4 (0.8-2.5) 
65-75 
Nr of cases 43 39 
Crude 1.0 (0.6-1.5) 0.9 (0.6-1.5) 
Fullmodelf 0.7 (0.4-1.2) 0.9 (0.5-1.5) 
> 75 
Nr of cases 46 32 
Crude 1.3 (0.8-2.2) 1.0 (0.6-1.7) 
Full modelf" 1.2 (0.7-2.1) 1.1 (0.6-2.0) 
t Additional adjustment was made for body mass index, 
systolic blood pressure, smoking (current, former, never), 
serum cholesterol levels and walking ability 
Upper tertile 
OR (95% CI) 
21 
1.0 
1.0 
40 
1.0 
1.0 
40 
1.0 
1.0 
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.Abstract 
Estrogens play an important role in the development of breast cancer, but 
studies on serum levels of estrogens have shown inconsistent results. Bone 
mineral density is considered to be a marker for lifetime estrogen e>.-posure. 
Some studies have suggested that a higher bone mass is associated with an 
increase in breast cancer risk. We investigated the association between bone 
mineral density, as measured at the lumbar spine and femoral neck, and the risk 
of breast cancer in women aged 55 or over in the Rotterdam Study, a 
population-based cohort study in the Netherlands. Information on baseline 
lumbar spine and femoral neck bone mineral density, as measured by DEXA 
(Lunar DPX-L), and cancer incidence was available for 3107 women. The 
Rotterdam Cancer Registry provided information on follow-up of incident 
cancer. After an average follow-up time of 6.5 years, 74 new cases of breast 
cancer occurred. Z-scores of lumbar spine and femoral neck BMD were divided 
into tertiles and risk estimates for breast cancer were computed by Cox' 
proportional hazards model, using the middle tertile as a reference. Breast cancer 
risk in the upper tertile of lumbar spine B.MD was doubled as compared to the 
reference after adjustment for age, weight and age at menopause (HR = 2.1 [1.1-
3.8]), whereas risk estimates for women in the lower tertile did not significantly 
differ from the reference (HR = 1.5 [0.8-2.9]). For femoral neck BMD, neither 
women with a low B.MD nor women with a high BMD had an increased breast 
cancer risk as compared to the reference. The results of this study suggest that in 
elderly women an association between lumbar spine BMD and incident breast 
cancer exists. Stimulating effects of estrogen on both trabecular bone and 
mammary cells may be responsible. 
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Introduction 
Both osteoporosis and breast cancer are common diseases in elderly women. 
There are two main reasons for studying the association between these diseases. 
First of all, exposure to estrogens may stimulate the development and 
progression of breast cancer, by stimulating mitotic activity of mammary cells 
and thereby increasing mutation risk. (1) Studies on serum estrogen levels, 
however, have shown inconsistent results, because these levels strongly vary over 
time, especially in premenopausal women. (2,3) Therefore, it is difficult to 
classify a woman's long-term exposure to endogenous estradiol by a single 
measurement. Bone mineral density, in contras~ is regarded to be a marker for 
lifelong estrogen exposure. ( 4) A high bone density, reflecting high estrogen 
exposure throughout life, may therefore be a predictor of incident breast cancer. 
The second reason for studying the association between B:MD and breast cancer 
is that hormone replacement therapy (HRT) is one of the therapeutical options 
for osteoporosis. Simultaneously, these drugs are thought to increase breast 
cancer risk. (5) Therefore, it is important to know how these two diseases 
interrelate to one another. 
Several studies have already shown a high B:MD to .be associated . ._,,ith an 
increased breast cancer risk. (6-12) Most of these studies, however, were 
performed in US populations. In these studies, the percentage of cunent 
hormone replacement therapy (HRT) users was much higher than in the 
Netherlands. (7,9,12) Although often either cunent users at baseline were 
excluded, or adjusnnent was made for use of HRT for in the analyses of these 
studies, we have to take into account that the percentage of CUrtent HRT users is 
much higher than observed in the Netherlands. This might affect the 
generalisability of these results. Furthermore, the incidence of breast cancer 
varies between countries. At age 65 or over, the breast cancer incidence rate was 
4.1 per 1000 PY in the US and 2.8 per 1000 PY in Western Europe. (13) 
The aim of this study was to investigate the association between B:MD and 
breast cancer in over 3000 Dutch women from the Rotterdam Study. 
Materials and methods 
The Rotterdam Study 
The Rotterdam Study is a prospective population-based cohort study that was 
initiated in 1990 to assess the prevalence, incidence, and determinants of diseases 
of the elderly. (14) The study focuses on cardiovascular, neurogeriattic, 
ophthalmologic, and locomotor diseases. All inhabitants aged 55 and over 
(n=10,275) of the district of Ommoord in Rotterdam, were invited to take part 
in the study. A total of 7,983 subjects (78%), 4,878 of which were women, 
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entered the study. The Medical Ethics Committee of the Erasmus Medical 
Centre has approved the Rotterdam Study. 
Baseline data collection 
Home interview and research centre visit 
A trained research assistant interviewed all participants at home. Information 
was obtained on medical history, surgical interventions, current health, and 
medication use. Detailed information was obtained on lifestyle and other 
potential risk indicators for chronic diseases. Lower limb disability was assessed 
using a modified version of the Stanford Health Assessment Questionnaire, as 
described previously. (15) Smoking status was assessed, and classified as current, 
former or never. 
At the research centre, an extensive clinical examination was performed, and 
non-fasting blood samples were tal<en. Amongst various other measurements, 
weight was measured at the research centre with the subject wearing indoor 
clothing without shoes. Bone mineral density measurements of the lumbar spine 
and femoral neck were performed by dual energy X-ray absorptiometry (DXA, 
Lunar DPX-L densitometer) as described previously. (16) In addition, lumbar 
spine and femoral neck bone mineral density were also measured at the first 
follow-up visit, between 1994 and 1995, using the same methods. 
Hormone-related determinants 
Data on age at and type of menopause (spontaneous or artificial) were collected 
during the home interview. Menopause was defined as the cessation of menses 
for at least one year. For women reporting natural menopause, age at menopause 
was defined as the self-reported age of last menstruation. For all women who 
reported menopause after gynecologic surgery and radiotherapy, and for those 
who reported any other operations before age 50 that might have induced 
menopause, information on the exact date and type of operation were verified 
using general practitioners (GP) patient records. Every individual is registered in 
the practice of one specific GP, who offers the only access to specialist and 
hospital care, and centralizes physician and hospital notes. The GP thus has a 
gatekeeper function in the Netherlands. Data on hormone replacement therapy 
(HRT) were obtained during the home interview. For all women who reported 
ever use of female hormones, data were verified in GP records. For the present 
analysis, HRT comprises hormonal substitutes for the indication of menopausal 
complaints or after oophorectomy (with or "'~thout hysterectomy) and excludes 
oral contraceptives. 
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Follow-up procedures 
Follow-up within the &tterdam Study 
The present analysis is based on follow-up data collected from baseline (1990-
1993) until December 31" 1998, comprising an average follow-up period of 6.5 
(SD 1.5) years (20,229 person-years for women). Information on vital status was 
obtained continuously from the municipal population registry. Additionally, 
follow-up events were reported by general practitioners (GPs) in the research 
area (covering 80% of the cohort) by means of a computerized system. 
Information from GPs outside the research area was obtained by regular 
checking of the patient records by research physicians. All reported events were 
verified by research physicians who independently reviewed and coded the 
information. Subsequently all coded events were reviewed by a medical expert in 
the field for final classification. 
Cancer follow-up at &tterdam Cancer Registry (IKR) 
The Netherlands Cancer Registry is population-based, i.e. a systematic collection 
of data on all maJi,onant neoplasms and in situ malignancies occurring in a 
geographically defined population. (17) In the mid-1980s, a nation-wide cancer 
registry was set up based on nine autonomous regional registries, including the 
Rotterdam Cancer Registry (IKR) where data collection started in 1986. Since 
January 1" 1989, all Dutch hospitals are associated with one of the regional 
cancer registries and all registry data are submitted to a national database. 
Ascertainment takes place through the nation-wide pathology registration system 
(P ALGA), which is the basis for tracing medical records in hospitals. Cases with 
a clinical dia,onosis only are found through the. computerized hospital discharge 
registry (LMR). Co-workers of the cancer registry perform the coding of data 
according to a strict protocol. Repeated dia,onoses or hospitalizations for the 
same cancer are not recorded separately, so all registered events are true incident 
cases. 
Incident cancer 
Information on cancer incidence in women was obtained by linking the 
Rotterdam Study data files to the Rotterdam Cancer Registry (IKR). The IKR 
obtains data from hospitals in the Rotterdam City area and near surroundings. 
Incident cancers were coded according to the ICD-9 system. The present study 
focuses on first-ever incident breast cancers (ICD-9 code 174). Ascertainment of 
cancer was complete till December 31, 1998. 
Data available for analysis 
Of the 4878 women in our cohort, 151 did not sign the informed consent form 
for the retrieval of follow-up information, and were therefore excluded from the 
study population. Of the remaining 4 727 women, 125 had been dia,onosed with 
breast cancer before baseline. For 149 5 women, no information on either BMD 
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(lumbar spine or femoral neck), age at menopause or body weight was available. 
Tbis was primarily due to the fact tbat these women were not able to come to 
our research centre. Thus, these women were also excluded from the analyses, 
leaving data on 3107 women available for the present smdy. 
Statistical analysis 
Differences in baseline characteristics were compared using smdent's t- test for 
continuous variables and Chi-square for categorical variables. For all other 
analyses, Cox's proportional hazard regression analysis was used. We calculated 
follow-up time as the number of days from B.MD measurement until the first-
ever incident breast cancer, death or December 31" 1998, whichever occurred 
first. First, hazard ratios for incident first-ever breast cancer were calculated per 
standard deviation increase in absolute femoral neck and lumbar spine B.MD, 
both crude and after adjustment for age. 
Since B.MD is strongly age-dependent, we thereafter corrected for age by 
e"-pressing B.MD (both lumbar spine and femoral neck) as Z-scores; the 
deviation from the age adjusted average expressed in standard deviations (SD). 
Tbis Z-score was then divided into tertiles. 
Age at menopause was divided into quartiles, using the lowest quartile as a 
reference, since these women had the shortest rime of estrogen exposure. 
Potential confounders were tested for univariate association with breast cancer 
andB.MD. 
Relative risks for the lower and upper tertiles of B.MD were computed 
univatiately and multivatiately. We used the middle tertile as the reference, since 
these subjects have an average (normal') B.MD in the population. In the base 
analysis, adjustment was made for age only. In a second analysis, we additionally 
adjusted for other potential confounders, namely weight and age at menopause. 
Analyses were repeated "'ith additional adjustment for smoking habits, physical 
activity and ever use of HRT. 
Yearly percentages of bone loss between the baseline and first follow-up -,isit 
were calculated, and the average loss was compared between women "'ith and 
without breast cancer. Women who had their breast cancer before the first 
follow-up visit or women who did not have their B.MD measured at the follow-
up visit were excluded from these analyses (35 breast cancer cases). Adjustment 
was made for age and weight, and subsequendy for baseline B.MD. 
SPSS 10.0 for windows was used for all analyses. 
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Results 
After an average follow-up time of 6.5 years (SD 1.5), 74 new breast cancer cases 
occurred in 3107 individuals. Thus, the overall incidence in our study population 
is 3. 7 per 1000 person years. 
Table 4.2.1 shows the baseline characteristics of the study group. Women with 
breast cancer are on average nearly three years younger. They are also somewhat 
heavier, older at menopause and have a higher BMD (both femoral neck and 
lumbar spine) than non-cases. No differences in physical activity, smoking and 
other relevant lifestyle factors could be observed. 
Table 4.2.1. Baseline characteristics of women with and without breast 
cancer during follow-up 
Breast cancer No breast p-value 
cancer 
Number 74 3033 
Age (yrs) 65.5 (6.9) 68.1 (8.1) < 0.01 
Weight (kg) 71.4 (10.7) 69.8 (10.8) 0.21 
Age at menopause (yrs) 50.2 (4.6) 48.8 (4.9) 0.01 
Lumbar spine BMD (g/ cmZ) 1.08 (0.18) 1.03 (0.18) 0.05 
Femoral neck BMD (g/ cm2) 0.83 (0.12) 0.81 (0.13) 0.15 
Ever use of HRT 8(11.1%) 310 (10.4 %) 0.85 
Smoking habits 
Current 15 (20.3 %) 598 (19.7 %) 0.92 
Former 23 (31.1 %) 887 (29.3 %) 
Never 36 (48.6 %) 1543 (51.0 %) 
Lower limb disability 
No 37 (50.0 %) 1402 (46.3 %) 0.25 
Moderate 34 (45.9 %) 1326 (43.8 %) 
Severe 3 (4.1 %) 299 (9.9 %) 
Values are means 'IN--ith standard deviations or numbers with percentages. 
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Table 4.2.2 shows relative risks per standard deviation decrease in femoral neck 
or lumbar spine BMD. Both crude and after adjustment for age was a standard 
deviation decrease in lumbar spine BMD associated with a decreased risk of 
breast cancer, even though after adjustment for age this was only just failed to 
reach statistical significance (p-value 0.06), possibly due to low power. For 
femoral neck, no clear association between absolute BMD and incident breast 
cancer could be observed. 
Table 4.2.2. Relative risk of breast cancer per standard deviation decrease 
in femoral neck or lumbar spine BMD 
Breast cancer 
Crude 
Age adjusted 
FNBMDperSD 
decrease 
0.9 (0.7-1.1) 
1.1 (0.9-1.4) 
** p-value < 0.05, * p-value < 0.10 
LSBMD perSD 
decrease 
0.8 (0.6-1.0)** 
0.8 (0.6-1.0) * 
Table 4.2.3. Hazard ratio of incident first ever breast cancer in tertiles of 
Z-score oflumbar spine BMD 
Cases/total group 
Crude 
Age adjusted 
Age and weight 
Full mode]! 
Exclusion of women who ever 
used HRT before baseline I 
Exclusion of first vear of 
follow-up I . 
Tertiles ofZ-score ofLS BMD 
Lower tertile 
22/1020 
1.4 (0.7-2.6) 
1.4 (0.7-2.7) 
1.4 (0.7-2.8) 
1.5 (0.8-2.9) 
1.9 (0.9-3.8) 
1.3 (0.6-2.8) 
.i\llid tertile 
16/1024 
1 
1 
1 
1 
1 
1 
Upper tertile 
36/989 
2.3 (1.3-4.2) 
2.3 (1.3-4.2) 
2.3 (1.3-4.1) 
2.1 (1.1-3.8) 
2.5 (1.3-4.9) 
2.3 (1.2-4 .3) 
'
1Adjustment was made for age, weight and age at menopause 
Table 4.2.3 shows hazard ratios for breast cancer in tertiles of Z score of lumbar 
spine BMD, both crude and after adjustment for age, weight and age at 
menopause. After adjustment for possible confounders women with a lumbar 
spine BMD in the highest tertile have a 2.1 times increased risk of breast cancer 
as compared to the reference. The risk is also somewhat increased in the lowest 
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tertile but tbis is not statistically significant. To further test for a potential U-
shaped curve, Z-scores of lumbar spine BMD were added to the model both 
continuously and squared simultaneously. These terms are not statistically 
significant in the model, suggesting that no clear U-shape is present. 
With femoral neck BMD no significant differences were observed between 
tertiles, especially after exclusion of women who had ever used HRT (fable 
4.2.4). There was a slight trend, however, towards a decreased risk of incident 
breast cancer in women with a Z-score of femoral neck in the lower tertile as 
compared to the reference. 
Table 4.2.4. Hazard ratio of incident first ever breast cancer in tertiles of 
Z-score of femoral neck BMD 
Tertiles ofZ-score ofFN BMD 
Lower tertile :Mid tertile U1212er tertile 
Cases/total group 18/1009 27/1008 29/1016 
Crude 0.7 (0.4-1.2) 1 1.1 (0.6-1.8) 
Age adjusted 0.7 (0.4-1.2) 1 1.1 (0.6-1.8) 
Age and weight 0.7 (0.4-1.3) 1 1.0 (0.6-1.7) 
Full model~ 0.7 (0.4-1.4) 1 1.0 (0.6-1.7) 
Exclusion of women who ever 0.9 (0.4-1.6) 1 1.1 (0.6-1.9) 
used HRT before baseline~ 
Exclusion of first year of 0.7 (0.4-1.4) 1 0.9 (0.5-1.7) 
follow-u ~ 
,!Adjustment was made for age, weight and age at menopause 
Figure 4.2.1 and 4.2.2 show differences in time until breast cancer between 
tertiles of Z score oflumbar spine and femoral neck BMD, respectively. Women 
with a lumbar spine BMD in the highest tertile have a significantly shorter time 
till incident breast cancer as compared to women >.v:ith an average BMD. Women 
with a femoral neck BMD in the lower tertile have a somewhat longer time until 
breast cancer as compared with women in the mid tertile, even though tbis was 
not statistically significant. For women with a femoral neck BMD in the highest 
tertile, the survival curve completely overlaps with that of women in the mid 
terti! e. 
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Figure 4.2.1. Survival curve for breast cancer in tertiles of Z-score of 
lumbar spine BMD 
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Analyses repeated excluding women who ever used HRT (never, less than three 
years and more than three years) did not essentially change risk estimates (Tables 
4.2.3 and 4.2.4). Additional adjustment for smoking status or physical activity (as 
assessed by a lower limb disability score) yielded similar results (data not shown). 
To further investigate the increase in breast cancer risk in the lowest tertile of 
lumbar spine BMD, we repeated the analyses after exclusion of the first year of 
follow-up after bone mineral density measurement. We did this in order to 
exclude breast cancer potentially present at baseline (19 cases). 
For lumbar spine BMD, the hazard ratio in the lowest tertile now decreased, 
whereas the hazard ratio in the upper tertile was slightly increased (Table 4.2.3). 
For femoral neck BMD, hardly any changes were observed (Table 4.2.4). 
Finally we analyzed the association between age at menopause in quartiles and 
incident first ever breast cancer, using the lowest quartile as the reference 
category. Women whose menopause was at age 52 or above (the highest quartile) 
had a three times increased risk of developing breast cancer as compared to 
women whose menopause started before age 46 (the lowest quartile), whereas no 
difference could be observed for women in the two middle quartiles (Fig 4.2.3). 
No significant interaction between BMD and age at menopause was observed. 
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Figure 4.2.2. Survival curve for breast cancer in tertiles of Z-score of 
femoral neck BMD 
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startS to increase, whereas below that threshold the relative risk remains around 
one. In theory, vitamin D may also play a role in the observed association. One 
of the causes of low BMD in the elderly is a vitamin D deficiency. Vitamin D is 
known to be a stimulator of cell differentiation and an inhibitor of cell division, 
thereby decreasing tumor cell growth. (20) Therefore, a lack of vitamin D could 
be associated ><rith on the one hand a somewhat increased cancer risk and on the 
other hand a lower BMD. 
Some studies showed breast cancer to be associated with physical activity, even 
though these results were conflicting. (2,21) When we adjusted for physical 
activity in our analyses, by means of a lower limb disability index, we did not 
observe any change in risk estimates, suggesting that in our cohort low physical 
activity is not a likely explanation for the observed association between BMD 
and breast cancer. Smoking is thought to be associated with an increased breast 
cancer risk and a low BMD, (22) whereas ever use of HRT is associated "'ith an 
increased breast cancer risk and high BMD. (5,17) Adjustment for smoking, 
HRT use or both did not change the risk estimates, suggesting that these factors 
do not play an important role in e>:plaining the observed association either. 
A high BMD appeared to be associated with increased breast cancer risk, 
independent from higher age at menopause, suggesting that BMD is not an 
intermediary factor in the association between age at menopause and breast 
cancer risk .. Also, no interaction existed between high BMD and high age at 
menopause on breast cancer risk. 
Of course, BMD is not merely a marker for estrogen exposure. Other metabolic 
pathways and many growth factors and interleukins may be involved in the 
association between BMD and breast cancer, either alone or through stimulation 
of the estrogen pathway. For instance, both insulin and insulin-like groun:h factor 
type 1 (!GF-1) are thought to have anabolic effects on bone, and could also be 
related to the risk of breast cancer. (23-26) Also, interaction may exist between 
the IGF and estrogen metabolic pathways. (27) Furthermore, abnormalities in 
the transforming growth factor ~ (TGF-~) pathway may be involved in 
oncogenesis, particularly of breast cancer, (28) whereas they are also associated 
"'ith an increased BMD. (29) 
There are some limitations to our study. First of all, in order to have BMD 
measurements, subjects had to be able to come to the research centre. This 
could introduce a health selection bias. Breast cancer incidence rates in our study 
(3.7 per 1000 woman-years) were quite similar, however, to the incidence rate in 
women in the same age range from the general Dutch population (3.3 per 1000 
woman-years). Furthermore, a program for regular breast cancer screening in all 
women over age 50 was started in Rotterdam area in 1990. This could result in a 
relatively young age at diagnosis and therefore a higher BMD. Therefore, we 
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expressed the BMD as Z-scores, thereby adjusting for the potential confounding 
effect of age. 
The results of this study suggest that women with a lumbar spine BMD in the 
highest tertile are at a doubled risk of breast cancer as compared to women with 
an average BMD. For baseline femoral neck BMD, we could not observe a 
strong association with incident breast cancer. However, both for femoral neck 
and lumbar spine B:rvlD, in contrast to women without breast cancer, women 
with breast cancer on average gained bone. 
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Abstract 
Recent studies have shown that a low bone mineral density (BMD) is associated 
\\lith a higher risk of mortality. Most studies only investigated this relationship in 
women and presented their risk estimates per standard deviation change in 
BMD. However, when using this approach a threshold in BMD might be 
missed when relative risks are presented in the traditional way. Therefore, our 
aim was to model the relation between BMD and all cause mortality. In the 
Rotterdam Study, follow-up was complete for 5819 men and women aged 55 
and over for whom BMD data were available. During an average follow-up of 
5.4 years, 399 men and 317 women died. We calculated BMD Z-scores as 
measured at the femoral neck. Cox' proportional hazards regression was used to 
fit the model. An average BMD, reflected by a Z score of zero, was used as the 
reference. For women, no significant relationship between BMD and overall 
mortality was observed. For men, however, a cubic model best fitted the 
relationship under study, also after adjusting for age and body mass index. The 
risk of mortality increased when BMD was below average. Similar results were 
found when separate curves were made for diabetics and non-diabetics, smokers 
(ever or never), and tertiles of BMI. Excluding subjects who had suffered hip 
fractures or adjusting for the number of drugs used and for lower limb disability 
did not essentially change results. This suggests that low BMD is not mainly due 
to morbidity and impaired mobility in our cohort, which makes this a less likely 
e'--phnation for the observed relation with mortality. The results of our study 
suggest that in men a non-linear relationship between BMD and mortality e.x.ists, 
which is independent of co-morbidity, whereas in women no significant 
relationship can be observed. 
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Introduction 
It is well known that a low bone mineral density (BJVID) is a predictor for 
osteoporotic fractures (10,11,13,18). Furthermore, a positive association 
between BJVID and incidence of breast cancer has been observed, which might 
indicate that BJVID reflects lifetime exposure to estrogen (6,31). Recent studies 
suggested that a low BJVID is associated with an increased mortality risk 
(3,15,27). In addition, Kado et al. recently showed that an increased rate of bone 
loss at the femoral neck is associated with an increased mortality risk, especially 
from pulmonary causes in elderly women (16). 
Besides estrogen exposure, many other factors might affect the relationship 
bet:'\Veen BJYID and mortality, such as body mass index, smoking, or comorbidiry 
(1,4,7,12,19-21,26,28). These might affect the association between BJVID and 
mortality in several different ways. Therefore, it may not be biologically 
plausible to express the relationship between BJVID and mortality in relative 
risks per standard deviation change in BJVID, as done in previous studies 
(3,15,27). If a threshold in BJVID exists below which the risk increases, this will 
not be found when relative risks are expressed in the traditional way. 
Our aim was to investigate whether an association exists between BlviD and 
mortality and if so, what the nature of this relationship is in nearly 6000 elderly 
men and women from the Rotterdam Study. 
Materials and methods 
Study population 
The Rotterdam Study is a prospective cohort study of men and women aged 55 
and over and has the objective to investigate the incidence of, and risk factors 
for, chronic disabling diseases. The rationale and study design have been 
described previously (14). The focus of the Rotterdam Study is on neurologic, 
cardiovascular, ophthalmologic and locomotor diseases. All 10,27 5 inhabitants 
of Ommoord, a district in Rotterdam, the Netherlands, were invited to 
participate. Of these, 7,983 participated in the study (response rate 78%). BJVID 
was measured in 5819 participants (3374 women), all of whom were living 
independently and were able to visit the research center. The Rotterdam Study 
has been approved by the Medical Ethics Committee of the Erasmus University 
Medical SchooL 
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Clinical examination 
Between 1990 and 1993, an extensive baseline home interview on medical 
history, risk factors for chronic diseases and medication use was performed by 
trained interviewers. Lower limb disability was assessed using a modified version 
of the Stanford Health Assessment Questionnaire (22). A lower limb disability 
index was obtained by calculating the mean score of answers to questions 
concerning rising, walking, bending and getting in and out of a car. It is a 
continuous score ranging from zero to three, where a score of zero indicates no 
impairment and a score of three indicates severe impairment (4). 
After the home interview, subjects were invited to the research center for 
clinical examination and laboratory measurements. Height and weight were 
measured with subjects wearing indoor clothing without shoes. Body mass index 
was computed as weight in kilograms divided by height in meters squared 
(kg/m'). Subjects were classified as diabetics when they reported use of 
antidiabetic therapy (code A01 0 of the Anatomical Therapeutical Chemical 
classification index, WHO 1992), or when the pre- or postload serum glucose 
level was equal to or higher than 11.1 mmol/1. Serum albumin was measured in 
g/1 by standard laboratory methods. Bone mineral density measurement of the 
femoral neck was performed by dual energy X-ray absorptiometry (DXA, Lunar 
DPX-L densitometer) as described previously (5). 
Follow-up procedures 
For the entire cohort, information on vital status is obtained continuously from 
the municipal authorities in Rotterdam. For subjects who moved outside the 
research area, mortality data are obtained from general practitioners (GPs). GPs 
in the research area (covering 80% of the cohort) reported ali relevant fatal and 
non-fatal events, such as fractures, through a computerized system. Research 
physicians verified follow-up information by checking GPs' patient records. 
This is possible because in the Netherlands the GP has a gate keeper function, 
which means that the GP retains ali medical information of his patients. For the 
remaining 20 % of the population, research physicians collected data from their 
GP's patient records. For hospitalized patients, discharge reports and ietters 
from medical specialists were additionally used for verification. All non-fatal 
events, such as fractures, were coded independently by two research physicians 
according to the International Classification of Diseases, 10" revision (ICD-10) 
(30). If there was disagreement, consensus was reached in a separate session. A 
medical expert in the field reviewed ali coded events for a final classification. 
Data for overall mortality were available until 31st December 1997. 
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Statistical analysis 
Differences in baseline characteristics were compared using student's t- test for 
continuous variables and Chi-square for categorical variables. For all other 
analyses, Cox's regression analysis was used (9). We calculated survival time as 
the number of days from BMD measurement until death or December 31st 
1997, whichever occurred first. Outcome was overall mortality. First, we 
calculated hazard ratios in the traditional way, per standard deviation decrease in 
femoral neck BMD, in a full model 'vith all potential confounders for both 
genders. Variables were considered confounders when statistically significant 
when tested univariately with both BMD and mortality, and when they remained 
significant upon entering into the model. 
Then, in order to optimally correct for age, BMD was e"-pressed as Z-scores, the 
age adjusted deviation from the average t."<pressed in standard deviations (SD) 
for men and women separately. We divided the Z-score in tertiles. This resulted 
(as expected from normal theory) in a lower cut-off level of Z = -0.42 and a 
higher cut-off level of Z = 0.42. At 55 years, the cut-off for the lower tertile of 
Z-score for women was on average at a BMD level of 0.80 g/ em', and for the 
upper tertile at a level of 0.92 g/ cm2• For men, corresponding cut-off values 
were 0.87 and 0.96 g/ cm2, respectively. The corresponding values at other ages 
are listed in table 5.1.1. Furthermore, we divided the Z-score of BMD into 
quintiles, whereafter we calculated mortality incidence rates per quintile, to 
compare results to other studies. 
Table 5.1.1. Age-specific cut-off values in men and women for BMD at 
the femoral neck (g/ cm2), which correspond to the Z-score tertile cut-off 
values. 
Men Women 
Lower cut-off Upper cut-off Lower cut-off Upper cut-off 
55 yr 0.87 0.96 0.80 0.92 
60 yr 0.85 0.95 0.79 0.89 
65 yr 0.81 0.92 0.77 0.87 
70 yr 0.80 0.91 0.74 0.84 
75 yr 0.79 0.92 0.72 0.82 
80 yr 0.77 0.91 0.68 0.79 
85 yr 0.75 0.88 0.70 0.80 
Hazard ratios for the lower and upper tertiles were computed univariately and 
multi.variately, using the mid tertile as the reference. In the base analysis, 
adjustment was made for age only. 
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In a second analysis, we additionally adjusted for body mass index (BMI) 
(kg/ m~. Furthermore, we repeated tbe analysis 'Jlitb adjustment for all potential 
confounders, namely tbe presence or absence of diabetes mellitus type II, 
physical activity, as represented by tbe lower limb disability index, tbe use of 
diuretics and smoking habit. 
In order to fit tbe model tbat optimally reflects tbe true relationship between 
B:MD and mortality, Z-scores were first entered continuously into tbe model, 
and more terms were added until statistical significance (p < 0.05) was no longer 
reached. This was considered tbe optimal model. In tbese analyses, adjustment 
was made for age and B:tvll. All analyses were performed for men and women 
separately. 
We used SPSS for windows 9.0 in all our analyses. 
Results 
Follow-up on overall mortality was achieved for 2445 men and 3374 women 
after an average follow-up time of 5.4 years. Of tbese subjects, 399 men (16.3 
%) and 317 women (9.4 %) died. Table 5.1.2 a and b show baseline 
characteristics of tbe study population. The study generated 31.705 person years 
of follow-up. Since not all subjects had information on all confounders 
available, tbe population for study consisted of 2106 men and 2945 women for 
tbe multivariate model, whereas for all otber analyses, tbe entire cohort was 
used. 
Fig 5.1.1 shows mortality incidence rates per 1000 person years in quintiles of 
Z-score of femoral neck BMD for men and women separately. For men, more 
deaths occurred in the lowest quintile, whereas in women, there was no 
difference between quintiles. 
Hazard ratios for mortality were calculated per standard deviation (SD) decrease 
of femoral neck B:MD, botb age-adjusted and "'~tb adjustment for all potential 
independent confounders. After adjustment for age only, mortality risk 
increased per SD decrease in B:MD in men (hazard ratio (HR) = 1.14; 95% 
confidence interval 1.04-1.26), but not in women (HR = 1.06; 95% CI 0.95-
1.19). Hazard ratios after adjustment for potential confounders are shown in 
Table 5.1.3. For men, tbe risk of mortality increases "W~tb a decrease in B:MD, 
whereas tbis is not observed for women. 
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Table 5.1.2a. Baseline characteristics of 2445 men of the Rotterdam Study 
in tertiles of the Z-score of femoral neck BMD 
Lower Middle Upper 
tertile tertile tertile 
(n = 867) (n= 814) (n = 765) 
Age 67.9 (7.6) 66.7 (7.4) 67.9 (7.9) 
Follow-up rime (yr.) 5.1 (1.4) 5.4 (1.3) 5.4 (1.3) 
Body mass index (kg/ m') 24.7 (2.8) 26.0 (2.9) 26.5 (2.9) 
BMD femoral neck (g/ em') 0.74 (0.07) 0.88 (0.04) 1.03 (0.08) 
Smoking status (%) 
Current 35.6 27.6 23.9 
Former 58.2 64.6 65.4 
Never 6.1 7.8 10.6 
Disability (%) 
No 70.0 79.0 73.4 
Moderate 27.6 20.4 25.4 
Severe 2.4 0.6 1.2 
5 year history of hip fractures 3 (0.3) 2 (0.2) 5 (0.7) 
Incident hip fractures 23 (2.7) 7 (0.9) 
Diuretics users (all types, %) 73 (8.4) 73 (9.0) 74 (9.7) 
Diabetes mellitus (%) 75 (10.0) 66 (9.2) 97 (14.6) 
Seruru albumin level 43.0 (2.7) 43.2 (2.6) 43.2 (2.9) 
(mmol/L) 
Values are means with standard deviations or numbers with percentages 
* Data on smoking status were missing for 11 subjects; t Data on diabetes 
mellitus were missing for 316 subjects: :j: Data on mobility were missing for 14 
subjects 
In order to optimally adjust for age, we hereafter analysed Z-scores of BMD 
instead of the absolute BMD. 
When the mortality risk was analysed in tertiles of Z-score of BMD for men and 
women separately in a multivariate model using Cox' proportional hazards, men 
in the lower tertile of BMD had a hazard ratio of 1.4 (95 % confidence interval 
1.1-1.8), after adjustment for age. In the upper tertile mortality risk was not 
significantly different from the reference group (Table 5.1.4). For women, we 
did not find a significant increase in the lower tertile (HR=1.1 [0.8-1.4]. 
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Table 5.1.2b. Baseline characteristics of 3374 women of the Rotterdam 
Study in tertiles of the Z-score of femoral neck BMD 
Lower Middle Upper 
tertile tertile tertile 
(n = 1164) (n = 1149) (n = 1062) 
Age 68.3 (8.3) 68.3(8.1) 68.3 (8.3) 
Follow-up time (yr.) 5.5 (1.2) 5.6 (1.2) 5.6 (1.2) 
Body mass index (kg/ m"J 25.1 (3.5) 26.9 (3.8) 28.3 (4.1) 
BMD femoral neck (g/ em") 0.68 (0.07) 0.81 (0.05) 0.95 (0.09) 
Smoking status (%) 
Current 23.0 17.7 17.5 
Former 28.7 28.3 30.4 
Never 48.4 54.0 52.2 
Disability (%) 
No 56.9 60.3 55.9 
Moderate 27.1 29.4 31.9 
Severe 11.6 8.4 9.8 
History of hip fractures 25 (2.1) 7 (0.6) 3 (0.3) 
Incident hip fractures 59 (5.1) 20 (1.8) 16 (1.5) 
Diuretics users (all types,%) 156 (13.4) 183 (15.9) 215 (20.3) 
Diabetes mellitus (%) 98 (9.6) 96 (9.4) 133 (14.0) 
Serum albumin level 42.8 (2.4) 43.0 (2.5) 42.9 (2.5) 
(mmol/L) 
Values are means "IN"ith standard deviations or numbers with percentages 
Data on smoking status were missing for 23 subjects; t Data on diabetes 
mellitus were missing for 381 subjects: :j: Data on mobility were missing for 27 
subjects 
Subsequently, we modelled the true relationship between BMD and mortality. 
For men, the model was optimal when Z-scores were entered into the model 
continuously(~ = -0.042, p = 0.52), squared $ = 0.101, p = 0.00) and cubic (~ 
= -0.022, p = 0.04) simultaneously. Adjustment was made for age and body 
mass index. (Fig. 5.1.2). For women, even the continuous Z score was not 
significant upon entering into the model $ = -0.048, p = 0.45). 
A model that included all potential confounders resulted in a similar model. $'s 
now were -0.009, 0.121 and -0.046 for men, respectively, and -0.057 for 
women). We also repeated the analyses in strata of high and low BMI and 
smoking status. This resulted in similar results. (Data not shown). 
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Figure 5.1.1. Mortality incidence per 1000 person years during an average 
of 5,4 years of follow-up for men and women separately. 
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Table 5.1.3. Hazard ratio of all-cause mortality in a multivariate model for 
men and women se12arately 
Men Women 
HR(95% CI) p-value HR(95% CI) p-value 
Femoral neck 1.14 (1.02-1.28) 0.024 1.04 (0.91-1.19) 0.521 
BMD (perSD) 
Age (peryr) 1.09 (1.07 -1.1 0) 0.000 1.10 (1.08-1.12) 0.000 
BMl 0.96 (0.92-0.99) 0.026 0.97 (0.94-1.00) 0.055 
Presence of 1.74 (1.33-2.28) 0.000 1.82 (1.37-2.42) 0.000 
diabetes mellitus 
Use of diuretics 1.98 (1.51-2.60) 0.000 1.56 (1.18-2.05) 0.001 
Lower limb 
disability 
No 1 (reference) 1 (reference) 
Moderate 1.7 4 (1.33-2.28) 0.000 1.28 (0.91-1.80) 0.162 
Severe 1.95 (1.49-2.57) 0.000 148 (1.07 -2.03) 0.017 
Smoking 
Current 1.50 (0.91-2.48) 1.80 (1.31-2.48) 
Former 1.21 (0.75-1.97) 0.113 1.13 (0.85-1.52) 0.000 
Never 1 (reference) 0.436 1 (reference) 0.399 
tAll covariates are independent predictors for mortality 
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Table 5.1.4. Hazard ratio of all-cause mortality by tertiles of Z-score of 
BMD of femoral neck 
Z-score in tertiles 
Lower tertile lVlidclle tertile Upper tertile 
Men 
No. of cases 163/867 106/814 136/765 
Adjusted for age 1.42 (1.11-1.81) 1 1.18 (0.92-1.53) 
Adjusted for age 1.33 (1.03-1.70) 1 1.21 (0.94-1.57) 
andBMI 
Full modelt 1.33 (1.01-1.74) 1 1.17 (0.89-1.55) 
Women 
No. of cases 118/1164 109/1149 94/1062 
Adjusted for age 1.09 (0.84-1.41) 1 0.90 (0.68-1.19) 
Adjusted for age 1.06 (0.81-1.39) 1 0.92 (0.69-1.22) 
andBMI 
Full modelt 1.04 (0. 78-1.38) 1 0.89 (0.66-1.21) 
RR - relative risk for mortality obtained by Cox' proportional hazard analysis, 
95 % confidence interval between parentheses 
tFull model additionally included presence of diabetes mellitus, use of diuretics, 
lower limb disability and smoking status 
Figure 5.12. Relative risk of all-cause mortality in men and women. 
Adjustment was made for age and body mass index. 
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Analyses repeated with the exclusion of subjects who died during the first year 
of follow-up, with the objective to exclude serious diseases at baseline, yielded 
similar results. Also, analyses repeated after e:<clusion of diuretics-users or 
subjects who suffered a hip fracture or any clinical fracture during follow-up 
yielded similar results. The inclusion of serum albumin, as a prO'-)' of health 
status, had no additional effect on the risk estimates for mortality by BMD 
(8,29). Neither inclusion of the number of drugs used nor the lower limb 
disability index caused a significant change in relative risks. 
Discussion 
The results of our study show that in men, low BMD is associated with an 
increased risk of mortality. There seems to be a threshold around the age-
adjusted average of BMD (Z-score of zero). Above this threshold, there is no 
further decrease in relative risk. If anything, the risk appears to go up again in 
men with a high Z-score of BMD. In women, however, we could not identify a 
relationship between BMD and mortality. 
Bone mineral density may be regarded as a marker of general health and ageing, 
representing lifelong effects of hereditary, endocrine and life style factors. 
Therefore, when studying BMD in relation to mortality, it is important to take 
confounders such as body mass index, presence of diabetes mellitus type ll, 
lower limb disability and use of thiazide diuretics into consideration. These 
confounders do not all have the same effect on the relation between BMD and 
mortality and possibly have counteracting effects on the risk estimates. A higher 
body mass index is associated with an increase in BMD (4,21), but also with 
increased mortality (12,42). Also, presence of diabetes mellitus type ll and use 
of thiazide diuretics are both associated with a higher BMD (7,26,28) and an 
increased mortality risk (1,19). Disability and smoking are associated with a 
higher mortality risk, but are inversely associated with BMD (4,20). Because of 
these opposing effects, we decided to study their effect not only by simply 
adjusting for it in the model, but also by fitting our model for separate groups, 
in a separate analysis. 
In men, we found that a low BMD was significantly associated with an increased 
mortality in the total population, but also in subgroups. There appears to be 
threshold at a Z-score of zero below which the risk of mortality increases 
rapidly. When the BMD was analysed per standard deviation decrease, such 
thresholds were missed. 
In women, Browner et al. found an inverse relationship between BMD as 
measured at the radius and calcaneus, and mortality, especially from stroke in 
9704 elderly women, with a mean follow-up time of 2.8 years (3). The age 
121 
Chapter 5.1 
adjusted relative risk per standard deviation decrease in BlviD was around 1.2. 
However, they also show that when BlviD is divided in quintiles, more deaths 
occur in the lowest quintile, whereas the three mid quintiles have similar 
numbers of deaths. In the highest quintile less deaths are observed. Von der 
Recke et al. studied the relationship between bone mineral content (BMC) and 
mortality in a group of women soon after menopause and in a group late after 
menopause (2.7). They also found that relative risks of mortality increase when 
BMC is below the average, whereas under condition of BMC above average, the 
risk of mortality remains constant. An inverse relationship ofBlviD, measured at 
the calcaneus, with mortality in a general population of men and women aged 70 
years and older, was observed by Johannsen et al. (15). They found a stronger 
relationship in men than in women, which was confirmed in this study. 
However, all these previous studies have presented their relative risks only per 
standard deviation change in absolute BlviD. 
Unlike these previous studies, we did not observe a significant relationship 
between low BlviD and mortality in women. It might be postulated that women 
\N~th a low estrogen exposure during life have a lower BlviD and have an 
increased risk of cardiovascular disease, but a decreased risk of estrogen related 
cancers, such as breast- and endometrial cancer (2,17,23,25). Therefore, our 
findings may be due to the fact that the increased risk of cardiac mortality and 
the decrease in risk of cancer mortality counteract each other in the analysis of 
the relationship between BlviD and all-cause mortality. Furthermore, it could 
also be that in order to observe such a relationship in women, we have to follow 
them up for a longer period since women have a longer life expectancy. 
When studying the association between BlviD and mortality, it is important to 
thoroughly investigate whether a low BlviD is not merely a marker for 
underlying illness. There are several possible reasons for this to occur. First of 
all, when a person is very ill, quite often he or she will have less physical activity, 
resulting in a lower BlviD. In order to see whether this explained our results, we 
repeated the analyses excluding persons who had died during the first year of 
follow-up or excluding subjects who had a history of clinical fractures. 
Furthermore, we tried to correct for potential indicators for morbidity, by 
repeating the analyses adjusting for the number of drugs used and for lower 
limb disability. None of these analyses essentially changed the risk estimates. 
Another possibility is that unfavourable lifestyle habits, such as a low physical 
activity and smoking play a role. Therefore, we also adjusted for this in our 
analyses. All these analyses suggest that a low BlviD is not mainly due to 
morbidity and impaired mobility in our cohort, which makes these factors less 
plausible to e>.-plain the observed relation with mortality. There are, however, 
several other factors that may still play a role in the relationship between BlviD 
and mortali"Sl, for instance low estrogen exposure and genetic factors. 
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A potential limitation of our study is that selection bias may have occurred. Our 
study population consists of 5819 healthy independently living subjects, who 
were able to come to our research centre. Therefore, it is likely that there is an 
underrepresentation of persons with severe lower limb disability in our cohort. 
However, this potential selection bias would only dilute the observed 
association. 
In conclusion, the results of this study suggest that in men a non-linear 
relationship between BMD and mortality exists, which is independent of 
comorbidity and impaired mobility. In women, no significant relationship 
between BMD and all-cause mortality was observed. 
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.Abstract 
Osteoporotic fractures, especially fractures of the hip, are associated 'W-ith high 
morbidity, mortality and economic costs. Several therapeutical options for 
fracture prevention are avaihble, some of which might also influence breast 
cancer and cardiovascular disease risk. The aim of this study was to evaluate 
cost-effectiveness of hormone replacement therapy (HR1), selective estrogen 
receptor modulators (SER1\1s) and bisphosphonates on fracture prevention, 
taking into account the effect of these drugs on breast cancer risk. We used a 
mathematical model, based on a life-table approach. Whenever possible, we used 
Dutch reference data. Essentially, four treatment strategies were evaluated. For 
HRT, a hip fracture risk reduction of 10 % and 50 %, respectively, and a 
vertebral fracture risk reduction of 50 % were assumed. For SER.Ms and 
bisphosphonates the assumed risk reductions were 10 % and 50 % for hip 
fractures, respectively and 50 % for vertebral fractures. We evaluated women at 
ages 55, 65 and 7 5 years at various intervention thresholds. The results of this 
model suggest that when the effects of drugs on breast cancer are taken into 
account, SER.Ms are more cost-effective than either HRT or bisphosphonates, 
especially before the age of 75 years. Only at age 75, bisphosphonates become 
more cost-effective. In conclusion, the results of this model suggest that in terms 
of cost-effectiveness SER1\1s are to be preferred over HRT, mainly because of 
the potential effects on breast cancer. At older ages, bisphosphonates become 
more cost effective than SER.Ms, due to their large hip fracture risk reduction. 
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Introduction 
Osteoporotic fractures, especially hip fractures, are associated \'Vith increased 
morbidity, mortality, and substantial economic costs. (1-7) Due to demographic 
changes, the incidence of fractures is increasing over time, hereby increasing the 
population burden of fractures. (6) We and otbers have previously found tbat 
bone mineral density and fracture risk are associated 'W-itb tbe risk of breast 
cancer and atherosclerosis, as was described in detail in chapters 4.1 and 4.2. (8-
19) 
Several therapeutical options are available for tbe prevention of fractures. 
Estrogens, both endogenous and exogenous, are known to have bone-sparing 
effects.(20-26) Various studies have suggested tbat hormone replacement 
tberapy (HRT) prevents tbe age-related loss in bone mineral density (BMD) (27-
32) and decreases fracture risk in postmenopausal women. (31-44) Most of tbese 
studies, however, where designed as a case-control or cohort study, (34,37-44) 
whereas only few randomised controlled trials have been performed on HRT 
witb fractures as an endpoint. (31-33,36) Even tbough HRT has favourable 
effects on bone, it is tbought tbat women who use HRT are at increased risk of 
breast cancer (45,46), endometrial cancer (for unopposed estrogens) (23) and 
tbrombo-embolism (47,48). Furthermore, altbough not expected, tbe Heart 
Estrogen/ progestin Replacement Study (HERS) trial showed an increased 
myocardial infarction risk in women during tbe first year of taking HRT. ( 49) 
Selective Estrogen Receptor Modulators (SERMs) are also drugs tbat have 
estrogen-like effects on bone, (50) but, in contrast to HRT, tbese drugs appear 
not to have tbe negative effects on breast and endometrial cells. (51,52) In fact, 
tbere is evidence for a risk reduction of breast cancer. (53) In terms of costs, 
however, SERMs are more tban 4 times as expensive as HRT. Finally, 
bisphosphonates also increase bone density and decrease fracture risk, and are 
frequently described drugs for fracture prevention. (54-57) Bisphosphonates are 
not kno\V-n to have an effect on either breast cancer or cardiovascular disease. 
When comparing different treaunent strategies in terms of cost-effectiveness, it 
is important tbat besides numbers and costs of osteoporotic fractures, tbe loss in 
quality of life (QOL) after an event is also taken into account. Therefore, cost-
effectiveness will be expressed in Euros (€) per Quality Adjusted Life Year 
(QALY) gained. 
The aim of this study was to investigate tbe cost-effectiveness of prevention of 
osteoporotic fractures in elderly women from tbe Rotterdam Study, using several 
different scenarios and taking tbe effects of tbe different treatment strategies on 
breast cancer into account. 
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Materials and methods 
Model developmmt 
For the economic evaluation of different treatment strategies of fracture 
prevention, we developed a model based on a life-table design. 
Baseline incidence rates 
The baseline age-adjusted hip fractures incidence was derived from the Dutch 
hip fracture incidence data, based on nation.,~de hospital registration data 
gathered for the year 1999. (58) The baseline incidence of vertebral fractures was 
derived from the recent Dutch guidelines on osteoporosis. (59) The incidence of 
breast cancer was based on data from the Dutch cancer registry. (60) 
Baseline BMD and thresholdsfor ana!ysis 
The femoral neck B:MD distributions used were derived from the Rotterdam 
Study, as published previously. (61) A T-score of BMD was calculated, using 
average values for young adult women from a Dutch study, which were also 
measured using a Lunar DPX-L densitometer.(62) WJth those reference values, a 
T-score of- 2.5 corresponded to a B:MD level of 0.675 g/cm2 in women. (63) 
This value was very similar to the threshold value in the machine specific USA 
Female Reference population, which was 0.681 g/ cm2 (64) In the cost-
effectiveness analysis, we used a T -score of -2.5, and -1 as treatment thresholds 
as these thresholds are commonly used in clinical practice and well-accepted 
thresholds for the \VHO definition of osteoporosis and osteopenia, respectively. 
(65) 
Interrelation of events 
To describe the relation between B:MD and the endpoints of interest, the relative 
risk (RR) of the event at various levels of B:MD was calculated in reference to 
the average risk in the population. We previously described this technique for 
hip fracture risk. (61) When the risk is described as a fLxed relative risk per unit 
change (decline) of BMD, such as was done for hip fractures, the relative risk 
compared to the average in the population is obtained by RR =a-~ I C. Here "a" 
represents the risk per unit change of B:MD (2.6 in the case of the relation of hip 
fracture with femoral neck BMD) and "z" represents the Z-score of B:MD. The 
correction factor "C" is given by 
C - ~f 1 -0.5=' -= d- _ O.S.(In(a))' 
- _.f21i·e ·a · ~-e 
The relation of vertebral fractures with B:MD was derived from the incident 
vertebral fracture data from the Rotterdam Study, as was described in chapter 
2.1. (66) Similarly, the interrelation of B:MD with breast cancer was modeled 
based on data from the Rotterdam Study as described in this thesis (chapter 4.2). 
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Both for vertebral fractures and for breast cancer, a cubic model best described 
the association with BMD. In this case, the relative risk of an event compared to 
the average in the population can be calculated similarly by dividing the 
calculated risk by the correction factor "C". The relative risk compared to the 
average population will be given by: 
where C is given by 
C - OOI 1 -0.5=' e(a+f3t=+fJo='+fJ,=') d----·e . . / 
-_& -
The specific betas and correction factors are shown in Table 6.1.1 
Mortality 
General mortality was based on Dutch cross-sectional mortality data from 1999, 
(67) and modeled as a continuous function ·with the SPSS curve fitting function 
(SPSS for Windows, version 9.0). For the cost-effectiveness analysis, we 
estimated the increased mortality after hip fractures and after breast cancer. For 
hip fractures we used the in-hospital mortality after hip fracture obtained from 
Dutch registration data as a pro'-y for the hip fracture specific mortality. (67) For 
breast cancer, the rumor specific mortality in the first 5 years after dia,onosis, and 
again in years 6 until 20 after diagnosis was based on the relative survival in the 
Netherlands as described by Dutch cancer registration data. (68) For vertebral 
fractures, no excess mortality was assumed. 
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Table 6.1-1. Overview of the parameters and assumptions used in the 
model 
Baseline Incidences 
Hip fracture 
Vertebral fracture 
Breast Cancer 
Femoral Neck BMD 
Average Femoral Neck 
Bj\1[]) (g/ cm2) 
SD Femoral Neck Bj\1[]) 
(g/cm') 
Risk by femoral neck 
BMD Z-Score (z) 
Hip fracture 
Vertebral fracture 
Breast Cancer 
Mortality (per year) 
General Mortality 
Hip fracture specific 
mortality 
(first year only) 
Breast Cancer specific 
mortality (1-5 year) 
Breast Cancer specific 
mortality (6-20 year) 
Quality of life (QOL) 
Average QOL under 65 
Average QOL 65 and over 
Costs (€) 
Hip fracture 
Vertebral fracture 
Breast Cancer 
Utility loss (QALY loss) 
Hip fracture (under age 65) 
Hip fracture (65 and over) 
Vertebral fracture 
Breast Cancer 
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9.2.1 Q-1S*age8.9456 
1765.9+ 3!.7876*age+0.0514*a 
gel 
-3.4864+0.1679*age-0.001 *age2 
1.121284-0.00456*age 
0.134 
2.6·,/C 
(-0.652*z+0.113*z2+-
0.002*z3)/C 
(-0.1015*z-
0.2277*z2+0.0631 *z3)/C 
0.0508*e(0.086.ogo) 
1 j (1 +e-(-9.+144 +0.0812.ogoJ) 
31.6375+0.5664*age-
0.005*age2 
15.3793+0.2753*age-
0.0024*age2 
0.8 
0.715 
First Year 
9000 
500 
9500 
First Year 
0.2413 
0.2279 
0.0387 
0.1 
C=1.578541 
C=1.46 
C=0.832 
Subsequent years 
1700 
100 
170 
Subsequent years 
0.1284 
0.1284 
0.0227 
0.1 
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Costs and Utilities 
Cost of event 
Overall, in 1993 the healthcare costs due to osteoporotic fractures in the 
Netherlands were estimated at around € 210 million. (69) Over 85 % of these 
costs are due to hip fractures. In this estimation, only direct medical costs, as 
made in the hospital, the nursing homes and the ambulant clinical care are taken 
into account. The average hip fracture costs are estimated at € 9000 for the first 
year after fracture and € 1700 for the years thereafter. (70) (Table 6.1.1) In the 
current model, all costs were incremental costs only. For venebral fractures, it is 
difficult to estimate costs, and cost estimates differ between studies. The main 
reason for this is that there is no consensus about the definition of vertebral 
fractures. (71-75) Furthermore, about two-thirds of all vertebral fractures remain 
clinically unnoticed. The costs for vertebral fractures as used in this model were 
estimated in the Netherlands at € 500 in the first year and € 100 in the years 
thereafter (table 6.1.1). (70) For breast cancer, cost estimates were taken from a 
Swedish modeling study, since we did not have reliable Dutch cost estimates 
available. (76) 
Cost of intervention 
For interventions costs we used the average public prices of the drugs. (77) We 
did not take diagnostic and monitoring costs into account, because the aim of 
the study was to compare different drug regimens. \Y/ e therefore assumed that all 
costs, other d1an the costs of the drugs would be the same for all trearment 
strategies. This is also the reason why we did not take the additional costs of 
calcium and vitamin D suppletion into account. In our model, treatment costs 
per year were thus estimated as € 100 for HRT and € 450 for both SERMs and 
bisphosphonates. 
Effects of fractures and breast cancer on Quality of Ufe 
The effect of fractures on health related quality of life (QOL) was expressed as 
Quality Adjusted Life Years lost (QALY). In this measure the QOL loss is 
expressed as going from 0 (death) to 1 (perfect health). The loss in QOL is then 
multiplied by the time spent in this condition, resulting in a QOL measure 
weighted by time, the Quality Adjusted Life Year (QAL Y). A Dutch expert panel 
(Table 6.1) estimated the QALY loss in the first and subsequent years after both 
hip and vertebral fractures. A detailed overview of how this panel arrived at 
these estimates is described in the Dutch Guideline for Osteoporosis. (59) We 
used Swedish data to estimate the QAL Y loss related to breast cancer. (7 6) 
Again, estimates are sho"n in Table 6.1.1. 
Cost-effectiveness 
In general, thresholds for cost-effectiveness are disputable and there is currendy 
no consensus. Two thresholds are often used, one of € 20.000/ QAL Y gained 
and one of € 30.000 /QALY gained. The first is the cost-effectiveness threshold 
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that was used in the Dutch guidelines for Osteoporosis, as well as in other 
Dutch guidelines. (78-81) The second is based on the definition of cost-
effectiveness that is used in the NOF guidelines for osteoporosis. (82) 
Intervention scenarios 
The effects of the different intervention scenarios were expressed as the relative 
risk reduction for each of the outcomes under study and based on a literature 
review. (28,31-44,49,50,54-57,83-86) Because HRT risk estimates for hip fracture 
prevention are not straightforward in literature, we used 2 alternative scenarios, 
one with a hip fracture risk reduction of 10 % and another with a risk reduction 
of 50 %. The assumed risk reductions for different treatment strategies that were 
used in the model are presented in table 6.1.2 
Table 6.1.2. Assumed risk reduction in various intervention scenarios 
Risk reduction 
Hip fractures Vertebral Breast cancer 
fractures 
HRT 10% I so% 50% -10% 
(risk increase) 
SERi\1s 10% 50% 50% 
Bisphosphonates 50% 50% 0% 
We assumed an intervention for the duration of 5 years, corresponding to the 
time period for which data are available from most clinical trials. (Fig 6.1.1) We 
also assumed an offset of treatment effect period of 5 years. 
Fig 6.1.1. Assumed treatment effect over time 
100 
~ 80 
t; 
~ 60 
• c 
• 40. E ;; 
!: 20 ~ 
2 3 4 5 6 7 8 9 10 
Treatment duration (years) 
We assumed that through this offset of treatment period the risk reduction due 
to treatment linearly declined towards zero. Although little is known about this 
period of declining effect, it is widely believed that the effect of treatment does 
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not stop immediately after the cessation of treatment. On the other hand it is 
improbable that treatment effects would continue throughout life. 
Discounting 
In economic evaluations, it is common practice to discount all costs and effects 
of treatment. In short, discounting is a way to adjust for the fact that costs and 
effects are less valuable when they occur in the future as compared to current 
costs and effects. This difference in value is in part due to inflation, but also due 
to personal appreciation of both costs and events. (87) In concordance with 
those guidelines, all results are shown \Vith a discount rate of 4% per year for 
both costs and effects. 
Treatment scenarios 
We calculated the cost-effectiveness ratios for different scenarios of intervention 
in women with a T -score of BMD of- 2.5 and for women with a T -score of-
1.0. All analyses were performed for women aged 55, 65 and 75 years. 
We present the cost-effectiveness results for different simations: 
Scenario 1: the intervention has an effect on fracture risk only. In this scenario 
we do not include any effects on breast cancer. 
Scenario 2: the intervention not only has an effect on fracture risk, but also has 
an effect on breast cancer. To model this, we used the assumptions that are 
described in detail in table 6.1.1. In this scenario, however, we assume that breast 
cancer is not related to BMD, and is thus unrelated to fracture risk. 
Scenario 3: the intervention has an effect on both breast cancer and fracture risk, 
In contrast, we now assume that breast cancer is related to fracture risk through 
femoral neck BMD. Tbis association is described in figure 6.1.3. 
Results 
Figure 6.1.2 shows the baseline incidence rates of the various outcome events by 
age, as they were used in the model. These incidence rates were derived from the 
data sources as described in the materials and methods section. 
In the previous chapters of this thesis we examined the relation of these 
outcome events with BMD (chapters 2.1 and 4.2, for vertebral fractures and 
breast cancer, respectively). 
These associations were recalculated to reflect the relative risk compared to the 
average in the population. In figure 6.1.3 we show the associations between 
femoral neck BMD and bip fractures, vertebral fractures and breast cancer. The 
risk of both bip and vertebral fractures increases exponentially with decreasing 
BMD. Furthermore, in subjects at low BMD, the risk of breast cancer is lower 
than the average in the population. These analyses were repeated with lumbar 
spine BMD instead of femoral neck B1viD, and similar risk functions were 
observed (data not shown). 
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Figure 6.1.2. Baseline incidences in women of the various outcome events 
by age used in the modeL 
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Excess morutlity in the first year after diagnosis of hip fractures and breast 
cancer is shown in figure 6.1.4. 
We calculated the cost-effectiveness ratios for the different scenarios. Values are 
given for women with aT -score of femoral neck BMD of both -1.0 and -2.5. 
Figure 6.1.3. Relation of relative risk of different outcome events with 
femoral neck BMD in women (relative risk relative to average of 
population) 
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Figure 6.1.4. Excess mortality in the first year after diagnosis for hip 
fractures and breast cancer 
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Table 6.1.3 shows cost-effectiveness ratios for various treatment options in 
scenario 1. In scenario 1, the intervention has an effect on fracture risk only. In 
this scenario we do not include any effects on breast cancer. 
Table 6.1.4 then shows cost-effectiveness ratios for scenario 2: the intervention 
not only has an effect on fracture risk, but also has an effect on breast cancer. In 
this scenario, however, we assume that breast cancer and fracture risks are 
unrelated. 
Finally, the results of scenario 3 (the intervention has an effect on both breast 
cancer and fracture risk, and breast cancer is related to fracture risk via femoral 
neck BMD) are shown in Table 6.1.5. 
As an e."<am.ple of how these results should be interpreted, we go through the 
results for women aged 55 years at aT-score of -1.0. 
Wilen HRT is chosen for fracture prevention, and we assume that the hip 
fracture risk reduction is 10 % and vertebral fracture risk reduction is 50 %, 
costs per QALY gained are € 166,833 when only effects of treatment on fracture 
risk are taken into account (scenario 1, table 6.1.3). If we now assume that 
indeed there is a negative effect of HRT on breast cancer risk, and we assume 
that fracture risk and breast cancer risk are interrelated via femoral neck BMD, 
HRT now actually results in negative QAL Y s, and thus an overall decrease of 
QALYs (scenario 3, table 6.1.5). 
If the HRT analyses are repeated with assumed risk reductions for both hip and 
vertebral fractures of 50 %, we again find negative QAL Y s, suggesting that at 
age 55, the effects of HRT on breast cancer outweigh the effects on osteoporotic 
fractures in women. 
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When we assume that SERJV[s only have effects on fracture risk, the costs per 
QALY gained are € 776,340 (scenario 1, table 6.1.3). Thus, overall SERJV[s are 
expensive drugs, and if no effect on breast cancer is assumed, this type of drug is 
far less cost-effective than HRT. However, if we now assume that indeed 
SER.J."\fs result in a 50 % breast cancer risk reduction, and that fracture risk and 
breast cancer risk are associated via femoral neck BMD, the costs per QAL Y 
gained drop dramatically to a cost-effective value of € 24,773. Thus, when the 
effects of drugs on breast cancer are taken into account, SER.J."\fs become 
favourable over HRT (scenario 3, table 6.1.5). 
For bisphosphonates, no effect on breast cancer risk is assumed. Thus, costs per 
QAL Y gained are € 416,390 at age 55 years, which is the same for all three 
scenanos. 
Table 6.1.3. Results from scenario 1: treatment effect only on fracture risk, 
no effect on breast cancer risk 
Age 
55 65 75 
HRT (10/50/-)1 
T-Score -1 € 166,833 € 94,989 € 77,248 
T -Score -2.5 € 42,281 € 22,392 
€ 15,550 
HRT (50/50/-)2 
T-Score-1 € 84,201 
€ 36,187 € 18,715 
T -Score -2.5 
€ 14,003 € 438 Net savings 
SERMs (10/50/-)3 
T-Score-1 € 776,340 € 456,240 
€ 381,596 
T -Score -2.5 € 217,173 € 131,970 
€ 107,301 
Bisphosphonates 
(50/50/ -)4 
T-Score -1 € 416,390 € 203,866 € 128,635 
T -Score -2.5 € 102,339 € 45,377 € 23,506 
Values are costs (€) per QAL Y gained 
1 10 % hip fracture risk reduction, 50 % vertebral fracture risk reduction, 0 % 
breast cancer risk reduction 
2 50 % hip fracture risk reduction, 50 % vertebral fracture risk reduction, 0 % 
breast cancer risk reduction 
3 10 % hip fracture risk reduction, 50 % vertebral fracture risk reduction, 0 % 
breast cancer risk reduction 
4 10 % hip fracture risk reduction, 50 % vertebral fracture risk reduction, 0 % 
breast cancer risk reduction 
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Table 6.1.4: Results from scenario 2: treatment effect on fracture risk and 
breast cancer risk, but fracture risk and breast cancer are unrelated 
HRT (10/50/-10)1 
T-Score -1 
T -Score -2.5 
HRT (50/50/-10)2 
T-Score -1 
T -Score -2.5 
SERMs (10/50/50)3 
T-Score-1 
T -Score -2.5 
Bisphosphonates 
(50/50/0)4 
T-Score-1 
T -Score -2.5 
55 
NegQALYs 
NegQALYs 
NegQALYs 
€ 45,062 
€ 29,779 
€ 27,154 
€ 416,390 
€ 102,339 
Values are costs (€) per QAL Y gained 
Age 
65 
NegQALYs 
€ 62,094 
€ 953,038 
€ 1,502 
€ 37,815 
€ 30,428 
€ 203,866 
€ 45,377 
75 
NegQALYs 
€ 26,373 
€ 35,931 
Net savings 
€ 51,316 
€ 36,011 
€ 128,635 
€ 23,506 
1 10 % hip fracture risk reduction, 50 % vertebral fracture risk reduction, -10 % 
breast cancer risk reduction (increased risk) 
2 50 % hip fracture risk reduction, 50 % vertebral fracture risk reduction, -10 % 
breast cancer risk reduction (increased risk) 
3 10 % hip fracture risk reduction, 50 % vertebral fracture risk reduction, 50 % 
breast cancer risk reduction 
4 10 % hip fracture risk reduction, 50 % vertebral fracture risk reduction, 0 % 
breast cancer risk reduction 
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Table 6.1.5. Results of scenario 3: treatment effect on fracture risk and 
breast cancer risk, and fracture risk and breast cancer are related to each 
other via femoral neck BMD 
HRT (10/50/-10)1 
T-Score -1 
T -Score -2.5 
HRT (50/50/-10)2 
T-Score-1 
T -Score -2.5 
SERMs (10/50/50)3 
T-Score -1 
T -Score -2.5 
Bisphosphonates 
(50/50/0)4 
T-Score-1 
T -Score -2.5 
55 
NegQALYs 
€ 583,213 
NegQALYs 
€ 27,868 
€ 24,773 
€ 37,124 
€ 416,390 
€ 102,339 
Values are costs (€) per QAL Y gained 
Age 
65 
NegQALYs 
€ 55,323 
NegQALYs 
€ 1,400 
€ 33,734 
€ 32,381 
€ 203,866 
€ 45,377 
75 
NegQALYs 
€ 28,138 
€ 36,437 
Net savings 
€ 50,546 
€ 33,620 
€ 128,635 
€ 23,506 
1 10 % hip fracture risk reduction, 50 % vertebral fracture risk reduction, -10 % 
breast cancer risk reduction (increased risk) 
2 50 % hip fracture risk reduction, 50 % vertebral fracture risk reduction, -10 % 
breast cancer risk reduction (increased risk) 
3 10 % hip fracture risk reduction, 50 % vertebral fracture risk reduction, 50 % 
breast cancer risk reduction 
4 10 % hip fracture risk reduction, 50 % vertebral fracture risk reduction, 0 % 
breast cancer risk reduction 
Discussion 
The results of this model show that in fracture prevention the inclusion of 
effects on breast cancer of the various intervention alternatives has an important 
influence on the cost-effectiveness balance. SERMs are, in this model, more 
cost-effective for fracture prevention than either HRT or bisphosphonates in 
women aged 55 or 65 years. Only at age 75 years and over, bisphosphonates 
become more cost-effective. 
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\Vhen testing different drugs for cost-effectiveness of fracture prevention only, 
HRT is favourable over both SERMs and bisphosphonates at all ages and for 
both aT-score ofBMD of -1.0 and -2.5. This is due to fact that effects of HRT 
on vertebral fracture risk and perhaps on hip fracture risk are substantial and 
costs are low. 
However, when breast cancer was added to the model, at age 55 years, a 5-year 
treatment strategy of HRT results in a QALY loss rather than a gain due to the 
increase in breast cancer incidence. An important part of the loss of QALYs is 
due to the actual loss of life years. This can be explained by the fact that 
although at age 55 years, incidence rates of breast cancer, hip fracture and 
vertebral fractures are comparable, there are substantial differences in reduction 
in quality of life (QOL) due to these diseases. Most importandy, the mortality 
rate after breast cancer is higher than after hip fracture and that breast cancer 
mortality occurs at younger age, resulting in much more life years lost. This 
strongly influences the total QALY lost due to breast cancer cases. Since the 
health related QOL is age dependent, we adjusted for this by using the average 
heald1 related QOL during the lost life years. (88) 
A scenario with SE&'\is now becomes much more attractive, and, depending on 
the definition used, might even be considered cost-effective. These results 
suggest that especially at younger ages, the effects on breast cancer out\\Teigh the 
effects on fracture prevention. At age 65 years, results are still quite comparable 
to those at age 55 years. 
At age 75 years, however, bisphosphonates become more cost-effective than 
SER.l\is are. At this age, the incidence of hip fractures is increasing rapidly, and 
as of age 80, hip fracture incidence rates are higher than either vertebral fracture 
and breast cancer incidence rates. 
In contrast to SERMs, bisphosphonates largely reduce hip fracture risk 
(estimated risk reductions 50 % and 10 %, for bisphosphonates and SER..1v!s, 
respectively). Hip fractures are associated with higher costs than either vertebral 
fractures or breast cancer. At younger ages, breast cancer played an important 
role in determining cost-effectiveness ratios, but at age 75, the total number of 
life years lost is no longer as high as it was at ages 55 and 65. Thus, due to the 
strong effects on hip fractures, as well as the diminished effect of breast cancer 
on total cost per QALY gained, it is not surprising that at older ages, 
bisphosphonates, are more cost-effective than SERl\ls. 
It should be noted that HRT was more cost-effective at age 75 years, but the 
compliance of HRT is likely to be low at old age, given the fact that with 
opposed estrogens a withdrawal bleeding is also reintroduced into a woman's 
life. 
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There are disadvantages to using modelling to test cost-effectiveness of different 
treatment scenarios for fracture prevention. The main problem is that the model 
is based on various assumptions. We estimated the effectiveness of the various 
drugs in terms of both fracture prevention and breast cancer risk by a thorough 
review of existing medical literature. 
For HRT, only few and relatively small trials have been performed. (28,31-
33,36,49) In the larger trials, which often were not primarily designed for 
osteoporosis research, a hip fracture risk reduction of about 5 to 15 % was 
observed, (28,49) whereas from smaller trials and population-based cohort 
studies a risk reduction of around 50 % was observed. (31-44) A recent meta-
analysis showed an overall risk reduction of 27 % that was statistically significant. 
(35) Since such large discrepancies were observed, we decided to use different 
scenarios for HRT on fracture prevention. 
For SERMs, we assumed a 10 % hip fracture risk reduction. The MORE trial, 
however, suggested that SERl\ils did not significandy reduce hip fracture risk 
(RR 1.1; 95 % C.L 0.6-1.9), whereas for all non-vertebral fractures, a non-
significant 10% risk reduction was observed. (50) The fact that no effect on hip 
fractures was observed may be due to low power, and indeed a higher femoral 
neck BMD was observed in women taking SERMs as compared to the placebo 
group. If, however, there truly is no hip fractures risk reduction, this still would 
not essentially change our results, especially at ages 55 and maybe at 65, since 
results are mainly driven by breast cancer. 
For SERM breast cancer risk reduction, we again based risk estimates on the 
MORE trial, which showed a 70 % breast cancer risk reduction. (53) However, 
because these results were obtained from one trial only, and because this trial did 
not have breast cancer as a primary outcome, we used a somev.~hat conseDlative 
breast cancer risk reduction of 50 %. True risk reductions may be somewhat 
different, but when higher, this would only stren,othen our results. 
Furthermore, for this model, we assumed that for all drugs a similar wear-off 
pattern lasting five years, after which no effects of the drug were present. The 
true wear-off pattern is not exacdy known for any of the drugs studied, and may 
differ from the assumed pattern. If the wear-of pattern were similar for all drugs, 
but different from what we assumed, this would not alter the message of this 
study. In addition, 100 % compliance is assumed in this study, although this may 
not be very realistic. Again, as long as compliance rates are comparable between 
drugs, this will not change the message of the paper. 
It is known that besides breast cancer, both SEfuYis and HRT also influence 
cardiovascular risk factors. (23,47,48) (51,89) The Heart and Estrogen/progestin 
Replacement Study (HERS) trial, however, overall did not show a risk reduction 
on cardiovascular disease. ( 49) In the first year, even an increased risk of 
myocardial infarctions was observed. Ongoing trials, including the Women's 
Health Initiative (WHI) and the Women's International Study of Long Duration 
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Estrogen after Menopause (WISDOM), will determine whether HRT is or is not 
effective in primary coronary heart disease prevention. (90,91) For SERi\1s, the 
Multiple Outcomes of Raloxifene Evaluation (MORE) trial recently showed that 
in women at increased cardiovascular risk, SER..\is reduced cardiovascular 
disease risk by 40 %. (92) This trial, however, was not designed to study 
cardiovascular endpoints. In the Raloxifene Use for The Heart (RUTH) trial, 
coronary heart disease is a primary endpoint, but this trial is currently still 
ongoing, (93) Since there are currently so many uncertainties about the potential 
protective effect of both HRT and SER..\1s on cardiovascular disease, we decided 
not to consider any potential effect on cardiovascular disease in the current 
model. 
It is not feasible to give preventive treatment to entire elderly population with a 
T -score at or below -1.0. This would be far too expensive, side effects would be 
considerable, individual effects and consequently compliance would be very low. 
Thus, tools are needed to identify subjects who are eligible for fracture 
prevention. For this model, we examined the costs and effects of the different 
treatment scenarios in women at different values ofT-score of BMD. \Ve used 
the values of aT-score of -1.0 and -2.5 since these values represent the cut-off 
values for definitions of osteopenia and osteoporosis, respectively. The T -score 
was developed by a working group of the World Health Organisation (\X7HO) 
and the definition on osteoporosis was ori,oinally intended for dia,onostic 
purposes only. In clinical practice, though, it is currently often used as a 
treatment threshold. As described in chapters 3.1 and 3.2, there are also 
disadvantages to the use of T -scores in fracture prevention. When using a T-
score of BMD of -2.5 as a threshold for fracture prevention, two thirds of all 
non-vertebral and vertebral fractures and about 50 % of hip fractures would be 
missed. Thus, from a public health point of view, a screening strategy based on 
bone mineral density alone is unlikely to be sufficient for prevention of fractures. 
Thus, there is a need to develop more adequate tools for identification of 
subjects who will fracture. 
In conclusion, the results of this model suggest that at ages 55 and 65 years, 
SERMs are more cost-effective for fracture prevention than HRT, mainly 
because of the effects on breast cancer. At older ages, bisphosphonates become 
more cost-effective than SERMs. As soon as the results of trials on 
cardiovascular effects become available, further study is necessary to extend the 
model with effects of drugs on cardiovascular disease. 
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Chapter 7 
General discussion 

General discussion 
In this thesis, we invesD,o-ated several aspects of osteoporosis, as osteoporosis is 
more than just fractures alone. All studies were performed in the Rotterdam 
Study, which is a large population-based cohort study among men and women 
aged 55 years and over from Ommoord, a suburb of Rotterdam, the 
Netherlands. 
First, we evaluated the incidence of, and risk factors for vertebral fractures. 
Then, we studied fracture prevention, and examined whether current methods 
for identifying subjects at risk for fractures are adequate. We investigated the 
interrelations between bone mineral density, atherosclerosis and breast cancer, 
and also the association between B:MD and overall mortality was studied. Tne 
thesis ends with a comparison of the cost-effectiveness of hormone replacement 
therapy (HRT), Selective Estrogen Receptor Modulators (SEfu\1s) and 
bisphosphonates for fracture prevention. 
Main findings 
Vertebral fractures 
Vertebral fractures are common fractures in osteoporosis, and these fractures are 
associated with increased functional impairment, (1) back pain and k-yphosis. 
(2,3) Furthermore, even in subjects without symptoms, vertebral fractures are 
associated with a decreased quality of life, which is not only the result of back 
problems, but also of other conditions, such as depression. (4,5) Several studies 
have shown that the presence of a vertebral fracture is associated with increased 
mortality, as well as with an increased risk of both new vertebral and non-
vertebral fractures, such as hip fractures. (6-12) 
Nonetheless, in contrast to non-vertebral fractures, only few studies on 
incidence of vertebral fractures have been performed, especially in men. (8-
10,13-15) 
This is because three important factors complicate the study of vertebral 
fractures. 
First of all, in contrast to non-vertebral fractures, vertebral fractures mainly 
occur spontaneously (or without major trauma), and only in about one third of 
all cases clear symptoms, leading to clinical recognition of a fracture, are present. 
(13) Thus, many vertebral fractures remain clinically unnoticed. This means that 
for the follow-up of vertebral fractures, it does not suffice to regularly check 
with General Practitioners' patient records and hospital records to find all new 
cases, as is standard procedure for non-vertebral fracture follow-up. Instead, one 
has to evaluate radiographs of the thoracolumbar spine at (at least) two points in 
time, if one wants to assess vertebral fracture .incidence. 
Here a second complication becomes evident. Currently, there is no consensus 
about the definition of a vertebral fracture. (16-20) Several methods have been 
developed for the evaluation of spinal radiographs. Every method uses slightly 
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different cut-off values in loss of vertebral height. In tbis thesis, we used the 
McCloskey-Kanis method, which is especially developed for assessing both the 
prevalence and incidence of vertebral osteoporosis in the population and in 
prospective studies. (16) In contrast to other methods, tbis method predicts 
vertebral heights and ratios for the individual patient rather than comparing 
them exclusively to a reference population, resulting in a lower false positive rate. 
However, it may well be that some misclassification has occurred due to the 
method used for fracture identification. 
The fact that we chose for a morphometrical assessment instead of a visual 
semiquantitative assessment by an experienced radiologist might result in higher 
numbers of both false positive and false negative vertebral fractures. (21) To 
reduce numbers of false positives, all fractures were confirmed by visual 
interpretation by an expert in the field, in order to rule out artefacts and other 
etiologies, such as pathological fractures. Therefore, we will mainly have false 
negatives, because, as compared to the semiquantitative approach, the ability to 
detect the milder vertebral fractures is supposedly lower for the morphometrical 
approach. (21) Consequently, tbis "'ill result in a potential underestimation of the 
true incidence of vertebral fractures in our population. 
A tbird important complication when studying the incidence of vertebral 
fractures is that a substantial selection bias arises in the study population. This is 
due to the fact that subjects had to survive up to the second follow-up visit in 
order to have a second radiograph of their spine taken. Because of tbis bias, it is 
likely that the incidence rates, as described in chapter 2.1, are an 
underrepresentation of the true incidence of vertebral fractures, especially at 
older ages. Also, the generalisability of our results to the general population may 
be hampered by tbis selection bias. 
Incidence of vertebral fractures 
The results of our study showed that although the absolute incidence of 
vertebral fractures is lower in men than in women, the risk of an incident 
vertebral fracture is similar at any given level of lumbar spine B:MD in men and 
women after adjustment for age and the presence or absence of prevalent 
vertebral fractures (chapter 2.1). Therefore, the difference in absolute incidence 
in men and women may be due to the fact that overall, men have a higher peak 
bone mineral density and loose bone at a lower rate than women do. (22) In line 
with tbis finding, Lunt and colle"<,oues also suggested that B:MD, together with 
age, explain much of the differences in risk of vertebral fractures between men 
and women in a cross-sectional analysis. (23) 
Risk factors for incident vertebral fractures 
In chapter 2.1 we show that both a low B:MD and the presence of baseline 
prevalent vertebral fractures are strong and independent risk factors for incident 
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vertebral fractures. For women only, one previous study has suggested that both 
these risk factors were indeed predictors for incident vertebral fractures. (8) For 
men, no evidence was available thus far. 
The main problem for both BMD and prevalent vertebral fracture assessment is 
that expensive methods of measurement are required, which currently cannot be 
performed in the general practice. In addition, the patient is exposed to 
irradiation. Thus, there is a clear need for more easily measurable risk factors for 
incident vertebral fractures, as was described in chapter 2.2. 
\'V' e tested whether risk factors are independent from BMD and prevalent 
vertebral fractures, to assess whether these factors yield additional information 
other than that provided by BMD and prevalent vertebral fractures. The results 
of this study provide new insight in the etiology of incident vertebral fractures. 
In women, the risk of incident vertebral fractures increased strongly with age. In 
men, however, no clear association between age and incident vertebral fractures 
could be observed. Cross-sectional data from the multi-centre European 
Vertebral Osteoporosis Study (EVOS) study have already suggested that age was 
more strongly associated with prevalent vertebral fractures in women than in 
men. (24) The lack of association between increasing age and incident vertebral 
fractures in men is probably partly related to the health selection bias during 
follow-up that was described above. 
Low body weight was a univariate risk factor for incident vertebral fractures, but 
this association disappeared after adjustment for BMD. This suggests that 
weight, at least in part, is a reflection of BMD. Burger et al previously showed 
this to be true for hip fractures. (25) Therefore, when the aim is to create a risk 
assessment tool for prediction of vertebral fractures, weight might be used as a 
measure ofBMD, instead of actually measuring BMD. 
Current smoking at baseline was associated "'ith an increased incident vertebral 
fracture risk in both men and women, even though only statistically significant in 
women. Several studies have suggested an inverse relation between smoking and 
BMD. (26-28) The mechanism through which smoking influences BMD and 
fracture risk is not fully elucidated. Some research suggests that nicotine directly 
influences bone metabolism. (29) Smoking might also influence BMD and 
fracture risk through its effect on body weight, sex steroid hormone levels and 
other hormones and enzymes involved in bone regulation or overall lifestyle. 
(30-37) Finally, there is indirect evidence that smoking may damage blood supply 
to bone. (38-40) Other risk indicators for incident vertebral fractures in women 
were the use of a walking aid, probably as a measure of low physical activity and 
co-morbidity, and an early age at menopause (at or before age 45). For men, the 
only additional significant risk factor besides low BMD and the presence of 
prevalent vertebral fractures was a positive history of non-vertebral fractures at 
or after age 50. 
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We evaluated the predictive power of only the easily assessable risk factors (age, 
weight, use of a walking aid, history of non-vertebral fracrures, current smoking 
and - for women - early age at menopause), only BMD and the presence of 
prevalent vertebral fractures or all factors combined. Overall, incident vertebral 
fracture prediction was strongest when combining all factors. In women, though, 
the clinical risk facrors alone also provided a relatively good prediction model. 
For men, vertebral fracture prediction was much improved when (additional) 
information on BMD and prevalent vertebral fractures was present. This could 
be expected since in men, only a histOry of non-vertebral fractures was a 
significant and independent risk factor for incident vertebral fracture. 
Based on these and perhaps also other easily assessable risk factors, it would be 
very interesting to develop a risk score for vertebral fractures, which can be used 
by the general practitioner tO screen for subjects who are be eligible for fracture 
prevention or for bone strength assessment. The aim would be to create a risk 
score, which the general practitioner can fill out rogether with the patient. The 
odds ratios, as presented in this thesis, might be used to create a weighted risk 
score, on basis of which an estimate of the patient's absolute vertebral fracture 
risk can be calculated, in a similar way as was previously presented for hip 
fractures by Burger et a!. (25) This might help the physician tO decide whether or 
not it is informative to have the patient's B.NID measured or a radiograph taken, 
or even just to initiate therapy. Once a risk score is developed, it has to be 
validated in other population-based cohort studies with data on incident 
vertebral fractures present, such as the Study of Osteoporotic Fractures. 
It might well be that, especially for men, there is insufficient power to create 
stabile risk scores. However, there are several possibilities available to increase 
power. 
First of all, it might be worth'Wile to evaluate the radiographs of the third follow-
up visit, which is currently ongoing, for the presence of incident vertebral 
fractures. 
Furthermore, now only radiographs of subjects who visited both the baseline 
and second follow-up examination were evaluated, but it would also be of 
interest tO evaluate their first follow-up radiographs to see whether the incident 
vertebral fracture was already present at that time. 
To substantially increase power in this respect, we could also evaluate 
radiographs of subjects who only went tO the baseline and first follow-up visit, 
""-o-ai.n using the McCloskey-Kanis method. Based on these data, it will be 
possible to study differences in risk factors for incident vertebral fractures soon 
after the baseline visit and those that occurred after a longer time period. Such 
an analysis will provide additional information on the etiology of vertebral 
fractures. 
Given recent technological developments, it is currently also possible to evaluate 
the spine for vertebral fractures by the same machine that is used for BMD 
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measurement. Using this approach, one can assess both BMD and the presence 
of prevalent vertebral fractures, the strongest risk factors for incident vertebral 
fracnrres, during a single measurement session. There are disadvantages of using 
such an approach for assessing the presence of vertebral fractures, for it is 
uncertain whether the sensitivity of detecting vertebral fractures is quite as high 
as when using the morphometrical approach based on radiographs. It might give 
a good first impression on whether a vertebral fracture is present or not, 
especially in those subjects in whom BMD measurement \vill be performed 
anyway. Since we already have data on morphometrically assessed vertebral 
fractures available, we should consider studying the sensitivity and specificity of 
using the DXA to assess presence or absence of prevalent and I or incident 
vertebral fractures in a pilot study "l.vithin the Rotterdam Study. 
Interrelations between bone mineral density, atherosclerosis and breast 
cancer 
Estrogen levels, both endogenous and exogenous, are widely considered to 
influence bone mineral density and fracture risk, as well as breast cancer and 
cardiovascular disease risk. (37,41-60) It is difficult, however, to classify a 
woman's long-term exposure to endogenous estradiol by a single measuremen~ 
since these levels strongly vary over time, especially in premenopausal women. 
Bone mineral density, in contrast, might be regarded as a crude marker for 
lifelong estrogen exposure, with high bone density reflecting high estrogen 
exposure throughout life. (43) Based on this, we hypothesized that a low BMD 
would be associated with an increased risk of atherosclerosis, whereas a high 
Bl'vill would be associated with an increased breast cancer risk. 
BMD and peripheral arterial disease 
As a marker of generalised atherosclerosis, we studied peripheral arterial disease 
(PAD) in association with BMD. In women, low femoral neck BMD was 
associated \vith an increased risk of peripheral arterial disease, which is in lioe 
with the hypothesis that BMD is a marker for life-time estrogen exposure, since 
both could be a reflection of estrogen deficiency. (Chapter 4.1) (45,56,58,61,62) 
Several other studies have also reported similar associations between BMD and 
PAD, as well as between BMD and atherosclerosis at several other sites, such as 
in the coronary arteries, and the aorta. (63-65) We did not, however, observe an 
association between lumbar spine BMD and PAD. 
There are some methodological considerations. First of all, in contrast to the 
other studies presented in this thesis, this was a cross-sectional study. Therefore, 
no conclusions on causes or consequences can be made. Therefore, the 
association observed might be due to low physical activity or co-morbidity. The 
prevalence of intermittent claudication in subjects \vith PAD was low (around 10 
% for men and 5 % for women). Thus, most subjects with PAD were 
asymptomatic. In addition, adjustment for walking ability did not essentially 
!57 
Chapter 7 
change results. Unfortunately, we do not have detailed information on physical 
activity for the entire cohort. Thus, there might still be some residual 
confounding due to physical activity. To test whether co-morbidity plays an 
important role in e:-.-plaining the observed association, the analyses were repeated 
excluding diabetics, subjects who had suffered a myocardial infarction before 
baseline or subjects who used diuretics. Again this did not change risk estimates, 
suggesting that co-morbidity does not play an important role in this association. 
Also, there is a possibility that measurement error amongst various potential 
confounding factors exists, but this would only have biased results towards no 
effect. 
There are several possible explanations for the fact that the assooanon was 
observed for femoral neck B:MD only. In contrast to femoral neck B:MD, both 
spinal osteoarthritis and aortic calcification influence lumbar spine BJ:v!D. (66-68) 
Especially the latter, which is also a marker of generalised atherosclerosis, may 
dilute the association between lumbar spine BJ:v!D and PAD. In addition, it 
might be that, since the presence of PAD is a marker for generalised 
atherosclerosis, in PAD cases also atherosclerosis of the renal arteries exists. (69) 
This, in turn, could result in both lower serum vitamin D and higher serum 
parathyroid hormone (PTH) levels (secondary hy-perparathyroidism) due to renal 
dysfunction, and PTH is known to mainly affect cortical bone. (70) High levels 
ofPTH are also associated with increased risk of cardiovascular disease. (71,72) 
However, the association between femoral neck BJ:v!D and PAD might also be 
due to the fact that atherosclerosis of the arteries in the femoral neck result in a 
locally reduced blood flow, affecting bone remodelling. Vogt et al. showed that 
the relationship between the ankle-arm index and BJ:v!D also exists when BJ:v!D is 
measured at the wris1; hereby suggesting that the association bet\\reen ENID and 
PAD is not based solely on a localised process. (65) 
BMD and breast cancer risk 
For incident breast cancer, we found that a high lumbar spine BJ:v!D was 
associated 'W-ith increased breast cancer risk, and that a low femoral neck BJ:v!D 
was associated with a decreased breast cancer risk, even though the latter was 
not statistically significant (chapter 4.2). In support of this finding, several other 
studies also showed that a high BJ:v!D, as measured at several sites, was 
associated with increased breast cancer risk in elderly women. (73-76) Higher 
BJ:v!D is associated with higher body weight. (77,78) It is known that 
aromatization of adrenal androgens ill. peripheral fatty tissue is the main source 
of estrogen in post-menopausal women. The fact that results remained similar 
after adjustment for body weight suggests that the observed association is not 
explained by the fact that women 'W-ith a high B:MD have a higher rate of 
estrogen production in fatty tissue. In addition, the association observed was also 
independent from age at menopause. 
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The main disadvantages of this study were the relatively low power and short 
follow-up period. It might well be that, when power is increased, the association 
between femoral neck BMD and breast cancer does become statistically 
significant. Therefore, it would be very interesting to repeat the analysis when 
follow-up of breast cancer is complete until the beginning of this century. 
FUrthermore, in order to have BMD measurements, subjects had to be able to 
come to the research centre. This could introduce a health selection bias. 
However, breast cancer incidence rates in our study (3.7 per 1000 woman-years) 
were quite similar to the incidence rate in women in the same age range from the 
general Dutch population (3.3 per 1000 woman-years). Finally, a program for 
regular breast cancer screening in_ all women over age 50 was started in the 
Rotterdam area in 1990. This could result in a relatively young age at diagnosis 
and therefore a higher BMD. We tried to correct for this issue by expressing the 
BMD as Z-scores, thereby adjusting for the potential confounding effect of age. 
Similar to the analysis performed on the association between BMD and breast 
cancer, it would also be interesting to study the association between BMD and 
endometrial cancer. Because of the low incidence of this specific type of cancer, 
power is currendy too low to really study that association. 
Overall, the results of the associations between BMD, PAD and breast cancer 
suggest that BMD can indeed be regarded as a crude marker for long-term 
estrogen e...\:posure. 
BMD and cardiovascular endpoints 
Besides effects on atherosclerosis, estrogens are thought to influence other 
cardiovascular disease risk factors. (58) High estrogen exposure has been 
reported to be associated with decreased LDL-cholesterol, increased HDL-
cholesterol, and lower blood pressure. Thus, if BMD is indeed a marker for 
long-term estrogen exposure, we might expect that women with a low BJV[[) 
would be at increased risk of both MI and stroke. Preliminary analyses, however, 
did not reveal any clear association between baseline BMD, MI and stroke risk. 
It is too soon to really exclude that there is an association between BMD and 
cardiovascular disease, given the limited power of our current study. It might be 
relevant to study the association between rates of bone loss and cardiovascular 
endpoints. It is known that estrogen deficiency results in increased bone loss. 
(45,61) In addition, trials have shown that HRT inhibits the bone loss. 
(42,49,59,79-83) Therefore, it is of interest to study whether a change in sex 
steroid hormones over time, and estrogen in particular, is associated with the 
rate of bone loss. In strata of change in sex steroid hormones, one could study 
the rate of bone loss during the same period. In addition, as soon as the data, 
which are currendy being collected at the third follow-up visit, become available, 
one could study rates of loss in sex steroid hormones in the elderly in relation to 
absolute BMD, BMD change over time, and also body composition values. 
Finally, it is also well possible that BMD is simply too crude a measure of 
estrogen exposure to reveal an association \':vith cardiovascular disease, especially 
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since many factors other than estrogen exposure also play a role in the etiology 
of cardiovascular disease. 
Bone mineral density and overall mortality 
In addition to studies into the potential interrelations between BMD and 
diseases, which are potentially estrogen-related, the association bet\Veen B]V[]) 
and overall mortality in both men and women was investigated. In men, low 
femoral neck BMD is associated with an increased risk of mortality. There seems 
to be a threshold around the age-adjusted average of BMD (Z-score of zero). 
Below this threshold, mortality risk starts to increase rapidly. Above this 
threshold, though, there is no further decrease in relative risk. If anything, the 
risk appears to go up again in men with a high Z-score ofBMD. This association 
appears to be independent from co-morbidity. In women, however, we could 
not identify a relationship between BMD and mortality. We hypothesized that 
the absence of an association between BMD and mortality in women could be 
due to counteracting associations with cardiovascular and cancer mortality. As 
discussed above, high BMD is associated with increased breast cancer risk, and 
extrapolating from this result it is not unthinkable that high BMD is also 
associated '-'<rith increased cancer mortality. Following the hypothesis that low 
B11D, as a measure of low estrogen exposure, is associated v.rith increased 
cardiovascular disease, it might also be that low BMD is associated with 
increased cardiovascular mortality. Unfortunately, at the time this study was 
performed, data on cause of death were not available, but when they \Vill become 
available it \Vill be interesting to test whether the hypothesis postulated is correct. 
In addition, here also a relatively low power in women ~oht play a role, since 
men on average die at a younger age than women do. 
Fracture prevention 
As described in the general introduction (chapter 1), osteoporosis is a common 
disease in the elderly. Osteoporotic fractures, the clinical endpoint of 
osteoporosis, are associated with increased morbidity, mortality and high socio-
economic costs. (3,5, 7 ,84-87) Therefore, there is a clear need for adequate 
fracture prevention. Several therapeutical options are available for fracture 
prevention, and overall efficacy is considerable. However, before prevention can 
be initiated, sensitive screening tools are necessary to accurately identify subjects 
who are most likely to fracture. 
A working group of the World Health Organisation (WHO) has defined 
osteoporosis as a bone mineral density of 2.5 standard deviations or more below 
the average bone mineral density in young adult women (the T-score). (88) This 
cut-off value was originally intended for diagnostic purposes only, and not, as is 
common practice nowadays, for use as a treatment threshold. In chapter 3.1, we 
evaluated the sensitivity of using such a threshold for fracture prevention. 
Overall, about two-thirds of subjects who will sustain a fracture will not be 
offered treatment when a T-score of -2.5 is used as a treatment threshold. For 
hip fractures only, approximately 50 % of all fractures occurred in women with a 
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T-score at or below -2.5. This is probably due to the fact that hip fractures on 
average occur at an older age than either vertebral fractures or wrist fracmres do, 
and the prevalence of osteoporosis also increases with age. Thus, although 
subjects with a T -score at or below -2.5 are at a highly increased fracmre risk, 
using only a T -score at or below - 2.5 alone is not a tool that is sensitive enough 
for identifying subjects who should receive fracture prevention. 
Geoffrey Rose already spoke about the prevention paradox: a large number of 
people at a small risk may give rise to more cases than the small number of 
people who are at high risk. (89) He proposed that two strategies for prevention 
are available: the population-based approach and the high-risk approach. Ideally, 
the population-based approach is preferable over the high-risk approach, but a 
treatment often is expensive, and probably results in an extremely low 
compliance with a high percentage of adverse effects. One way to implement the 
population-based approach in practice would be to promote a change to a 
healthier life-style. Even though this might work in theory, there is not much 
evidence that this would substantially reduce the population-burden of fractures 
in the general population. Thus, practically speaking, the high-risk approach is 
more feasible at present in general practice. 
Therefore, since B1ID measurement alone clearly is not enough, it is necessary 
that more sensitive tools than the T -score alone are developed for identification 
of subjects at high risk. Burger et al. have previously created risk assessment 
models for short-term hip fracture risk estimation, both with and without BMD. 
(25) These analyses merit further research, using an "-"tended follow-up. In 
addition, risk scores for osteoporotic fracmres, other than hip fractures, should 
be developed in order to identify subjects who would benefit from preventive 
treatment. 
The Rotterdam Smdy provides a good basis for such an analysis, especially now 
that follow-up time is extended to an average of 10 years. In addition, it might be 
worth'W-ile to consider conducting a meta-analysis of all large population-based 
cohorts, in order to have optimal power. 
Of course, it should be noted that the prevention paradox does not diminish the 
value of the T -score in identifying subjects at high risk for fractures. This 'high-
risk' approach offers these individuals the opportunity to reduce their fracture 
risk substantially through intervention. 
In chapter 3.2 we showed that, when using the same absolute BMD threshold in 
men as in women, in men the proportion of hip fractures below that (female 
specific) value was much lower than in women. Therefore, if we have the 
intention to evenly reduce the burden of illness in both men and women, the 
absolute BMD cut-off value will always be higher in men than in women. The 
use of a gender-specific T-score largely solves this diagoostic problem. (88) 
In contrast, when cost-effectiveness of interventions is the goal, absolute 
fracture risks are more important since the numbers needed to treat with an 
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intervention are directly influenced by the fracture incidence in those in whom 
an intervention is undertaken. This is demonstrated in intenrention trials where 
including populations with a different fracture incidence leads to different 
numbers needed to treat even with the same intervention. (90,91) Since men 
have a loWer hip fracture incidence than women, fewer men than women reach 
the required fracture risk threshold to make an intervention cost-effective. 
Therefore, when cost-effectiveness is the main concern, a similar B:J\ID 
threshold in men and women should be used to assess the need for intervention. 
Therefore, fewer men than women "'ill now be treated. 
Economic evaluation of therapeutical options 
Of course, there is no use in identifying subjects eligible for fracture prevention, 
unless (cost-) effective interventions can be offered. There are currently many 
pharmaceutical treatments available for fracture prevention, amongst which are: 
hormone replacement therapy (HRT), Selective Estrogen Receptor Modulators 
(SERMs) and Bisphosphonates. In our modelling study, we compared the cost-
effectiveness of these three drugs on fracture prevention in women, assuming a 
5-year treatment period 'W"ith a subsequent 5-year offset period. For HRT, a hip 
fracture risk reduction of 10 % or SO %, and a vertebral fracture risk reduction 
of 50 %were assumed. For SERl\is, the assumed reductions were 10 % for hip 
fractures and 50 % for vertebral fractures. Finally, for bisphosphonates, a 50 % 
risk reduction was assumed for both hip fractures and vertebral fractures. 
It is thought that both HRT and SERl\is also have an effect on the incidence of 
breast cancer. (46,53,92) To take these effects into account in our model, we 
assumed a 10 % breast cancer risk increase for HRT, a 50% breast cancer risk 
decrease for SERl\is, and no effect on breast cancer risk for bisphosphonates. 
We evaluated women at ages 55, 65 and 75 years at T-scores of femoral neck 
BMD of -2.5 and -1.0. 
When we consider an effect present on fractures only, HRT is very cost-
effective, whereas especially SERMs are very e..xpensive, with relatively few 
Quality Adjusted Live Years (QALYs) gsined. When, however, effects of HRT 
and SER..'.is on breast cancer are taken into account, results change dramatically. 
Especially at younger ages, HRT actually results in a decrease in QAL Y s instead 
of an increase. An important part of the loss of QAL Y s is due to the actual loss 
of life years. Although incidence rates of breast cancer, hip fracture and vertebral 
fractures are comparable at 55 years, breast cancer mortality rates are much 
higher than hip fracture mortality rates and breast cancer mortality occurs on 
average at younger ages, resulting in much more life years lost. This strongly 
influences the total QAL Y loss due to breast cancer cases. Instead, due to a 
breast cancer sparing effect, SER..'.is now become the most cost-effective drug at 
ages 55 and 65 years in the model. 
At older ages, bisphosphonates become more cost-effective than SERMs. This is 
mainly due to the fact that at older ages, hip fracture incidence rates increase 
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rapidly, and bisphosphonates are thought to prevent hip fractures more 
adequately than SER\\1s do. Furthermore, at older ages, there are less life-years 
lost due to breast cancer. 
These results could be important for determining the clinical approach to 
fracture prevention. But of course, one has to bear in mind that this is only one 
study, and that it is based on a mathematical model, which involves several 
assumptions. 
For instance, even though we assumed SER.i."\1s to result in a 10 % hip fracture 
risk reduction, the MORE study reported a non-significant relative risk of 0.97 
for hip fractures. However, even if our risk estimate were an overestimation, the 
cost-effectiveness ratios would still remain similar since results are primarily 
driven by the strong breast cancer risk reduction, especially at younger ages. 
Similarly, a different HRT hip fracture risk reduction would also hardly affect the 
cost-effectiveness ratios. 
For this thesis, the model was confined to women only. This was mainly done 
because we included the effects of therapy on breast cancer. In addition, for 
bisphosphonates only few and relatively small trials have been performed on the 
effects on fracture prevention in men, and for SERMs no trials in men have 
been performed at all. (93-95) Still, it would be interesting to study the cost-
effectiveness of bisphosphonates on fracture prevention in men, assuming the 
same effect size on fracmre prevention as in women. 
Overall methodological considerations 
Apart from the methodological 1ssues that have been discussed rn the 
appropriate sections, there is an overall issue that warrants some further 
discussion. 
An appropriate study design is essential for epidemiological research. Most of 
the studies presented in this thesis are follow-up studies. Follow-up studies are 
widely believed to have many advantages over cross-sectional and case-control 
designs, mainly because a follow-up design is the design that optimally enables 
the researcher to follow the course of a disease from e.."posure to disease, thus 
allowing to make inferences in terms of causes and consequences. The precision 
of the effect estimates observed are directly dependent on both the study size 
and the total numbers of cases, which in the case of the Rotterdam Study are 
quite large (given that the disease of interest is not rare). 
In addition, it is thought that follow-up studies have fewer disturbances due to 
bias. 
Generally speaking, there are three types of bias, namely selection bias, 
information bias and confounding. \Vhenever we felt that results could have 
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been distorted by such a bias or confounder, we have described this in the 
previous section of the general discussion. 
In general, it is thought that the longer the follow-up, and the more cases are 
available, the stronger the results of the study are. However, now that the follow-
up within the Rotterdam Study is more than a decade long, it is time to re-
evaluate the methods of analysis that are so commonly used. 
Of course, the further away we get from the baseline of the study, the more 
factors can be of influence on the exposure status that was measured at baseline. 
For instance, in the case of osteoporosis research, it may well be that those 
subjects who had a high BMD at baseline might be the ones who loose more 
bone during follow-up. This might, in time, dilute the results of associations 
under study. This phenomenon probably "ill not have a big influence in studies 
"'~th a relatively short follow-up time, but the larger the follow-up time gets, the 
stronger the influence becomes. It would be of interest to perform our analysis 
for both a short-term and a long-term follow-up, to study the magnitude of this 
problem. 
However, primarily in etiologic research, more and more we v.rill have to 
additionally evaluate changes in exposure in relation to different outcomes of 
interest, such as rates of bone loss besides studying a baseline measurement only. 
Such an analysis might provide us with more insight in the pathophysiology of 
fractures. For instance, is it really the status of low bone mineral density itself, or 
perhaps more the State of rapid bone loss that results in fragile and therefore 
fracture-prone bones? 
In this respect, it is also very much of interest to study interactions bet\XTeen 
bone mineral density and other exposures related to fracture risk, on overall 
fracture risk. 
In addition, whenever possible, we may have to consider taking the change in 
exposure status over time into account in our analysis, by using a time-varying 
exposure analysis or other analyses allo'\V"'ing for changes in exposure over time. 
Nevertheless, especially for longer-term prediction models and for intervention 
studies, analysis of a baseline measurement alone in relation to events during 
follow-up remains of extremely important. 
As an example of how important it is to take changes in exposure over time into 
account, in chapter 4.2 we presented the association bet\veen BMD and breast 
cancer both using merely the baseline BMD levels and the rates of loss between 
the baseline and first follow-up visits. Although using the baseline femoral neck 
B11D, no strong association could be observed, a clear association was apparent 
when studying the change in BMD over time. Now, it was apparent that women 
who were to suffer from breast cancer had gained bone in the years prior to 
diagnosis, a finding which was consistent for both femoral neck and lumbar 
spine BMD. These additional analyses provided strong extra support for an 
association beNreen B:MD and breast cancer, an association that is potentially 
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explained by differences in estrogen exposure between women with and without 
breast cancer. 
Suggestions for further research 
The results of the studies presented in this thesis give rise to new hypotheses for 
further research. Many of those have already been presented in the course of this 
general discussion. 
Apart from those suggestions, we here present some additional ideas for further 
research following the results presented in this thesis. 
For the cost-effectiveness model described in this thesis, the association between 
BMD and breast cancer has been taken into account. It is thought, however, that 
both HRT and SERMs also influence cardiovascular risk factors. (58,96,97) 
(98,99) Since there are currently so many uncertainties about the potential 
protective effect of both HRT and SER[\I[s on cardiovascular disease, we decided 
not to consider any potential effect on cardiovascular disease in the present 
model. Several trials are currently being performed on the effects of HRT and 
SER1\I[s on cardiovascular disease. Trials, such as the Women's Health Initiative 
(\VHI) and the Women's International Study of Long Duration Estrogen after 
Menopause (\mSDOl\1), will determine whether HRT is effective in primary 
coronary heart disease prevention. (100,101) For SERc\1s, the Multiple 
Outcomes of Raloxifene Evaluation (MORE) trial recently showed that in 
women at increased cardiovascular risk, SER.J.\1s reduced cardiovascular disease 
risk by 40 %. (1 02) This trial, however, was not originally designed to study 
cardiovascular endpoints. In the Raloxifene Use for The Heart (RUTH) trial, 
coronary heart disease is a primary endpoint, but this trial is currently still 
ongoing. (1 03) As soon as the results of these trials become available, the model 
can be extended further, to also take the potential protective effect on MI 
and/ or stroke into account. 
In addition to this, it would be interesting to also evaluate the assoc1at1ons 
between BMD and dementia, and BMD and depression in the Rotterdam Study, 
as recent literature suggests that both these diseases are also associated 'W~th 
estrogen exposure. (104-106) Eventually, it would then be interesting to take the 
potential effects of HRT and SERMs on both dementia and depression into 
account. But as for cardiovascular disease, double-blind randomized trials will 
first have to provide us 'W~th reliable evidence before this can actually be 
implemented into our model. 
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Summary 
Osteoporosis is a systemic disease that is characterized by low bone mass and 
micro-architectural deterioration of bone tissue, leading to enhanced bone 
fragility and a consequent increase in fracture risk. Fractures, the clinical 
outcome of osteoporosis, and hip fractures in particular, are associated v.-ith 
increased morbidity, mortality and substantial economic costs. 
The overall aims of this thesis were to study the incidence of and the risk factors 
for venebral fractures, and to evaluate the interrelations bet\."lleen bone ~"leral 
density, atherosclerosis and breast cancer. Furthermore, we evaluated the 
sensitivity of using a T -score of bone mineral density (BMD) at or below -2.5 as 
a treatment threshold for fracture prevention. We also investi,<>ated whether in 
elderly men a similar BMD threshold should be used as is currently used in 
women. The results of all these studies were combined to investigate the cost-
effectiveness of fracture prevention in women. 
For all analyses that were presented in this thesis, we used data from the 
Rotterdam Study, a large prospective population-based cohort study in the 
Netherlands. Participants of this study were men and women aged 55 years or 
over liv1ng in Ommoord, a suburb of Rotterdam. 
In Chapter 2, the epidemiology of vertebral fractures was studied. In chapter 
2.1 we showed that in subjects with a baseline prevalent vertebral fracture, the 
incidence of vertebral fractures increases strongly with age. Although overall 
incidence rates are higher in women than in men, the risk of an .incident 
vertebral fracture at any given level of absolute bone mineral density (BMD) is 
similar for men and for women. Furthermore, the presence of a prevalent 
vertebral fracture and a low BMD are strong and independent risk indicators for 
incident vertebral fractures in both men and women. 
In chapter 2.2 we continued on this subject and showed that besides prevalent 
vertebral fractures and low BMD, in women age, early menopause (at or below 
age 45), current smoking and the use of a walking aid are also strong 
independent risk factors for incident vertebral fractures. In men, only a positive 
history of non-vertebral fractures at or after age 50 is an additional independent 
risk factor. Current smoking was associated with an increased vertebral fracture 
risk in men, but this did not reach statistical significance. 
In chapter 3 we evaluated whether the T -score should be used in the 
identification of subjects who will fracture, and if so, whether the same threshold 
should be used for men and women. As described in chapter 3.1, two thirds of 
all fractures occurred in women with a T -score above -2.5. Thus, although a T-
score of- 2.5 SD (and below) identifies individuals at high fracture risk, overall 
most fractures occur in subjects with a BMD above this threshold. The public 
health burden of fractures will not be alleviated using the current WHO criterion 
for osteoporosis. In chapter 3.2 we then studied whether the association 
between BMD and fracture risk is similar in men and women and whether the 
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same T-score ofBMD should be used for men and women or whether a gender-
specific T -score would be better. Overall, hip fracture risk in men and women of 
the same age and at the same absolute BMD is very similar but, due to the 
different BMD distribution, the average BMD in men who fracture their hip is 
higher than in women. To capture the same proportion of hip fractures in men 
the threshold BMD needs to be higher than in women but the use of a gender-
specific T -score largely solves tbis for di~onostic purposes. The overall hip 
fracture incidence is lower in men than in women and we propose the use of the 
same absolute BMD thresholds in men and women for decisions about 
interventions. 
In chapter 4 the interrelations between BMD, atherosclerosis and breast cancer 
are investigated. Both atherosclerosis and breast cancer are also considered to be 
related to estrogen exposure. The underlying hypothesis was that BMD may be 
regarded as a marker for lifetime estrogen exposure. 
First, in chapter 4.1 the association between BMD and peripheral arterial disease 
(PAD) was described. PAD is a marker for generalized atherosclerosis. We 
observed an association between low BMD and PAD in women, but not in men. 
Possibly, part of tbis difference between men and women may be explained by 
the direct and indirect influences of the sudden decrease in estrogen following 
menopause. 
In chapter 4.2 we investigated the association between BMD and incident first-
ever breast cancer in women. The results of tbis study suggest that women with 
a lumbar spine BMD in the highest tertile are at a doubled risk of breast cancer 
as compared to women with an average BMD. For femoral neck BMD, even 
though not statistically significant, women with a low BMD were at a somewhat 
decreased breast cancer risk. 
In chapter 5 we studied the association between BMD and overall mortality in 
both men and women. In men a non-linear relationship between BMD and 
mortality exists, which is independent of comorbidity and impaired mobility. In 
women, no significant relationship between BMD and all-cause mortality was 
observed. 
The results of the studies as described in all previous chapters were now 
combined and used to develop a model on cost-effectiveness of fracture 
prevention. This model and the results were described in chapter 6. In the 
model, the cost-effectiveness of fracture prevention was evaluated for hormone 
replacement therapy (HRT), selective estrogen receptor modulators (SERt\is) 
and bisphosphonates in women at the ages of 55, 65 and 75 years. For HRT, we 
assumed a risk reduction of 10 % or 50 % for hip fractures and a risk reduction 
of 50 % for vertebral fractures. For SERt\is and bisphosphonates the assumed 
hip fracture risk reductions were 10 % and 50 %, respectively. For both these 
drugs, a 50 % risk reductions for vertebral fractures was assumed. We assumed a 
5-year trearrnent period and a 5-year offset period for all trearrnent strategies. In 
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addition, the effects of HRT and SERJY!s on breast cancer were taken into 
account. The results of this model strongly suggest that in terms of cost-
effectiveness SER[Y!s compare favorably with HRT for fracture prevention, 
mainly because of the effects on breast cancer. At older ages, bisphosphonates 
become more cost-effective than SERJY!s. This is mainly due to the fact that at 
older ages, hip fracture incidence rates increase rapidly, and bisphosphonates are 
thought to prevent hip fractures more adequately than SERJY!s do. Furthermore, 
at older ages, there are less life-years lost due to breast cancer. 
Finally, in chapter 7 a general discussion of the results described in this thesis is 
presented. We discuss the main pitfalls in studying vertebral fractures. 
Furthermore, we elaborate on strategies for fracture prevention. What would be 
the best approach to optimally identify subjects who will fracture in the near 
future. Finally, we further discuss the results and pitfalls of the cost-effectiveness 
model described in chapter 6. We finish the discussion by giving some 
suggestions for further research following the results that were presented in this 
thesis. 
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S amenvatting 
Osteoporose, oftewel botontkalking, is een aandoening die wordt gekenmerkt 
door een !age bot massa en een achteruitgang van de microarchitectuur van het 
bot weefsel. Dit leidt tot een verhoogde botfra_,oiliteit, welk resulteert in een 
verhoogde kans op botbreuken. Fracturen (oftewel botbreuken), de klinische 
uitkomst van osteoporose, en dan met name heup fracru.ren, gaan gepaard met 
een verhoogde kans op ziekte en sterfte, maar ook met hoge sociaal-
economische kosten voor de maatschappij. 
In dit proefschrift, hebben we ook gekeken naar het v66rkomen van 
wervelinzakkingen, waarbij we ook de belangrijkste risicofactoren voor deze 
inzakkingen hebben bestudeerd. Daarnaast bestudeerden we de onderlinge 
relaties tussen botmineraal dichtheid, atherosclerose ( oftewel sla,rraderverkalkirg) 
en borst kanker. Tevens hebben we onderzoek verricht naar preventie van 
fracturen; zijn de huidige methoden die gebruikt worden voor de identificatie 
van mensen met een hoge kans op een fracmur goed genoeg en zo ja: zouden 
beslissingen over interventie gemaakt moeten worden bij eenzelfde drempel in 
botmassa bij mannen als bij vrouwen. Tot slot werden de resulraten van alle 
voorgaande hoofdstukken gecombineerd in een model naar de kosten-
effectiviteit van fracruur preventie bij vrouwen, rekening houdend met potentiele 
effecten van de geneesmiddelen op het voorkomen van borstkanker. 
Voor dit onderzoek hebben we gebruik gemaakt van gegevens van her Erasmus 
Rotterdam Gezondheid en Ouderen (ERGO) onderzoek. Dit is een grote 
populatie-gebaseerde studie onder mannen en vrouwen van 55 jaar en ouder uit 
Ommoord, Rotterdam. 
In hoofdstuk 2 wordt de epidemiologie van wervelinzakkingen bestudeerd. In 
hoofdstuk 2.1laten we zien dat in mensen die aan het begin van de studie reeds 
een wervelinzakking hadden, het v66rkomen van "\vervelinzakkingen sterk 
toeneemt met de leeftijd. Hoewel algemeen genomen wervelinzakkingen vaker 
voorkomen bij vrouwen dan bij mannen, was de absolute kans op inzakkingen 
gelijk bij eenzelfde absolute botmineraal dichtheid (BMD). Daamaast bleken 
zowel de aanwezigheid van een wervelinzakking aan het begin van de studie als 
een !age BMD sterke voorspellers te zijn voor nieuwe wervelinzakkingen. 
In hoofdstuk 2.2 toonden we aan dat naast reeds bestaande wervelinzakkingen 
en een !age BMD, in vrouwen leeftijd, een vroege menopause (voor of tijdens 
het 45e levensjaar), roken en het gebruik van hulpmiddelen bij het !open ook 
sterke voorspellers zijn voor nieuwe inzakkingen. In mannen was aileen een 
voorgeschiedenis van een botbreuk op of na het 50e levensjaar een additionele 
voorspellende factor. Hoewel dit niet sratistisch significant was, leek roken ook 
in mannen gerelateerd te zijn aan meer wervelinzakkingen. 
In hoofdstuk 3 bestudeerden we of de T -score van de BMD gebruikt kan 
worden voor identificatie van personen die een frac.mur zullen krijgen, en zo j~ 
of eenzelfde drempelwaarde zou moeten worden gebruikt voor mannen als voor 
vrouwen. 
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Zoals bescbreven in hoofdstuk 3.1, komt twee-derde van aile fracturen voor in 
personen met een T -score boven de -2.5. Dit suggereert dat, hoewel een T -score 
van -2.5 of lager mensen met een hoge kans op fracturen wei identificeert, de 
meeste fracturen voorkomen in mensen met een B:MD hoven deze 
drempelwaarde. De totale ziektelast ten gevolge van fracturen voor de populatie 
wordt niet sterk verminderd wanneer de huidige criteria voor osteoporose 
worden gehanteerd voor fractuur preventie. 
In hoofdstuk 3.2 bekeken we of de relatie tussen BMD en fractuur kans gelijk is 
voor mannen en "v-rouwen, en of we beter een geslachtsspecifieke of een gelijke 
BMD T -score kunnen gebruiken. De kans op een heup fractuur is zeer 
vergelijkbaar voor mannen en vrouwen met eenzelfde leeftijd en BMD, maar 
door een andere BMD verdeling in de mannelijke bevolking, is de gerniddelde 
BMD bij mannen met een fractuur hager dan bij vrouwen. Wanneer we 
eenzelfde proportie heup fracturen willen voorkomen bij mannen als bij 
V"TOuwen, moet de drempelwaarde in B:MD voor mannen hager zijn dan voor 
vrouwen, en het gebruiken van een geslachtsspecifieke BMD T -score zal dit 
probleem grotendeels oplossen. Echter, wanneer het doe! is beslissingen te 
nemen aangaande interventie, lijkt het beter eenzelfde drempel in absolute BMD 
te hanteren voor zowel mannen als vrouwen. 
In hoofdstuk 4 worden de onderlinge relaties tussen BMD, atherosclerose en 
borstkanker, welke oak gerelateerd zijn aan blootstelling aan oestrogenen 
(vrouwelijk hormoon), nader onderzocht. De onderliggende hypothese is dat 
BJVID beschouwd mag worden als een maat voor oestrogeen blootstelling 
gedurende het Ieven. 
In hoofdstuk 4.1 wordt de relatie tussen BMD en perifeer vaatlijden bescbreven. 
Perifeer vaatlijden is een maat voor gegeneraliseerde atherosclerose. We vonden 
een relatie tussen een !age BMD en perifeer vaatlijden in vrouwen, maar niet in 
mannen. Mogelijk wordt dit verschil ten dele verklaard door de directe en 
inclirecte invloeden van de snelle daling van oestrogenen ten gevolge van de 
menopause. 
In hoofdstuk 4.2 bescbreven we de relatie tussen BMD en borstkanker in 
vrouwen. Vrouwen met een hoge BMD, zoals gemeten aan de !age wervelkolom, 
hebben een twee keer zo hoge kans op het ktijgen van borstkanker dan vrouwen 
met een gerniddelde BMD. Hoewel niet statistisch significant, hadden vrouwen 
met een !age BMD, zoals gemeten aan de heup, een wat verlaagde kans op het 
ktijgen van borstkanker. 
In hoofdstuk 5 bestudeerden we de relatie tussen BMD en sterfi:e in mannen en 
vrouwen. In mannen is er een niet-lineaire relatie tussen BlviD en sterfte, welke 
onafhankelijk is van co-morbititeit en verrninderde lichamelijke activiteit. In 
vrouwen werd geen duidelijke relatie tussen BMD en sterfi:e gevonden. 
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De resultaten van bovenstaande hoofdstukken werden gecombineerd en 
gebruikt om een model te ontwikkelen ter bestudering van kosten effectiviteit 
van fractuur preventie, welk beschreven werd in hoofdstuk 6. In het model 
wordt de kosten-effectiviteit van fractuur preventie vergeleken voor hormoon 
substitutie therapie (HRT), selectieve oestrogeen receptor modulatoren (SERMs) 
en bisfosfonaten in vrouwen van 55, 65 en 75 jaar. Voor aile dtie de 
geneesmiddelen schatten we de effecten op fractuur kans. Voor HRT werd een 
risico reductie van 10 % of 50 % voor heup fracturen en een risico reductie van 
50 % op wervelinzakkingen aangenomen. V oor SERMs en bisfosfonaten waren 
de geschatte heup fractuur risico reducties respectievelijk 10 % en 50 %. V oor 
beide geneesrniddelen werd een 50 o/o vermindering van wervelinzakkingen 
geschat. In het model was de behandelduur 5 jaar, waama er nog 5 jaar een na-
effect zichtbaar bleef. Tevens werden de effecten van HRT en SER1\1s op 
borstkanker meegenomen in de analyses. De resultaten van het model 
suggereren dat op de leeftijd van 55 en 65 jaar, SERMs kosten-effectiever zijn 
dan HRT. Dit wordt met name verklaard door de borstkanker verlagende 
effecten van SEfu\1s. Op latere leeftijd zijn de bisfosfonaten het meest kosten-
effectief. Dit wordt verklaard door het feit dat op oudere leeftijd het voorkomen 
van heup fracturen sterk roeneemt, en bisfosfonaten een groter effect hebben op 
heup fracturen dan SERMs. Bovendien zijn er op oudere levensjaren minder 
levensjaren die verloren gaan ten gevolge van borstkanker. 
In hoofdstuk 7 worden aile resultaten sarnen besproken in de algemene 
discussie. We bespreken de grootste problemen bij het bestuderen van 
wervelinzaklcingen. V erder gaan we wat gedeta.illeerder in op strategieen voor 
fractuur preventie. Tot slot gaan we dieper in op de resultaten en problemen van 
het kosten-effectiviteitsmodel, zoals beschreven in hoofdstuk 6. \'V'e eindigen de 
discussie met het aanreiken van suggesties voor verder onderzoek volgend uit 
het onderzoek wat beschreven is in dit proefschrift. 
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